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ABSTRACT
The seven transmembrane a-helices of the human 5 - H T ^ ,  5 -H T jj)a  and 
5-HTi£)p receptors have been modelled using the 3-dimensional coordinates of  
the seven transmembrane a-helices of the bacterial protein bacteriorhodopsin as 
a template. The probable 5-HT binding site was identified between helices 3, 4, 
5 and 6. Interactions between the natural ligand 5-HT (A) and the receptor 
models are described in detail and the agonist binding site is further validated by 
the docking of four known 5-HT receptor ligands. The models are able to 
account qualitatively for the receptor binding affinities of the studied ligands.
Small molecule similarity studies suggest that a thieno[2,3-b]pyridine analog (B) 
of 5-HT could possibly act as a bio-isostere for 5-HT. This was further 
corroborated when (B) was docked into the 5-HT receptor models and was found 
to be accommodated easily in the 5-HT binding site participating in the same 
interactions as observed for 5-HT.
Thieno[2,3-b]pyridines similar to (B) were thus identified as synthetic target 
compounds. Furthermore, the models were used to provide suggestions for the 
design of novel, more selective, 5-HT receptor agonists.
The thieno[2,3-b]pyridine ester (C; R =C 0 2 Et) was reduced to the 
hydroxymethyl derivative (C; R=CH2 0 H) but the methylthio group could not be 
successfully removed in the presence of the thiophene ring.
Using a different approach the thieno[2,3-b]pyridine (D; R=CC>2Me, X =C N ) 
was synthesised as a model compound and converted through to the ^-BOC 
protected amines (D, R=NHC0 2C(CH3)3, X=C N ) and (D, R =N H C 02C(CH3)3 , 
X=CONH2). The same reactions were applied to ethyl-3-(5-cyanothieno[2,3-b]
v iii
pyridin-3-yl)propanoate (E, R =C 0 2 Et, X=C N ) but this unfortunately could not 
be converted through to the required /-BOC protected 5-HT analog (E, 
R =N H C 02C(CH3)3, X=CN ).
R
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FOREWORD
Bracketed arabic numerals in the text refer to the diagrams of the molecular 
formulae. Arabic superscripts indicate references. The following abbreviations 
have been used in the text.
A Angstrom unit 1 0 '10m
Ac Acetyl group CH3CO
ADP Adenosine diphosphate
Ar Aryl group
t- BOC /-Butoxycarbonyl group C0 2 C(CH3)3
nBu n-Butyl group CH2CH2CH2CH3
tBu /-Butyl group C(CH3)3
CNS Central nervous system
m-CPBA /w-Chloroperoxybenzoic acid
m-CPP w-Chlorophenylpiperazine
5-CT 5 -Carboxamidotryptamine
5 Parts per million
DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone
DMF N, jV-Dimethylformamide
DMSO Dimethylsulfoxide
(RM-)DOB (R)-(-)-l-(4-Bromo-2,5-dimethoxyphenyl)-2-
aminopropane
DPPA Diphenylphosphorylazide
E + Electrophile
Et Ethyl group CH2CH3
fs femtosecond 1 O' 15 s
GDP Guanosine 5'-diphosphate
GPCR G-protein coupled receptor
G-protein Guanine-nucleotide binding protein
GTP Guanosine 5'-triphosphate
h hour
[H] Reduction
HMPA Hexamethylphosphoric triamide
5-HT 5-Hydroxytryptamine (Serotonin)
ir Infrared
K degrees Kelvin
kcal kilocalorie 4.184 x  103 Joules
Ki Affinity constant
LC-MS Liquid chromatography mass spectrum
(+)LSD (+)-Lysergic acid diethylamide
Me Methyl group CH3
Mes 2,4,6-Trimethylbenzene
mmol millimole 10-3 mol
MMPP Magnesium monoperoxyphthalate
mp melting point
mRNA Messenger ribonucleic acid
MS Mass spectrum
NADH Nicotinamide adenine dinucleotide coenzyme I
nM nanomolar 10 '9 moldm-3
nmr Nuclear magnetic resonance
[0 ] Oxidation
8-OH-DPAT 8-Hydroxy-2-(di-«-propylamino)tetralin
5-OH-TMT 5-Hydroxy-N, N, 7V-trimethy ltryptamine
Ph Phenyl group C6H5
PPA Polyphosphoric acid
ps picosecond 10' 12s
PTC Phase transfer catalyst
XI
R f Retention factor
RMS Root mean square
THF T etrahydrofuran
tic Thin layer chromatography
TMEDA N, N, N, N-T etramethylethy lenediamine
XU
1 INTRODUCTION
1.1 5-HYDROXYTRYPTAMINE AND MOLECULAR MODELLING
1.1.1 Isolation of 5-hydroxytryptamine
It has been forty-seven years since Maurice Rapport crystallised the 
vasoconstrictor serotonin from blood serum 1 and subsequently identified this 
substance as 5-hydroxytryptamine^ (5-HT, 1). Around the same time in Italy, 
Vittorio Erspamer and colleagues were interested in a substance known as 
enteramine which was present in the enterochromaffin cells of the 
gastrointestinal tractM . Isolation of enteramine and characterisation^ showed it 
to be identical to 5-hydroxytryptamine which had been synthesised in 19516 . 
Serotonin was then discovered to be present within the mammalian central 
nervous system (CNS)^ and was postulated to be an invertebrate 
neurohormone^.
In the years since the mid 1950's serotonin has been studied quite extensively 
(over 1000 research papers on 5-HT have been published each year in the 
1990's). Serotonin is now known to be an important neurotransmitter in the CNS 
and is present in high concentrations in the blood platelets and the 
enterochromaffin cells of the gastrointestinal tract. 5-HT mediates its 
physiological effects from the interaction with an increasing number of 5-HT  
receptors and has been implicated in conditions such as obesity^, m igraine^, 
anxietyll, schizophrenia^, sleep s and several other processes.
H
(1)
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1.1.2 5-HT Receptors
Gaddum and Picarellil4? first suggested in 1957 that there may be multiple 5-HT  
receptors from a study of antagonists upon a guinea pig ileum preparation. It 
was found that 5-HT caused contraction of the ileum by two different 
mechanisms, one of which was blocked by dibenzyline (D-receptors) and the 
other by morphine (M-receptors). This work paved the way for others and in 
1979 two distinct 5-HT recognition sites were identified^ using radioligand 
binding. Since these early findings numerous other 5-HT binding sites have 
been identified and with the development of molecular biology many 5-HT  
receptors have been cloned and amino acid sequences deduced. Pharmacological 
characterisation has allowed matching of these cloned receptors to in vivo 5-HT 
binding sites. Some excellent reviews of the molecular biology of the 5-HT 
receptors 16-21 ancj 0 f  the pharmacology of 5-HT receptors^2-25 have been 
published. This introduction does not try to emulate these papers but attempts to 
give the reader an overview of the 5-HT receptors.
The 5-HT receptors are presently classified according to Hoyer et al.26 where 
the receptors have been divided into subfamilies dependant upon operational, 
transductional and structural characteristics. At present there are at least seven 
subtypes of 5-HT receptors, 5-HTj to 5-HT7 (Table 1), some of these are 
already known to be heterogeneous and it is suspected that others may also be.
The 5-HTj family exists as at least 5 subtypes 5-HTj A j 5 -H T jg , 5-HT^p), 
5-h tjg  and 5-ht|p receptors. Lower case notation is used to denote recombinant 
receptors with no decisive functional data. All these receptors belong to the 
superfamily of receptors that interact with their secondary messenger through the 
activation of a guanine-nucleotide binding protein and are thus known as
2
G-protein coupled receptors (GPCRs). The 5-HTj subfamily all inhibit the 
enzyme adenylyl cylase (the secondary messenger) and it may be possible that 
some of these receptors can also interact with other secondary messengers. 
Genes encoding two 5-HT id  receptor subtypes have been cloned and these have 
been designated the 5-H T iD a and 5-HTiDp receptors^?. The 5-H TjD p  
receptor is considered to be the non-rodent species homologue of the 5 -H T jg  
recep tor^  and is sometimes also referred to as a 5-H T jg  receptor. The receptor 
nomenclature of the 5-HTj d  receptors is known to be far from ideal^9 and a 
more general nomenclature has been proposed recently^.
The 5-HT2 receptor family is also heterogeneous and at present comprises of the 
5-HT2A) 5-HT2B and 5-HT2C receptors. All are GPCRs and are coupled 
preferentially to phospholipase C, hence receptor activation leads to stimulation 
of phosphatidyl inositol metabolism.
The 5-HT3 receptor seems to be the odd one out as it does not belong to the 
GPCR family but is a ligand gated ion channel. Receptor activation leads to the 
opening of a transmembrane ion channel. Evidence is presently gathering that 
this subfamily may indeed be heterogeneous.
The 5-HT4 receptor is positively coupled to adenylyl cylase and structurally 
belongs to the GPCRs. 5-ht5A and 5-ht5g  receptors are recombinant G-protein 
coupled receptors with at present no transductional data or functional role hence 
the lower case notation. The 5-HT5 receptor which has a similar pharmacology 
to the 5-HTj subtype, is a GPCR but shows poor structural homology to the 
other 5-HT receptors and is positively coupled to adenylyl cylase. Similarly the 
5-HT7 receptor is a GPCR, is positively coupled to adenylyl cylase but exhibits 
limited structural homology with other 5-HT subtypes.
3
There is also a number of 5-HT receptors that have been identified but do not 
satisfy the criteria for any subtype within the present classification system^6 and 
are known as "orphan" 5-HT receptors.
Receptor
Name
Previous Name Family Secondary
Messenger
Sequence Information
5-H T j a GPCR -A C 421 aa human
5-H T1b GPCR -A C 386 aarat
5-H T1D GPCR -A C 377 aa human 5 -H T idcc 
390 aa human 5 -H T id b
5-htiE GPCR -A C 365 aa human
5-htjp 5-HTi e b , 5-HT6 GPCR -A C 366 aa human
5-HT2a D, 5-HT2 GPCR +  PI 471 aa human
5-HT2B 5-HT2F GPCR +  PI 479 aa rat
5-HT2C 5-HT1C GPCR +  PI 458 aa human
5-HT3 M Ligand gated 
ion channel
487 aa mouse ion channel unit
5-HT4 GPCR +  AC Splice variants 
rat 407aa 5-HT4L  
rat 397aa 5-HT4S
5-ht5A 5-HT5 a GPCR Unknown 357 aa mouse, rat
5-ht5B 5-HT5B GPCR Unknown 370 aa mouse 371 aa rat
5-HT6 GPCR +  AC 437 aa rat
5-HT7 GPCR +  AC 448 aa mouse 446 aa g-pig
-  A C  n e g a tiv e ly  co u p led  to  ad en y ly l cy la se , +  A C  p o sitiv ely  co u p led  to  ad en y ly l c y la s e , +  P I  
p o sitiv e ly  cou p led  to  p h osp h olipase C .
Table 1 5-HT Receptor Subtypes
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Many compounds have been evaluated for biological activity at the 5-HT 
receptors and many high affinity agonists and antagonists are known. Due to the 
great wealth of information on 5-HT receptor ligands the subject is not reviewed 
here but the reader is directed to the reviews of 5-HT receptors 16-26 jn the 
1990's there has been a massive increase in 5-HT receptor research and this has 
been attributed to the increasing number of receptors and hence possible drug 
targets. One of the main areas of 5-HT related research has been that of migraine 
headache where many of the major pharmaceutical companies have been 
competing to develop compounds with antimigraine efficacy.
1.1.3 5-HT and migraine
Migraine headache affects many people causing considerable misery and 
disruption to everyday life for sufferers. 5-HT has long been associated with the 
pathophysiology of migraine headache and in 1960 it was discovered^ 1 that 
intravenous injection of 5-HT relieved migraine. Furthermore, 5-HT metabolites 
have been identified in the urine of patients during a migraine a ttack ^ . The use 
of 5-HT to treat migraine is unfortunately littered by unwanted side effects such 
as nausea and faintness^ however a number of other 5-HT related drugs have 
been used in the fight against migraine.
Prophylactic agents that are available which reduce the frequency and severity of 
attack include pizotifen, cyproheptadine and methysergide^^ which all show 
antagonistic activity at the 5-HT2 receptors. It is conceivable that these drugs 
may exert their effects centrally^ ^  possibly via the 5-HT2C receptor since all 
these compounds show high affinity for this subtype and the 5-HT2C receptor 
agonist m-chlorophenylpiperazine (m-CPP) has been found to trigger migraine 
like headaches in humans^ 5. Ergot compounds such as ergotamine (2) and 
dihydroergotamine (3) which are 5-HT\ agonists are known to relieve migraine
5
in 70%  of patients and are used as abortive antimigraine th erap ies^ . However 
chronic side effects have been experienced by patients.
The discovery of sumatriptan^ 7,3 8 (G R43175) (4) which was described as a 
novel selective agonist at 5-HT j like receptors in dog saphenous vein heralded a 
major breakthrough in the understanding and treatment of migraine. A review of 
the discovery of sumatriptan has been published by Oxford-^
H
Sumatriptan was shown to be effective in acute treatment of migraine^O and was 
found to bind with high affinity to 5-HTjp) sites with a moderate 5-fold 
selectivity over 5-HTj a  sites and was essentially inactive at numerous other
6
neurotransmitter binding sites^l. Comparison of the pharmacology of 
sumatriptan with that of dihydroergotamine showed both compounds shared 
affinity for 5-HT j a  and 5-HTjp) sites and suggested that the 5-HTjp) receptors 
may play an important role in migraine re lie f^ . This claim was disputed^ due 
to the inability of metergoline, a putative 5-HTj /5-HT2 antagonist, to block the 
effects of sumatriptan on the dog saphenous vein. This was resolved when it 
was found44 that metergoline acted as a partial agonist at cloned 5-HTuyp  
receptors^. This could explain the actions of metergoline on the dog saphenous 
vein and it was further suggested^ that sumatriptan may well exert its 
therapeutic effects by interaction with the 5-HTjp)p receptor.
The cloning of two subtypes of the 5-H T j d  receptor took the debate one step 
further since sumatriptan showed high binding affinity at both the cloned 
5-HTip)a  and the 5-HTip)p receptors^?. Therefore a number o f questions had 
to be answered such as, if sumatriptan elicits its pharmacological effects through 
a 5-HT j like receptor, is there a common receptor pathway and does it 
correspond to the 5-HTi d  receptors, and if so could it be the 5 -H T jj)a  or the 
5-HTiDp receptor.
Further studies of the potencies of agonists on the canine coronary artery and 
saphenous vein46 gave a relative order of potencies that was consistent with a 5- 
H T i d  receptor and confirmed the presence of 5-HTjp) mRNA. The authors 
concluded that the dog saphenous vein contains a 5-H T jj)LIKE receptor but this 
cannot be proved until more selective 5-HT j d  agents become available. This 
may also provide an explanation as to why sumatriptan may cause symptoms 
related to coronary artery constriction. Just as the site of action of sumatriptan 
has been debated the mechanism of action has also led to great d e b a te ^ >48 
Two mechanisms of action have been proposed, a vascular mechanism and a 
neurogenic mechanism, both believed to be peripheral since sumatriptan crosses
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the blood brain barrier poorly49,50 The vascular theory suggests that 
sumatriptan acts on postjunctional receptors and constricts cerebral arteries 
which have dilated during migraine. The neurogenic theory proposes that 
antimigraine drugs could block the release of pro-inflammatory 
neurotransmitters from trigeminovascular nerve endings within the meninges by 
the stimulation of presynaptic autoreceptors.
Rebeck et al.51 have demonstrated the presence of 5-H T iD a receptor mRNA in 
guinea pig trigeminal ganglia and human post-mortem trigeminal ganglia and 
propose that the development of selective 5-HT j D a agonists may lead to 
antimigraine therapies with a reduced risk of side effects such as stroke. It has 
also been shown^^ that in human and bovine cerebral arteries the 5-HT i Dp 
receptor gene is present and this receptor may mediate the cerebral vascular 
action of sumatriptan.
Summarising, two mechanisms have been proposed for the mode of action of 
sumatriptan each implying the involvement of a different receptor. A vascular 
mechanism has been postulated, possibly mediated through a 5-HT i Dp receptor. 
A neurogenic mechanism has also been postulated, possibly involving the 
5-HT j D a receptor. It is not known which mechanism is of primary importance. 
It may also be possible that these antimigraine drugs may induce their effects 
through a different receptor (5-HT or otherwise). The whole issue has been 
twisted a little further by the discovery of 311C9C)53 (5), a 5-HT i d  agonist 
which is known to activate trigeminovascular neurons both centrally and 
peripherally^. This has been compared to sumatriptan which is thought to have 
only peripheral effects and adds the possibility that central activity may be 
advantageous in the treatment of migraine. An excellent review on the 
involvement of 5-HT in migraine has recently been published^.
8
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The potential "blockbuster" status of sumatriptan has prompted many of the 
major pharmaceutical companies to develop other indole type compounds with 
antimigraine potential. Merck, Sharp and Dohme have developed 
L 694 ,24756>57 (6) and M K-046258>59 (7). SmithKline Beecham have been 
studying conformationally restricted 5-H T jd  a g o n ists^  and Pfizer also have 
been looking at conformationally restricted compounds^ l s62 Several other 
laboratories have also been active in studying 5-H T jj) receptor a g o n is t s ^ 8. 
It has therefore became apparent that to aid a better global understanding of  
antimigraine drugs there is a need for more selective ligands.
9
The use of molecular modelling has played an important part in rational drug 
design by using receptor mapping and structure affinity type studies. If the 
binding of agonists to the 5-HT receptors can be rationalised this will prove an 
invaluable tool in designing selective ligands. This project attempts to construct 
useful molecular models of the human 5-HT j d  receptors. Through a study of  
the binding site of these receptor models it may be possible to design and 
subsequently synthesise new heterocyclic ligands to probe the binding site 
further and possibly improve receptor selectivity. The 5-HT i d  receptors and 
indeed all 5-HT receptors except 5-HT3 belong to the GPCR superfamily. 
Therefore it is pertinent to this study to discuss the structure and modelling of  
GPCRs.
1.1.4 Structure and modelling of GPCRs
1.1.4.1 G-protein coupled receptor activation
The family of receptor proteins that interact with guanine-nucleotide binding 
proteins (GPCRs) is extremely diverse and covers sensory, small molecule, 
peptide and glycoprotein hormone receptors. Each of these integral membrane 
receptors has a common structure of seven putative membrane spanning 
a-helices (see section 1 .1 .4.2) and upon agonist activation the receptor interacts 
with its respective secondary messenger via a heterotrimeric G-protein.
The G-proteins belong to the large family of GTPase proteins and consist of a ,  p 
and y subunits. Upon activation of a GPCR the activated receptor interacts with 
the GDP bound inactive form of Ga  leading to the exchange of GDP for GTP 
and resulting in the dissociation of Ga  from both Gpy and the receptor. 
Ga -GTP can then interact with the respective secondary messenger (in some 
cases Gpy can also interact with the secondary messenger). The system returns 
to the inactive state when the bound GTP is hydrolysed back to GDP by the
10
intrinsic GTPase activity of the Ga  subunit. The a , p and y subunits of the 
G-protein then reassociate and the system is ready to be activated once again. At 
present the a , p and y protein families consist of 18, 5 and 7 distinct multiple 
subunits respectively^,70 and the crystal structures of some of these subunits 
have been elucidated^
1.1.4.2 Structure of GPCRs
The first GPCR to be studied in any great detail was the visual pigment 
rhodopsin. Rhodopsin is the photoreceptor membrane protein of rod cells in the 
vertebrate retina and is made up of a protein structure covalently attached to an 
11-cis retinal chromophore. Light activation of the chromophore initiates a 
cascade of events sending electrical impulses to the brain. Bovine rhodopsin 
was the first GPCR to be completely sequenced in 1982^4 and this was followed 
by human rhodopsin in 1984^5. Analysis of the protein sequences^,75 showed 
the presence of seven areas of high hydrophobicity. Biophysical and 
biochemical experiments have led to the deduction that the receptor contains 
seven transmembrane regions that were likely to be antiparallel a-helices. This 
work has been covered in three extensive reviews76-78 ancj allowed the proposal 
of 2-dimensional models for rhodopsin^^.
The availability of a low resolution 3-dimensional structure of the 
transmembrane protein bacteriorhodopsin^O allowed the work to be taken one 
step further. Although bacteriorhodopsin is not a GPCR it does have similarities 
to rhodopsin in that both consist of seven transmembrane helices and both bind a 
retinal chromophore to a lysine residue upon putative helix 7. However there is 
no sequence homology between the two proteins. Findlay and Pappin^? used 
the low resolution structure of bacteriorhodopsin in combination with structural 
predictions^ 1 and the proposed helix connectivity of Engelman et al.82 to
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construct the first, albeit crude, molecular model of the GPCR rhodopsin. The 
model showed that the likely ligand binding site was based within the 
transmembrane core region, with acidic residues being possible candidates as 
counterions for the positively charged Schiff s base attachment between the 
retinal chromophore and a lysine residue on helix 7.
Around the same time in 1986 the cloning and amino acid sequence o f the 
p2-adrenergic receptor which binds R-(-)-adrenaline (8) and R-(-)-noradrenaline
(9) as the natural agonists was reported^. This was the first neurotransmitter 
GPCR to be sequenced. Analysis of the receptor sequence also predicted that 
the protein consisted of seven hydrophobic stretches of 20-25 amino acids (the 
putative seven transmembrane helices) and exhibited significant sequence 
homology to the rhodopsin sequences^.
Many subsequent biochemical experiments took place upon the p-adrenergic 
receptors. Deletion mutagenesis indicated that the ligand binding site was in the 
transmembrane area of the receptor^ and further mutations showed that an 
aspartate residue on helix 2 had no effect on antagonist binding but reduced 
agonist binding^. Mutation of an aspartate residue of helix 3 showed 
significantly decreased agonist and antagonist binding and it was thus proposed 
that this residue may interact with the cationic amine of the natural ag o n ist^ , it 
was later found that the aspartate residue of helix 2 is conserved in almost all 
GPCRs whereas the aspartate of helix 3 is only conserved in all cationic amine 
neurotransmitter GPCRs. A 2-dimensional model, which was similar to that of
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rhodopsin79, 0f  how the receptor was arranged in the membrane was then 
proposed^ and consisted of seven transmembrane antiparallel a-helices with an 
extracellular N-terminus and cytoplasmic C-terminus. The N-terminus is known 
to be glycosylated86,87 ancj the C-terminal region can be phosphorylated^.
From a structural viewpoint Dohlman et al.%% studied the similarities of the 
postulated structures of rhodopsin and the p2-adrenergic receptor suggesting 
roles for transmembrane proline residues and that the third intracellular loop may 
be involved in G-protein coupling. The role of the third intracellular loop in G- 
protein coupling was confirmed later in 1987 from deletion mutagenesis
studies*^.
In 1988 the studies of the P-adrenergic receptors continued and in a rev iew ^  of  
the work carried out in the previous year it was speculated^ that a rhodopsin- 
like structure was increasingly likely to be the case for the P-adrenergic 
receptors. Further mutagenesis of the aspartates on helices 2 and 3^1 allowed 
the authors to propose an overlapping but not identical binding site for agonists 
and antagonists. It was proposed^! that in the agonist binding site the 
protonated amine of the ligand interacts with the aspartate of helix 3 and the 
aromatic moiety lies between helices 3, 4, 5, 6 and 7. The conserved aspartate of  
helix 2 was thought to play a role in maintaining the agonist bound 
conform ation^. Studies of chimeras of the P1/P2 adrenergic receptors have 
revealed that helix 4 participates in ligand specificity and helices 6 and 7 play a 
role in antagonist selectivity^.
Work with peptide antibodies convinced Wang and co-workers^-^ of the helical 
model and the authors speculated that this structure may be true for all 
membrane proteins belonging to the GPCR family. Using mutagenesis and 
chemical modification it was demonstrated^ that for the P2~adrenergic receptor
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the meta-hydroxyl of catecholamine agonists hydrogen bonds with SER 204 of 
helix 5 and the para-hy&xoxyX similarly hydrogen bonds with SER207 also of 
helix 5. A  topological model of the P2-adrenergic receptor agonist binding site 
was then proposed^ (Figure 1). Evidence was also accumulating for the role of 
a putative disulfide bond between cysteines on extracellular loops 1 and 2 
respectively^. This structural work on the adrenergic receptors has been 
reviewed96-98 covering the majority o f the experiments leading up to the 
proposed topology of the receptors in greater detail than is presented here. The 
conclusions of the adrenergic receptor studies has been the acceptance of the 
general assumption that the GPCRs encode a family of receptors whose 
membrane structure consists of seven antiparallel a-helices with extracellular N- 
terminus and cytoplasmic C-terminus. The structure and function of GPCRs in 
general has been reviewed99-101
Figure 1 Model of the P2-adrenergic receptor viewed from outside the cell
During the work on the adrenergic receptors a new GPCR was cloned 102 which 
had significant sequence homology with the P2-adrenergic receptor and was later 
identified as the human 5-HTj a  receptor, the first 5-HT receptor to be cloned 
and sequenced
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The amount of published work on the GPCRs since that first bovine rhodopsin 
sequence^ has been phenomenal with over 700 (including species variants) 
GPCR sequences known.
1.1.4.3 Mutation studies of the 5-HT receptors
There is also some limited mutagenesis data available for the 5-HT receptors 
which has greatly aided the modelling of these receptors. The 5-HT receptors 
are classed as belonging to the cationic amine neurotransmitter receptors, so 
called, since at physiological pH the natural agonist is characterised as having a 
protonated amine moiety and also includes adrenergic, muscarinic, dopaminergic 
and histamine receptors. This protonated amine group is generally thought to 
interact with an acidic residue of the receptor and this interaction is believed to 
be the primary interaction point of 5-HT receptor ligands with the receptors.
As with the p-adrenergic receptors^,91 two primary agonist binding sites have 
been proposed, the conserved aspartates of helices 2 and 3. Mutation of these 
residues to asparagine in the 5 -HTj a  r e c e p t o r ASP82-ASN and ASP 116- 
ASN gave a 60-100 fold decrease in affinity for 5-HT and it was suggested that 
both these residues may take part in agonist binding. Mutations of the same 
residues of the 5-HT2A receptor 105 ASP120-ASN and ASP155-ASN indicated 
similar results. The ASP120-ASN mutant showed a decreased and GTP- 
insensitive binding of agonists. Reduced binding affinity of agonists and 
antagonists was also observed for the ASP155-ASN mutant, however GTP 
sensitivity was retained. The results prompted the proposal that the aspartate of  
helix 3 was required for high affinity binding probably acting as a counterion for 
the protonated amine moiety and that the aspartate of helix 2 was necessary for 
allosteric activation of the G-protein.
15
Helix 5 mutants of the 5-HT j a  receptor SERI 98-ALA and TH R 199-A LA 104 
both exhibited a significant decrease in agonist affinity and for the THR200- 
A LA mutant the binding of agonists was not even detectable. A mutant of the 
human 5-HT2A receptor SER 242-A LA 106 (which does not correspond to the 
above serine or threonine residues of the 5-HT i a  receptor) was found to alter 
the pharmacology of the receptor to that of the rat 5-HT2A receptor. The inverse 
of this mutation has also been s t u d i e d M u t a t i o n  of A LA 242-SER  of the rat 
5-HT2A receptor resulted in a receptor which was similar to the 5-HT2A human 
receptor.
Mutations of helix 6 have centred around two conserved phenylalanine residues. 
Mutation of PH E339-LEU  and PH E340-LEU  in the 5-HT2A receptors have 
been investigated! 08. The PH E340-LEU mutation abolished the binding of 
agonists and some ergot derivatives but did not affect the 5-HT antagonist 
ketanserin (10) whereas the PH E339-LEU mutation only influenced ketanserin 
binding.
F
( 10)
The majority of the mutagenesis studies on helix 7 have been concerned with the 
residue equivalent to ASN385 of the 5-HTj a  receptor. Mutation of this residue 
of the 5 -HTj a  receptor to valine 109 resulted in a receptor with a significant
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decrease in affinity for the aryloxyalkylamine p-adrenergic antagonists e.g. 
S-(-)-propranolol (11) but only slightly altered the affinities of other 5-HT  
receptor agonists and antagonists. The human 5-HT i d  receptors have a 
threonine residue in the corresponding position and mutation of this in the 
5-HTip>p receptor to asparagine (THR355-ASN) resulted in a receptor 
pharmacology that resembled the rodent 5 -H T jg  receptor. This mutant receptor 
had a higher affinity for the aryloxyalkylamine p-adrenergic antagonists and a 
lower affinity for sumatriptan 110 - 1 1 2 , a  further publication 1 13 demonstrated 
that mutation of this threonine residue of the 5-H T jD a’ 5-HTjDp and 5-htu? 
receptors and the corresponding alanine of the 5-htjp receptor to asparagine 
increased the affinity for the p-adrenergic antagonists by 100-1000 fold without 
changing the affinity for 5-HT.
Other helix 7 residues of the 5-HT \ a  receptor have been mutated 114. Mutation 
of ASN396 to alanine, valine or phenylalanine decreased the binding affinity of  
the 5-HT j a  selective agonist 8-hydroxy-2-(di-«-propylamino)tetralin (8-OH- 
DPAT, 12) but the conserved change to glutamine had little effect. In addition, 
mutations of SER391 and SER393 to alanine were studied 114. The changing of  
SER391 had no effect but the SER393-ALA mutant reduced ligand binding. 
The authors then proposedl 14 that ASN396 may have either a structural role or a 
direct ligand binding role and SER393 may interact with the hydroxyl group of  
8-OH-DPAT.
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Deletion mutants of the 5-HT2A receptor have shown no loss of biological 
activity upon removal of the N-terminal and the majority of the C-terminal 
domains^ 15. 5-HT2A and 5-HT2C chimeric receptors have also been studied 
and it was discovered that structurally diverse 5-HT2A antagonists utilise 
distinct regions of the 5-HT2A receptor when binding! 16. The mutagenesis 
work on the 5-HT receptors up to 1993 has been reviewed! 17,118.
The growing wealth of mutation data available for the 5-HT receptors and indeed 
GPCRs in general leads to the temptation of assuming that any change in binding 
affinity associated with a mutant receptor implies a direct ligand interaction with 
the mutated residue. However this is not necessarily true and a change in affinity 
may be the result of a conformational change in the protein. Nevertheless the 
mutation work has been extremely useful, not only in aiding the modelling of 
these receptor but in the overall understanding of ligand binding and signal 
transduction of GPCRs.
1.1.4.4 Approaches to modelling GPCRs
With the advent of molecular modelling in the 1980's there has been a great 
interest in constructing molecular models of G-protein coupled receptors. These 
models have been created for two reasons; to aid our understanding of the
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requirements for ligand binding with a view to rational drug design, and perhaps 
more importantly, to allow the design of new experiments to investigate further 
the structure function relationships of these receptors.
At present there are no 3-dimensional crystal structure coordinates available for 
any G-protein coupled receptor. This has therefore rendered the molecular 
modelling of these GPCRs generally difficult and certainly quite speculative. As 
described previously biochemical and biophysical experiments have led to the 
conclusion that GPCRs are composed of seven helices.
The bacterial membrane protein bacteriorhodopsin has been the focus of many 
structural studies which resulted in the publication of a low resolution electron 
density map in 1975^0 showing seven transmembrane domains believed to be a -  
helices. Despite its name, bacteriorhodopsin is not a GPCR and is functionally 
unrelated to the GPCR rhodopsin and hence exhibits very little sequence 
homology with rhodopsin. A higher resolution structure of bacteriorhodopsin 
was revealed some 15 years l a t e r p r o v i d i n g  atomic coordinates of the 
membrane portion of the protein. At that time Henderson and Schertler 
discussed the similarities of bacteriorhodopsin and rhodopsin120 Although 
both proteins are certainly functionally different similarities do exist. Both 
proteins are activated by a light induced isomerisation of a retinal chromophore 
attached covalently to a lysine residue on putative helix 7. Both proteins also 
consist of seven antiparallel transmembrane a-helices with extracellular N- 
terminus and intracellular C-terminus leading to the proposal 120 that GPCRs 
and bacteriorhodopsin may share the same topology (Figure 2).
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Figure 2 Representation of the topology of bacteriorhodopsin as viewed from
the extracellular surface
In 1993 a significant breakthrough cam el21 when 2-dimensional crystals of  
bovine rhodopsin were obtained and a low resolution projection density map was 
calculated. This demonstrated experimentally for the first time the proposed 
seven helical structure of rhodopsin. On comparison with bacteriorhodopsin, the 
rhodopsin map was found to be less elongated and the helices were tilted 
differently. The projection map however provided no evidence of helix order 
and connectivity, thus Baldwin 122 studied the alignment of 204 GPCR  
sequences. Transmembrane helices were identified and plotted around helical 
wheels which were arranged to give an arrangement where each helix is adjacent 
in 3-dimensions to the helix next to it in the amino acid sequence, and the helices 
run clockwise as viewed from the cytoplasmic side. This arrangement was 
shown to be similar to that of the rhodopsin m ap!21 and allowed the tentative 
identification of peaks from that map, concluding that although rhodopsin shows 
a similar structure to bacteriorhodopsin there are definitely differences. It has 
been speculated 123 that the differences could be attributed to a 15° rotation 
around the axis perpendicular to the seven helices passing through helix 3 and 
that this may be caused by differences in crystallisation.
A low resolution 3-dimensional structure of bovine rhodopsin was then 
determined!24 in 1995. This allowed the identification of four of the seven a -  
helices where the remaining three were unresolved but it does correspond well
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with the work o f B a ld w in ^  ancj js certainly different from bacteriorhodopsin. 
A 2-dimensional projection map o f frog rhodopsin has also been calculated 125 
and this shows a very similar structure to that o f  bovine rhodopsin^l and puts 
the speculation! 23 regarding differences in crystallisation into grave doubt. It is 
also worth noting that in 1996 a revised set o f bacteriorhodopsin coordinates 
were made available 126 where the position o f the fourth helix has been 
modified.
For most molecular models o f GPCRs the starting point has been the sequence 
alignment o f the GPCRs which when combined with hydropathy analysis (e.g. 
Kyte and Doolittle 127) has allowed the identification o f the seven membrane 
spanning helices. From this common starting point some models have used a 
"de novo" approach where no assumptions o f the helix arrangements have been 
made, however by far the majority o f GPCR models have used the 1990 3- 
dimensional coordinates o f bacteriorhodopsinll^ either by attempting to align 
the GPCR sequence with bacteriorhodopsin or by using the arrangement o f  
helices as a template. More recently (1993 onwards) some models have utilised 
the bovine rhodopsin 2-dimensional map!21 and Baldwin's helix 
assignments 1 2 2 5 claiming that bacteriorhodopsin is not similar enough to the 
GPCRs to warrant its use in GPCR molecular modelling.
The following sections discuss some o f these models with particular attention 
being paid to the 5-HT receptor models. In the cationic amine neurotransmitters 
it is generally thought, from mutagenesis*^,91,104,105? that the protonated 
amine group will interact with the aspartate residue o f helix 3 which is only 
conserved in the cationic amine receptors. Therefore virtually all cationic amine 
neurotransmitter receptor models have used this residue as a counterion for the 
protonated amine during initial docking studies o f agonists. The models will be 
discussed according to the research group which produced them and it will
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become apparent that many research groups have changed their modelling 
strategy between publications.
1.1.4.5 Early models
The first published molecular model o f any GPCR7? used the low resolution 
structure o f bacteriorhodopsin^O to produce a 3-dimensional model o f  
rhodopsin^. Other early (pre-1990) models have been limited to the 
P2 -adrenergic receptors. Single helix models have been studied for the 
P2 -adrenergic receptor! 28-130 The low resolution map o f  bacteriorhodopsin^O 
was also used for a seven helix model o f the P2  receptor! 31 however the 
sequence o f helices ran clockwise from the extracellular surface which was later 
proven to be incorrect! 19.
1.1.4.6 Models from the University of Leeds
With an ever increasing number o f GPCRs being sequenced a discriminating 
fingerprint o f the GPCR sequences was developed 132 which could identify and 
align the GPCRs from primary structure analysis. This approach afforded a 
sequence alignment o f GPCRs which was used to construct molecular 
models^33 based upon the original rhodopsin molecular model^?. GPCR 
models developed from the 1990 bacteriorhodopsin structure using Fourier 
transforms 134 have also been published. In 1993 the low  resolution map o f  
rhodopsinl^l was used to construct a modified 3-dimensional rhodopsin 
model 135 which was to aid protein engineering studies. This model was 
extrapolated to other GPCRs including the adrenergic, muscarinic and 
neurokinin receptors 135 using the discriminating fingerprint approach!32,136 t0  
align the sequences, and the Fourier transform techniques developed by 
Donnelly et al. 132 to predict which face o f each helix is lipid accessible.
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By 1994 the fingerprint methodology had been used to locate and align 393 
GPCR sequences! 38 and a more detailed discussion o f this GPCR modelling 
work was published! 39. The predicted seven a-helices were identified, helices 
1, 2 and 7 were superimposed directly onto the equivalent helices o f  
bacteriorhodopsinl 19 and helices 3, 4, 5 and 6  were positioned according to the 
density map o f rhodopsin^l using interactive graphics. The helix connectivity 
o f Baldwin! 22 was assumed, which is the same as that o f bacteriorhodopsinl 19 
The internal faces and relative depths o f each helix were determined from the 
Fourier transform work o f Donnelly et at/. 137,140 a  detailed model o f  the 
P2 -adrenergic receptor 139 was then described. The adrenaline binding site was 
found to be between helices 3, 5, 6  and 7 with the cationic amine forming an ion 
pair with the aspartate o f helix 3 and the catechol hydroxyl groups hydrogen 
bonding with the serines o f helix 5. The binding site model o f the P2 ~adrenergic 
receptor was subsequently used to study other GPCR binding sites.
For the 5-HT receptors it was proposed!39 that the indole N-H o f 5-HT could 
interact with a serine or cysteine residue on helix 3 for the 5-HT2 and 5-HT \ 
subtypes respectively. The hydroxyl group formed a hydrogen bond to the 
serine/threonine residue on helix 5 which corresponds to one o f  the important 
serine residues that bind the catecholamines in the p2 -adrenergic receptor. The 
same modelling procedure was again used to construct a neurokinin NK/? 
receptor model 141. Donnelly and Findlay have also published a brief review 142 
o f some o f the modelling procedures that have been applied to GPCRs 
discussing in particular the use o f the bacteriorhodopsin structure!^ and the 
rhodopsin density m apl^l.
A homology model o f the muscarinic M} receptor 143 has been described using 
the early rhodopsin m odel^ . The docking o f agonists and antagonists prompted
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the proposal 1^3 that antagonists interact with an aspartate o f  helix 3 and block 
the entrance to the central cleft o f the receptors. Agonists similarly are 
thought 143 to bind to this residue then move down the central cleft to interact 
with the aspartate o f helix 2  and in some way induce a conformational change o f  
the receptor. This proposal has been updated 144 more recently.
1.1.4.7 Models from the University of Tromso, Norway
The group o f Dahl, Edvardsen and Syltel45,146? jn Norway, first produced a 
dopamine D 2  receptor model in 1990. Transmembrane helices, identified by 
hydrophobicity, were assumed to be 27 amino acids in length and were arranged 
in a circular antiparallel sequence running clockwise as viewed from outside the 
cell (opposite to that o f bacteriorhodopsin). Molecular dynamics simulations 
were then used to study the interactions o f dopamine within the receptor model.
The same modelling procedures were applied to the 5-HTj a  and 5-HT2A  
receptors, studying the potential binding modes o f some antipsychotic drugs 147. 
By 1992 the models were modifiedl48? still using a circular arrangement o f  a -  
helices, however the helices were now ordered anticlockwise as viewed from 
outside the cell. This was applied to the 5-HT2A receptor investigating the 
dynamics and electrostatics o f the binding o f 5-HT and the 5-HT2 receptor 
antagonist ritanserin (13)148.
It was found 148 that the protonated amine o f 5-HT could interact with the 
conserved aspartate on helix 2 and other residues situated upon helices 1, 3, 5 
and 7 whereas ritanserin formed strong interactions with the aspartates on helices 
2 and 3. A more detailed model o f  the 5-HT\ a  receptor was later published 149 
again using the anticlockwise arrangement o f helices. From molecular dynamics 
simulations o f 5-HT and other active compounds at this receptor the 5-HT
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binding site was proposed to include residues on helices 1, 2, 3 and 7 most 
notably the aspartate o f helix 2 but not the aspartate o f helix 3. The aromatic 
moiety o f 5-HT could form interactions with residues on helix 7 with the 
conserved tyrosine residue stacking against the phenyl ring o f  the ligand.
F
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A similar process was used!50 to study the interactions o f  the 5 -HT2  receptor 
antagonist ketanserin (10) with the 5-HT2A receptor. The protonated piperidine 
ring could interact with the aspartate o f helix 3 and favourable interactions were 
observed with residues upon the other six helices. The aspartates o f  helices 2 
and 3  were mutated on the model to asparagine and the mutant models exhibited 
a significant decrease in interaction energy between the ligand and receptor.
The models were modified once again in 1996 using the electron density map o f  
bovine rhodopsin^l and the helical arrangement proposed by B a ld w in !^  ancj 
the interactions o f some derivatives o f 8 -OH-DPAT with the 5-HTj a  receptor 
were described^ 1. The ligands were docked in order to form interactions 
between the protonated amine of the ligand and the aspartate residue o f helix 3. 
Following dynamics simulations, agonists were found to interact with both 
aspartates on helices 2 and 3 whereas antagonists did not show any interaction 
with the helix 2  aspartate.
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A  similar description o f the interactions o f  ketanserin, ritanserin and 5-HT with 
the 5-HT2C receptor has been published 152 5-HT was found to interact with 
the aspartate o f helix 3 and some helix 7 residues via the protonated amino 
sidechain. The indole N-H could interact with a serine residue o f helix 3 and the 
hydroxyl group could hydrogen bond to a serine o f helix 5 and an asparagine 
near the extracellular end o f helix 6 . It was further suggested that the structural 
differences o f the antagonists ketanserin and ritanserin afforded non-identical 
overlapping binding sites. Differences in binding affinity between the two 
antagonists were proposed to arise from interactions with cysteine and serine 
residues on helices 7 and 3 respectively.
It has become increasingly evident that the dynamical simulations described by 
this group 145-152 have implied that a relatively high number o f residues are 
involved in ligand binding without much consistency between the different 5-HT 
receptor subtypes. This may be attributed to the dynamical approach adopted 
and this particular approach to modelling GPCRs has been described, by other 
workers in this area as rather ambitious
1.1.4.8 GPCR Modelling at Marion Merrell Dow
Much o f  the pioneering modelling work in the last six years has been carried out 
by Marcel Hibert and co-workers at Marion Merrell Dow in Strasbourg. The 
group constructed molecular models o f many GPCRs using the high resolution 
structure o f bacteriorhodopsinl 53-157_ Their modelling procedure used 
hydropathy indices and sequence alignments to identify the seven 
transmembrane a-helices. Transmembrane domains 3, 6  and 7 were positioned 
according to low sequence homology with the corresponding helices o f  
bacteriorhodopsin. At this point it is worth noting that the alignment o f  helix 3
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was changed, without reason, between the 1991 models153,154 an(j the more 
recent models 156,157 The remaining helices 1, 2, 4 and 5 were orientated to 
allow conserved and charged amino acids to protrude into the central core o f the 
receptor to give a similar overall structure to that o f bacteriorhodopsin.
Energy minimisation and ligand - receptor docking then provided some 
remarkable results for the cationic amine receptors. The cationic head group o f  
the ligands could interact with the aspartate residue on helix 3 and the ion pair 
was stabilised by a surrounding pocket o f aromatic residues. The conserved 
aspartate o f helix 2 was postulated to play an allosteric role. The catecholamines 
dopamine, adrenaline and noradrenaline could form hydrogen bonding 
interactions with two serines upon helix 5 (one serine is mutated for cysteine in 
the a 2 -adrenergic receptor) at their respective receptors.
Models o f the 5-HT2A receptor have also been described in some detail however 
only one o f the serine residues is present on helix 5 (threonine for 5-HTi 
subtype) and this could interact with the hydroxyl group o f 5-HT. The indole 
N-H was found to hydrogen bond with a serine on helix 4 and the aromatic 
portion o f the ligand could interact with conserved phenylalanines on helices 5 
and 6 . It was also proposed that conserved tryptophan and tyrosine residues on 
helices 6  and 7 respectively can form hydrogen bonds with the conserved 
aspartate o f helix 3 in the inactivated receptor and it was further suggested that 
upon ligand binding a conformational change would be induced involving one or 
both o f  these residues possibly leading to signal transduction.
This ligand activation process was updated^ 8  where it was suggested that the 
tyrosine o f helix 7 can interact with both important aspartate residues o f  helices 
2 and 3 ensuring a connection between the upper ligand binding region o f  the 
receptor and the lower G-protein coupling region o f the receptor. More recently
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detailed models using the same modelling procedures have been published for 
the transmembrane domains o f peptide receptors!59,160 and glycoprotein 
hormone receptors*^. An overview o f the group’s modelling o f GPCRs has 
also been published
In 1995 the original models were updated to account for the electron density 
footprint o f bovine rhodopsin^l. Dismissing their own speculative viewpoint 
that the differences between bacteriorhodopsin and rhodopsin could be 
accounted for by a 15° tilt o f the projection m a p l^  the original models were 
modified to obtain a "perfect match" o f calculated electron density with that o f  
rhodopsin 163. This produced structurally similar models which differed mainly 
in the tilt o f  specific helices. No revised binding site models were described for 
any o f the 5-HT receptors but the authors claimed that the models are 
"qualitatively excellent", identifying the correct ligand binding sites and 
accounting for the gathering wealth o f experimental data relating to ligand 
binding studies.
Due to the static nature o f the models the more subtle interaction differences 
between ligands could not be accounted for and it was suggested that it would be 
very difficult for those who are attempting to construct quantitatively useful 
models. The rhodopsin approach has since been used to produce molecular 
models (including loop regions) o f the V i a  vasopressin receptor!64,165
1.1.4.9 The models o f Glennon and W estkaemper
Glennon and Westkaemper originally constructed single helix models * 6 6  which 
examined the interactions o f various ligands with models o f helices 2 and 3 o f  
the 5-HT2A> 5-HT2C and 5-HT\ a  receptors. Docking was performed, 
permitting the protonated amine o f  the ligand to interact with the important
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aspartates o f both helices. From the calculated interaction energies it was 
demonstrated that the ligand - helix 3 complex was more favourable than the 
helix 2  complex and it was therefore concluded that the aspartate o f helix 3  was 
important for binding. The single helix models proved to be a springboard 
towards more detailed receptor models 167.
Models o f the 5-HT2A> 5-HT2C and 5-HT j a  receptors were built 167 usjng an 
alignment with bacteriorhodopsin. The alignment by helix centres was similar to 
that o f Hibert et al. 154 ancj was used directly without helical translation or 
rotation. Models o f the 5-HT2A> 5-HT2B and 5-HT2C were subsequently 
presented in much greater detail 168. Helical centres were aligned and 
graphically evaluated with the best alignment o f the centres used for the ligand 
docking experiments. The interactions o f the agonists 5-HT (1), (+)LSD (14) 
and (R)-(-)DOB (15) were assessed.
O
It was found that! 6 8  the indole ring o f 5-HT interacted with hydrophobic and 
aromatic residues o f helices 4, 5 and 6 , an ion pair was formed with the aspartate 
o f helix 3, and the 5-HT hydroxyl group hydrogen bonded with the serine 
residue o f helix 5. (+)LSD binds similarly to 5-HT but (R)-(-)DOB was able to 
interact in two distinct manners both maintaining the aspartate - amine ion pair,
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and characterised by the position o f the methoxy groups. Preliminary results o f  
this study have also been p u b lish ed ^
The 5-HT2A receptor model was used in a mutagenesis study170 correlating the 
binding affinities o f simple ergolines (e.g. ergonovine (16)) and ergopeptines 
(e.g. ergotamine (2)) with respect to mutations o f PHE340 and PHE339 o f helix 
6.
OH
The binding o f all simple ergolines was decreased by the non-conserved 
mutation o f  PHE340 and unaffected by PHE339 mutations. This is in contrast to 
the binding affinities o f the ergopeptines which were unaffected by either 
mutation. These findings were supported by the molecular models which show  
that simple ergolines can interact with PHE340, but because o f their more 
sterically demanding C- 8  position, the ergopeptines could not adopt the 
orientation observed for the ergolines and are too far away to interact with either 
phenylalanine.
Further models o f the 5-H T u)a , 5-HT]£)p and 5-HT^g receptors were 
published in an overview o f 5-HTi d  r ecep to rs^ . These models were used to
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discuss non-conserved residues in the possible binding site and the importance o f  
a threonine residue o f helix 7 was suggested. When this residue is mutated to 
asparagine as is observed for the 5-HTj a  and 5-HTj b  receptors the mutant 
receptors show a dramatic increase in affinity for the P2 "a<frenergic receptor 
antagonists * 10-113 which may be indicative o f a ligand receptor hydrogen bond 
interaction. This point has been investigated further 172 >
Mutation o f THR355 o f the 5-HTijyp receptor to ASN increased the affinity for 
the p2 -adrenergic antagonist (-)-propranolol (11)172 The previously 
constructed 5-HTjp)p model was used to create the mutant model^^l. 
(-)-Propranolol was docked into both the wild type and mutant models with the 
naphthyl ring towards helices 1, 2 and 7 and the protonated amine o f  the ligand 
interacting with the aspartate o f helix 3. The models suggested that the threonine 
o f the wild type 5-HT jp>p receptor can interact with the ether oxygen but not the 
hydroxyl group o f the ligand. The mutant receptor model showed a different 
picture, both oxygens o f the ligand could form hydrogen bonds with the 
asparagine sidechain suggesting that both these hydrogen bonds are crucial for 
the high affinity binding o f (-)-propranolol. This has been further supported 172 
by binding studies o f analogs o f (-)-propranolol that lacked either one or both o f  
the oxygens.
1.1.4.10 The 5-HTid  receptor models of Smolyar and Osman
The mutation o f THR355 o f the human 5-HTip>p receptor to asparagine alters 
the pharmacology o f the receptor to that o f the rodent 5 -H T |g  receptor 110-112 
and this resulted in a 5 to 15 fold decrease in affinity for sumatriptan. Smolyar 
and O s m a n s  have addressed this point by investigating the interactions o f  
sumatriptan (4) with the human 5-HTjj) receptors. The 5-HTjp)a  receptor was 
modelled using the general topology o f bacteriorhodopsin and sumatriptan was
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docked into the model, creating the protonated amine - aspartate helix 3 
interaction and so that the sulfone group was near to the threonine residue 
(THR342 for 5-HTip)a ). The complex was refined by energy minimisation and 
subjected to a dynamics simulation.
Sumatriptan was found to be surrounded by 14 residues and the aspartate - amine 
ion pair was maintained. Interactions with the residues were monitored 
throughout the simulation and it was observed that the threonine residue had 
turned away from the ligand and formed a hydrogen bond with the helical 
backbone. This change o f interaction prompted the authors to p r o p o s e ^  that 
this hydrogen bond stabilises the ligand - receptor complex. Mutation o f  the 
threonine residue to asparagine would not allow this stabilisation and hence 
would alter the affinity o f sumatriptan. It was further suggested^  that this 
indirect effect is totally different from the change in binding affinity observed 
with some p2 -adrenergic antagonists where the large increase in affinity 
accompanied by the THR-ASN mutation suggests a direct effect o f the residue. 
Osman has also co-authored a series o f papers modelling the thyrotropin 
releasing hormone174-177 using Baldwins analysis o f sequences'122
1.1.4.11 Models from Uppsala University and Astra pharmaceuticals
Nordvall and H acksell^^ initially modelled the muscarinic M \ receptor based 
upon the bacteriorhodopsin structure 1 ^ .  A strict alignment with 
bacteriorhodopsin was applied which was derived from assessing the feasibility 
o f several different alignments using experimental data and analysis o f  
conserved and hydrophobic amino acids. The process rejected all but one o f  the 
alignments studied therefore this was used to model the receptor. The model 
was used to investigate the interactions o f some muscarinic agonists and later, to 
construct D 2 A and D 3  dopamine receptor models 179 #
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A 5-HTi a  receptor model 180 was used to account for the binding differences 
over the dopamine D 2 A receptor o f (R)-11 -hydroxy- 10-methylaporphine (17). 
The models suggest that the ligand can be accommodated at the 5-HT i a  
receptor with the protonated amine - aspartate helix 3 ion pair and aromatic 
interactions between the substituted phenyl ring o f the ligand and a 
phenylalanine o f helix 6 . The C-10 methyl group was found to be 
accommodated by a lipophilic pocket which is not present in the D 2 A  receptor 
and the methyl group thus caused steric repulsion. The increased van der Waals 
contact surface for (17) at the 5-HTj a  receptor was thought to account for its 
higher affinity for the 5-HTj a  receptor over the D2 A receptor. A  similar 
approach has been used* 81 to study the human galanin receptor.
1.1.4.12 The contribution of Harel Weinstein’s group
The group headed by Harel Weinstein has been one o f the most significant 
contributors to modelling and simulations o f GPCRs in the 1990s. The first 
computational simulation o f 5-HT receptor activation was published 182 jn 1 9 9 0  
and did not use a molecular model o f the receptor but a hypothetical model based 
upon the protein actinidin. After the publication o f the bacteriorhodopsin 
structure!^ a controversial alignment 183 0f  GPCR helices with 
bacteriorhodopsin was proposed. The assumption that the sequential order and 
packing arrangement o f GPCRs is the same as bacteriorhodopsin was
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questioned. It was proposed^ , from low sequence homologies, that GPCR 
sequences could be aligned with bacteriorhodopsin when the sequential order o f  
these helices is ignored.
A  further publication^  discussed some o f the criteria used in GPCR 
modelling. The "positive-inside" rule was described where positively charged 
lysine and arginine residues are found at the cytoplasmic ends o f the helices 
interacting with the phospholipid head groups o f the lipid bilayer. This 
work! 83,184 jater aided Zhang and W e in ste in ^  in modelling the 5-HT2A  
receptor. Full details o f the modelling procedure were not given but a 
topological template different from bacteriorhodopsin (Figure 3) was used where 
the relative positions o f the transmembrane helices differed from the more 
conventional models.
Figure 3 Representation o f Zhang and Weinstein’s 185 5-HT2A receptor model
viewed from the extracellular side
The ligand binding site incorporated the aspartate o f helix 3 and residues o f  
helices 5, 6  and 7 with a serine residue o f helix 7 forming a hydrogen bond with 
the hydroxyl group o f 5-HT. It was further discovered during molecular 
dynamics simulations o f the receptor complexed with various ligands, agonists 
would induce conformational changes in the backbone o f helices 5 and 6  but an
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antagonist would not. A  partial agonist studied, induced a change that was 
intermediate o f  the above extremes. It was therefore concluded that the induced 
change may be responsible for signal transduction.
Following the publication o f the low resolution rhodopsin m apl21? Zhang and 
Weinstein 186 stated that their model o f the 5-HT2A receptor has the same shape 
as the rhodopsin map. Previous work!85 was then extended to study the 
conformational changes induced by ligands which belong to diverse structural 
families 186. Correlation was found between ligand binding affinities and the 
ligand - helix 7 interaction energy, which was improved by adding the 
interaction energies between helix 7 and the other helices o f the receptor. 
Furthermore it was proposed 186 that a primary event in signal transduction 
could be the development o f an angular force acting upon helix 7 which is 
induced by agonist binding.
The dynamics trajectories o f the 5-HT2A receptor were subsequently used 187 to 
investigate the ligand-induced conformational changes o f  the transmembrane 
domains. An algorithm was developed which treated the ligand induced 
movement o f the helices as rigid domain movements. Results demonstrated that 
an agonist-induced torque upon helix 7 exerts movement o f  helix 6  which is 
directly attached to the large intracellular loop that is involved in G-protein 
coupling. Helix 4 was also affected which in turn moved helix 5 which is also 
connected to the third intracellular loop. When partial agonists were studied 
movements were still induced but by a smaller magnitude and antagonists 
exerted a torque opposing the movement o f the helices.
A double mutant^88 0f  the 5-HT2A receptor has been studied where the 
conserved aspartate o f helix 2  was mutated to asparagine resulting in loss o f  
receptor coupling. The reciprocal mutation o f a conserved asparagine o f  helix 7
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to aspartate restored this loss o f function, albeit lower than the wild type 
receptor. It was proposed that the restoration o f function by the double mutant 
was due to the direct interaction o f  the two residues probably by a hydrogen 
bond. The model o f Zhang and Weinstein! 85 was used 188 to construct the 
mutant models and results from ligand receptor binding interactions appeared to 
be consistent with the hydrogen bond theory.
The implications from the receptor - ligand simulations described 
previously! 85,187 were used! 89 to probe the 5-HT2A agonist binding site by 
mutagenesis. Mutation o f SERI 59 o f  helix 3 to alanine resulted in an 18 fold 
decrease in 5-HT binding affinity but unaffected (+)LSD (14). The mutation o f  
the same residue to cysteine gave only a 3 fold decrease in 5-HT binding affinity 
with again having no effect on (+)LSD. The 5-HT2A receptor model 185,187 
was used!89 to show that the protonated amine o f 5-HT can, additionally, form a 
hydrogen bond with this serine residue but the ring embedded nitrogen o f  
(+)LSD cannot form such an interaction.
Differences in helix 5 between the 5-HT2A and 5-HT2C receptors have also 
been investigated!90 Mutations o f the equivalent residues SER242-ALA for 
the 5-HT2A receptor and ALA222-SER for the 5-HT2C receptors were studied. 
Ergoline compounds with high affinity for the wild type 5-HT2C receptor now  
had a higher affinity for the mutant 5-HT2A receptor and vice versa. 
Indoleamines behaved differently and the 5-HT2A mutation decreased their 
binding affinity but the 5-HT2C mutation did not alter indoleamine binding 
affinity. These results were shown!90 to be consistent with the models. 
Ergoline compounds that are N -l unsubstituted (e.g. (+)LSD (14)) have a free 
N-H available for hydrogen bonding hence the higher affinity at receptors with a 
serine residue. Ergoline compounds that are substituted at the N -l position 
prefer the hydrophobic alanine residue o f the 5-HT2C wild type receptor.
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Models using the conventional order o f transmembrane helices have also been 
published for the gonadotropin-releasing hormone receptor!9 1>192 and the 
cannabinoid CBj receptor! 93. The entire process o f modelling GPCRs has been 
reviewed 1^4 however receptor binding sites are not discussed.
1.1.4.13 The 5-HTja  and 5-HT2A models of Taylor and Agarwal
Contrary to the controversial alignment o f Pardo et a l183 it has been 
hypothesised! 95 that any sequence homology between GPCR helices and 
bacteriorhodopsin may be explained by the process o f gene duplication. The 
bacteriorhodopsin structure! 19 was use(\ to produce homology models o f  the 
5-HTi A  and 5-HT2A receptors!96 The agonist binding process proposed is 
similar to that o f Saunders 144. An agonist initially interacts with the aspartate 
o f helix 3 then moves down the cleft to form similar interactions with the 
aspartate o f helix 2. This second residue is antagonist inaccessible and hence 
differences between agonists and antagonists can be accounted for!96.
1.1.4.14 The step by step procedure of Henri Moereels
Henri Moereels found that modelling GPCRs using bacteriorhodopsin was 
unsuccessful and decided to use a step by step procedure to model the 5-HT2A  
receptor! 97. Starting with 5-HT the way in which the hydroxyl group o f  the 
ligand could interact with helix 5 in isolation was examined. The energy 
minimised complex was used to model the interaction o f 5-HT with helix 5 o f  
the other 5-HT receptors which all showed a hydrogen bond between the 
hydroxyl group and a serine/threonine residue o f helix 5. The relevance o f  this 
hydrogen bond was then discussed and the possibility o f adding other helices to 
the model was mentioned. A similar model has been studied for the dopamine
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receptor 198. This model looks at the interactions between the natural agonist 
and helices 3, 4 and 5 o f the receptor with particular attention being paid to the 
roles o f  serine residues upon helix 5 and potential disulfide bonds.
1.1.4.15 Miscellaneous 5-HT receptor models
When studying the 5-HT receptor binding affinities o f N-hydroxytryptamine 
derivatives some o f  the 5-HT receptors were modelled 199 based upon the 
methods o f Hibertl54,156 The models were used!99 to explain why 
N-hydroxytryptamine was moderately selective for the 5-HT2C receptor. The 
models suggested that at the 5-HT j a  receptor the aspartate o f helix 3 interacted 
with the protonated amine o f the ligand and an asparagine residue o f helix 7. 
The equivalent residue to the asparagine o f the 5-HT2C receptor is a valine 
which leaves the aspartate residue o f helix 3 with a free oxygen which hydrogen 
bonds with the N-hydroxy group o f  the ligand in addition to the interaction with 
the protonated amine. This greater stabilisation is said to account for the 
differences in binding affinity.
The 5-HTi a  receptor has also been modelled^OO using a sequence alignment 
with bacteriorhodopsin. The agonist binding site was determined by a three 
point interaction o f the agonists, with the aspartate o f helix 3 and THR200 and 
SERI 99 o f helix 5. The selectivity o f 8-OH-DPAT (12) is accounted for by the 
hypothesis that one o f the bulky ^-propyl groups can form lipophilic interactions 
with small hydrophobic residues between helices 3 and 4 which are not present 
in the other 5-HT receptors. The aryloxypropanolamine antagonist binding site 
also involved the aspartate o f helix 3 but the aromatic moiety was in the region 
o f helices 1, 2 and 7. The model was further used in a study o f  structure-affinity 
relationships o f arylpiperazines at the 5-HTj a  receptor^ 1.
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Holtje had originally built a two helix model o f the 5-HT2A receptor using 
helices 2 and 3^02. This was recently updated^ 3 when a binding site model o f  
the 5-HT2A receptor around the antagonist ketanserin (10) was constructed. It 
was proposed203 that the fluorobenzoyl moiety o f the antagonist takes part in a 
charge transfer complex with an electron rich tryptophan residue and that the 
purpose o f the carbonyl group o f the ligand is to render the phenyl ring electron 
deficient and not to act as a hydrogen bond acceptor. This possibility was 
confirmed from modelling the interactions o f ketanserin with a truncated 
tryptophan residue. A  carboxylate anion was then positioned to interact with the 
protonated nitrogen and the binding site model was completed by the addition o f  
hydrophobic residues. Interaction energies o f ligands within this model 
correlated well with binding affinities and this correlation was improved when a 
correction was made to account for the charge transfer complex.
A remarkable success in the prediction o f affinities o f new compounds has been 
claimed203 an(j the model has been further modified by the addition o f a serine 
and a phenylalanine residue to account for agonists. A full molecular model o f  
the 5-HT2A receptor is now being constructed^^ using bacteriorhodopsin. 
Ketanserin has been docked into the initial model using the developed binding 
site as a guide and refinement of the ketanserin - receptor complex has resulted 
in a binding site comparable to the predicted binding site model^^^
Friedrich Rippmann has used a sequence alignment with bacteriorhodopsin to 
model GPCRs in particular the 5-HTj a  receptor204-206 Some 5-HT agonists 
have been docked into the aspartate helix 3 binding site and their affinities have 
been accounted for but a detailed publication o f this model is lacking.
A collaboration between some o f the more prominent workers in GPCR 
modelling and research has provided a greater insight into the possible mode o f
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interaction o f a number o f ligands at the 5-HT receptors^07 a  multiple 
sequence alignment o f many GPCRs has been used to correlate binding affinities 
o f ligands with the variability o f amino acid residues. Therefore without even 
building a model the residues that may confer specificity can be identified for the 
5-HT receptors. Results indicated that the ASN/THR/VAL residue o f helix 7 
gave a 100 % correlation with the binding affinities o f the aryloxypropanolamine 
p-adrenoceptor antagonists. The difference in 5-HT receptor affinity o f  
5-carboxamidotryptamine (5-CT, 18) could be attributed to the presence or 
absence o f a proline residue at the extracellular end o f helix 6. This residue 
could induce kinking in the helix allowing the ligand to form a hydrogen bond 
with the unsatisfied backbone carbonyl o f the residue directly below the proline. 
The proline residue is only present in the 5-HTi a > 5-HTj3 ,  5-HTjp), 5-ht5 and 
5 -HT7  receptors and hence these have high affinity for 5-CT. The remaining 
5-HT receptors do not have this residue and hence exhibit low affinity for 5-CT. 
Other ligands have also been studied however results have not been as clear cut 
as the examples cited^O?
1.1.4.16 The ”de novo” approach of Lybrand
"De novo" modelling o f GPCRs has been studied extensively by 
Lybrand208,209# Contrary to the template approaches using bacteriorhodopsin 
or rhodopsin no assumptions were made upon the helix packing arrangement. 
The p2 -adrenergic receptor including the loop regions was modelled208,209
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from analysis o f many possible packing arrangements o f the transmembrane 
domains. This provided two favourable models, one similar to 
bacteriorhodopsin with the helices running anticlockwise sequentially as viewed  
from the extracellular surface and the other where the helices were arranged 
sequentially in a clockwise direction viewed from the extracellular surface 
(mirror image o f bacteriorhodopsin). This latter model was favoured since it 
accounted for the stereoselectivity o f adrenaline.
The models have been further studied^lO using molecular dynamics simulations 
in vacuo, in vacuo with a bilayer model, and using a bilayer model which 
accounts for solvent effects. The motions o f the loop regions in the bilayer 
model simulations were found to be unrealistic and it was suggested that this 
approach may only be useful for modelling the helical domains o f the receptor. 
A discussion o f the pitfalls o f GPCR modelling has also been published^! 1.
1.1.4.17 The EMBL models
The lack o f  any real sequence homology between bacteriorhodopsin and the 
GPCRs was side-stepped by Cronet, Sander and Vriend^^ Assuming that 
bacteriorhodopsin and the GPCRs have the same overall topology, the 
p2 _adrenergic receptor sequence was fitted to bacteriorhodopsin according to the 
preferred environment o f the amino acids o f the a-helices. This threading 
algorithm was used to model the p2 -adrenergic receptor giving reasonable 
agreement with experimental data. A  more conventional approach was then 
adopted^ 13 using a modified GPCR alignment with bacteriorhodopsin to model 
many GPCRs. These models have been made publicly available in the "7TM" 
database^ 4. Further publications have discussed the possible role in signal 
transduction o f the arginine residue o f the conserved DRY m otif at the 
cytoplasmic end o f helix 3^15 and a brief review o f GPCR modelling216.
41
1.1.4.18 A threading approach to GPCR modelling
The general arrangement o f the helices o f bacteriorhodopsinl 19 was usecj 
initially^!? to model the human C5a receptor. More recently a threading 
method o f modelling GPCRs^lS similar to the method o f  Cronet et cr/.212 but 
based upon interaction energies has been used. The seven identified 
hydrophobic domains were taken one by one, threading the region through the 
corresponding helix o f bacteriorhodopsin. Each alignment was scored upon 
sidechain interaction energies and evaluated with respect to structure function 
data.
In a subsequent publication^^ the same group investigated their models more 
extensively using experimental data in an effort to reduce the uncertainty 
associated with the models. From their model o f rhodopsin, the glutamic acid 
residue o f helix 3 was too distant to act as a counterion for the Schiff base o f  the 
retinal binding site. This was overcome by moving helix 7 towards the 
cytoplasm since moving helix 3 would have disrupted the disulfide bond 
between the cysteine at the extracellular end o f helix 3 and the cysteine in the 
loop between helices 4 and 5. The new orientation o f helix 7 conformed to the 
experimental data and additionally a conserved asparagine o f helix 7 could 
interact with the important aspartate o f helix 2. It was concluded that in the light 
o f the low resolution map o f rhodopsin^l, bacteriorhodopsin 119 js still a good 
template for modelling GPCRs.
1.1.4.19 The ’’heuristic direct” method
An Italian group have developed a "heuristic-direct" approach to quantitative 
structure-activity relationships. Models o f some o f the cationic amine
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neurotransmitter receptors have been made and agonists, antagonists and partial 
agonists have been docked into the models. Correlations were studied between 
ligand receptor interactions and experimentally determined binding affinities and 
efficacies. This approach has been applied to the M \ muscarinic220,221 and 
oq-adrenergic222 receptors.
These bacteriorhodopsin based models were updated223 using the GPCR 
topography o f B a ld w in ^ . The authors modelled the hamster a  -adrenergic 
receptor in the first instance and then used this model as a template for other 
receptors. The bacteriorhodopsin based models, the rhodopsin based models 
and bacteriorhodopsin were all subjected to molecular dynamics simulations223. 
It was found that the bacteriorhodopsin based GPCR model and the rhodopsin 
based GPCR model, after dynamics, gave similar refined models, which were 
noticeably different from the bacteriorhodopsin structure before and after 
dynamics.
The rhodopsin derived models were then used to model the rat muscarinic M3  
receptor correlating ligand binding affinities with ligand receptor interaction 
energies224i a  dynamics study o f the possible mode o f signal transduction o f  
the cqB-adrenergic and the muscarinic M3  receptors was performed, suggesting 
that movement o f the arginine residue o f  the conserved DRY m otif at the 
intracellular end o f helix 3 may be an important step in signal transduction225
1.1.4.20 The unconventional binding site models of the dopamine receptors
Almost all the models o f the cationic amine receptors have described the agonist 
binding site as involving the aspartate o f helix 3 and residues o f helices 4, 5, 6  
and possibly 7. Charles Hutchins at Abbot Laboratories has questioned the 
validity o f this binding site model226# Using the low resolution
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bacteriorhodopsin map80 and the connectivity o f Engelman et al.%2 a model was 
made o f  the dopamine D 2  receptor. Site directed mutagenesis o f the cationic 
amine neurotransmitter receptors has implicated the aspartate residues o f  helices 
2 and 3 in agonist binding^,91,104,105 ancj Hutchins has paid particular 
attention to this.
Dopamine was docked into the receptor model to interact, forming an ion pair, 
with the aspartate o f helix 3. The aspartate o f helix 2 was found to act as a 
hydrogen bond acceptor to one o f the hydroxyl groups and the ligand was 
orientated vertically within the binding cleft between helices 2, 3, 6  and 7. The 
model was modified to account for the 1990 bacteriorhodopsin structure ^  ^  and 
a dopamine D j receptor model was built using the D 2  model^26 The 
interactions o f many ligands with the binding site model have been studied. 
Antagonists have been shown to occupy the same binding site as the agonists but 
do not interact with the aspartate o f helix 2  and partial agonists are proposed to 
bind in several orientations with only one o f these activating the receptor.
1.1.4.21 Automated GPCR modelling
An automated method for modelling seven helix transmembrane receptors has 
been presented^27> Numerous structural constraints were applied and the 
authors were able to produce a bacteriorhodopsin model from the low resolution 
density map80 and a rhodopsin model from its density m apl^ l. The rhodopsin 
model has been used to assign helices to the density map and is consistent with 
the work o f B a l d w i n I t  is intended^e that future versions o f the algorithm 
will incorporate proline induced kinks into the helical models.
An alternative automated GPCR modelling approaches has also been 
presented. The program incorporates hydropathy analysis, moment
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vectors 1 3 1 4 0  an(j helical wheels to model GPCRs upon known templates. The 
program has additionally been used to study the solvation o f GPCRs.
1.1.4.22 Miscellaneous GPCR models
A  sequence alignment o f bacteriorhodopsin with adenosine receptors was used to 
create a receptor model for the adenosine A \ receptor in order to study ligand 
receptor binding229 Similar models have also been described for adenosine 
A 2 A ^ ^  and A 3 231 receptors. A review o f adenosine A \ receptor modelling 
and drug design is also available232#
Analysis o f sequence variability o f the opsin family was used to model 
rhodopsin233 without using any template. This gave a good agreement with the 
bovine rhodopsin fo o tp r in t^ . A model o f bovine rhodopsin has also been 
described234,235 which used the helical axis positions o f bacteriorhodopsin^ 9 
to position the helices o f rhodopsin. Numerous other bacteriorhodopsin derived 
models have been published since 1990236-238
The P2 -adrenergic receptor model o f Lewell236 was interesting as she proposed 
that the classical p2 -adrenergic antagonists could bind between helices 1, 2, 3, 6  
and 7 creating an overlap with the agonist binding site which involved residues 
on helices 3, 4, 5 and 6 . Dopamine receptor models have been reported239,240 
The model o f Teeter et al.240 Was very meticulous suggesting that the 
differences in the electron density maps o f bacteriorhodopsin and rhodopsin may 
evolve from differences in state (active versus inactive).
The olfactory OR5 receptor and the interactions o f an odour molecule with the 
receptor were modelled241. Bacteriorhodopsin derived models o f the pj-
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adrenergic242> M \ -muscarinic243; B2 bradykinin^44 and ATj angiotensin^45
receptors have also been published.
A most stimulating bacteriorhodopsin based model o f  the p3 -adrenergic receptor 
has been published^46 using a similar modelling procedure to that o f  Trumpp- 
Kallmeyer et a lA ^ .  Additionally, available crystal structure coordinates o f  
GTPases were used to model^46 the Gs G-protein that interacts with the 
P3 -adrenergic receptor. The C-terminus o f Gs was docked against the C- 
terminus and third intracellular loop o f the P3  receptor. Analysis o f the 
complex o f the a-subunit o f Gs with the receptor showed general agreement with 
experimental data.
When discussing GPCR work mention must be made o f the contribution o f  Thue 
Schwartz in Copenhagen. Although primarily concerned with mapping peptide 
GPCR binding sites through mutagenesis, he has constructed real 3-dimensional 
models and molecular graphics models o f some peptide receptors^47 using the 
electron density map o f rhodopsin^l. From this work, the common theory o f  a 
GPCR being activated by an agonist key is challenged, and it was suggested that 
an agonist may only need to stabilise the receptor in the activated state to allow  
G-protein interaction and signal transduction^48
1.1.5 5-HT receptor agonists and bio-isosterism
The predominant chemical class o f  full 5-HTj agonists has been the indole 
derivatives such as 5-HT (1), sumatriptan (4) and 5-CT (18) however exceptions 
such as the aminotetralin 8 -OH-DPAT (12) which is a selective 5-HT \ a  
agonist^  do exist. The chemistry and biological activity o f indole compounds 
with respect to 5-HT receptors has been studied extensively and in recent years
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much work has been undertaken in synthesising indoles with high 5-H Tjj) 
receptor affinity57,58,60-68
Instead o f looking at this extensively studied class it is proposed that it may be 
possible to replace the indole nucleus o f 5-HT like compounds with a thiophene 
containing moiety, in particular a thieno[2,3-b]pyridine ring system. The 
thieno[2,3-b]pyridines have been o f interest to the workers o f the University o f  
Abertay Dundee for the last ten years and novel preparative routes to these 
compounds have been developed249-251
The concept o f bio-isosteric replacement is well known^52,253 ancj traditionally 
thiophene rings have been used as bio-isosteres o f phenyl rings in known active 
compounds254-256 jn the indole series benzo[b]thiophene-3-acetic acid, an 
analog o f the plant growth hormone indole-3-acetic acid shows retention o f  
biological activity albeit lower than the parent indole compound^54 Some 
patents o f indole compounds relating to 5-HT receptor research have also 
subsumed their benzo[b]thiophene counterparts^7^  Thienopyridines themselves 
are known as quinoline and isoquinoline isosteres and medicinal chemists have 
exploited this in drug design (see section 1.2.6). No references to 
thienopyridines as analogs o f 5-HT have been found during the research for this 
project, however there is the possibility o f thieno[2,3-b]pyridine analogs o f  5-HT 
agonists showing similar biological activity^ 8#
This project therefore aims to construct molecular models o f the 5-HT receptors 
that may be involved in migraine headache. The agonist binding site will be 
identified and validated by the docking o f some known 5-HT receptor agonists. 
The possibility o f thieno[2,3-b]pyridine analogs o f 5-HT acting as 5-HT receptor 
agonists will be assessed and the models can be further used to provide 
suggestions to improve 5-HT receptor selectivity. Target thieno[2,3-b]pyridine
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compounds identified from molecular modelling as potential 5-HT receptor 
agonists will then be synthesised and tested for biological activity. Since the 
project deals with the synthesis of novel thieno[2,3-b]pyridines the chemistry o f  
these compounds must be discussed.
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1.2 THE CHEMISTRY OF THIENO[2,3-B]PYRIDINES
1.2.1 Introduction to thienopyridines
There are six possible thienopyridine ring systems and these can be classed into 
two groups: those that are analogs o f quinoline, the [b] fused systems (19-21), 
and those that are analogs o f isoquinoline, the [c] fused systems (22-24). In 
contrast to the quinolines and isoquinolines, thienopyridines do not occur widely 
in nature and have only been found in the basic extracts o f  shale oil o f  high 
sulfur con tent^^  The first synthesis o f a thienopyridine was by 
Steinkopf260,261 in 1912.
The parent thieno[2,3-b]pyridine (19) was obtained in low yield from the 
reaction o f the tin double salt o f 2-aminothiophene with glycerol in a Skraup 
type synthesis. Following these papers, work on thienopyridines was almost 
non-existent until the 1950's. Chemists then became interested in 
thienopyridines for two different reasons. From a chemical viewpoint 
thienopyridines were interesting compounds since they contained a fused system  
o f a Ti-excessive ring (thiophene) and a 7i-deficient ring (pyridine) and from a 
pharmacological viewpoint they could be considered as potential bio-isosteres o f  
biologically active quinoline and isoquinoline compounds.
The chemistry o f thienopyridines has been reviewed previously262-265 and it is 
therefore not the purpose o f this study to give a full thienopyridine chemistry 
review but to give merely an overview. Since the present study has concentrated 
only upon the [2,3-b] isomer this section will only discuss the important 
synthetic routes to, and the reactions of, thieno[2,3-b]pyridines.
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[3,2-b] (2 0 )
4
[3,4-b] (21)
1.2.2 Synthesis of thieno[2,3-b]pyridines from thiophene precursors
1.2.2.1 Skraup synthesis
Due to the notorious instability associated with aminothiophenes the more stable 
hexachlorostannate double salt o f 2-aminothiophene (25) was reacted260,261 
with glycerol to give a low yield o f the parent thieno [2,3 -b]pyridine (19) 
[Scheme 1].
[Scheme 1]
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In a variation o f this reaction, Russian workers^66 USed Friedel-Crafts 
conditions to prepare 4-methyIthieno[2,3-b]pyridine (26) from reaction o f  the 2- 
aminothiophene double salt (25) and methyl vinyl ketone.
When this reaction was repeated^67 by others, results were obtained that were 
inconsistent with the original report wherein the reaction afforded not only 4- 
methylthieno[2,3-b]pyridine (26) but also the 6 -methyl isomer.
1.2.2.2 Reactions of aminothiophenes with 1,3-dicarbonyl compounds
The 2,4-dimethylquinoline isostere, 4,6-dimethylthieno[2,3-b]pyridine (27) was 
synthesised^ 8  jn 80% yield from the reaction o f (25) with acetylacetone.
The cyclisation step could also be effected by the use o f zinc chloride or 
phosphorus pentoxide in xylene. The same reaction has also been reported by
Abramenko^b9>
Acetals and ketals o f 1,3-dicarbonyl compounds have similarly provided 
thieno[2,3-b]pyridines in moderate yields. Thieno[2,3-b]pyridine (19) was
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prepared267 from the reaction o f malondialdehyde tetraethylacetal with the tin 
salt (25).
// v
NH,
(25) ~ J 2
SnCl2-
CH2(CH(OEt)2)2 
ZnCl2 /EtOH
The mechanism was presumed to be a stepwise process o f hydrolysis o f  the 
acetal followed by Schiff base formation with the amine salt and dehydrative 
cyclisation. Thieno[2,3-b]pyridines were also prepared267 from reactions o f 2- 
aminothiophene with acetylacetone and 3-methylpentan-2,4-dione. It was also 
demonstrated267 that a deactivating 2-acetyl group on the thiophene ring does 
not prevent cyclisation and 2-acetylthieno[2,3-b]pyridine could be prepared 
using malondialdehyde tetraethylacetal in 10% yield. This reaction was repeated 
with acetylacetone to give 2-acetyl-4,6-dimethylthieno[2,3-b]pyridine (28) in 
42% yield.
SnClg
2
When the 2-aminothiophene salt (25) was heated with excess acetoacetaldehyde 
dimethylacetal in ethanolic hydrochloric acid, acetone was liberated and 
thienopyridine (29) was isolated as the main product (32%) with only 2-5% o f 4- 
and 6-methyl thieno[2,3-b]pyridines formed. The mechanism o f the reaction has 
been proposed [Scheme 2]267#
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o/ /  w
'S'
(25)
NH,
—  2
SnCl2-
CH3COCH2CH(OMe)2 h  A 
----------------------------- ►HCl/EtOH
CH3COCH2CH(OMe)2
O
CH,
[Schem e 2]
T he iso la ted  products from  this reaction d iffered  quite con sid erab ly  from  th e  
fin d in g s o f  Z hiryakov and Abramenko270 w h 0 c la im ed  that the o n ly  product 
iso la ted  from  the reaction o f  (2 5 ) w ith  acetoacetald ehyde d ieth y laceta l w a s  6 - 
m eth ylth ien o  [2,3 -b]pyridine.
In a study design ed  to syn th esise  annelated m o d e ls  o f  N A D H ^ l ,  
th ienopyrid in es (3 1 ) and (3 2 ) w ere prepared from  2-n itro -4 -acety lth iop h en e (3 0 )  
g iv in g  a  3:7  ratio o f  com pound s (3 1 ):(3 2 ) in  50%  overall y ie ld  [S ch em e 3].
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(i)= (M e0)2CH)2CHC02Me 
[Schem e 3]
H o w ev er  due to the d ifficu lty  in  preparing m alon d ia ld eh yd e d eriva tives th e  
en o la te  derivative 3 ,3-d im eth oxy-2-form ylp rop ion itr ile  sod iu m  sa lt w a s  
reacted^ 1,272  w ith  the tin  salts o f  2 -am inoth ioph en e, 2 -a m in o th io p h en e-4 - 
carb oxy lic  acid  and 2 -am inobenzo[b]th ioph en e to  g iv e  the corresp on d in g  
th ien o[2 ,3 -b ]p yrid in es in  good  y ie ld s [Equation 1].
MeO CN
[Equation 1]
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1.2.2.3 Cyclisation of 2-amino-3-carbonylthiophenes
T he first application  o f  th is Friedlander type syn th esis to th ien o[2 ,3 -b ]p yrid in es  
w as in  the syn th esis273  o f  6-phenylth ieno[2 ,3-b]pyrid ine (3 4 ) from  2 -  
nitroth iophene-3-carboxaldehyde (33) [Schem e 4].
1 Sn/H Cl
2 KOH
▼
[Schem e 4]
T his m eth od o logy  w as then a d o p te d ^ ^  to syn th esise  substituted th ienopyrid in es  
[Equation 2]
[Equation 2]
T he V ilsm eier  reaction has been  utilised275,276 convert various 2- 
acylth ien ylam in es into the 3 -form yl derivatives w h ich  w ere cy c lised  b y  
com pound s contain ing an active m ethylene group [Schem e 5].
5 5
CHO
[Schem e 5]
Schafer and co-w orkers had m ade u se  o f  a conventional approach initially^?? 
then  in  a variation l,l-d im eth y lth io -2 -n itroeth yIen e w as used  as the cy c lis in g  
agent^78 [Equation 3].
[Equation 3]
1.2.2.4 Base catalysed cyclisation of thiophene amides
In a n o v e l variant o f  C am p’s q u inoline synthesis, the th ienopyridone (3 6 ) w as  
prepared279 fr0m  the cyclisa tion  o f  ch loroacetylch loride w ith  the  
am inoth iophene-2-carboxylate derivative (3 5 ) [Schem e 6].
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o o
Me
/ C0CH2C1
\Me
Me
C 02Et
(3 6 )
[Schem e 6]
M ich ael adducts (3 7 ) have a lso  been  shown^SO to undergo base catalysed  
cy c lisa tio n  to g iv e  th ienopyridine (38).
(3 7 ) (3 8 )
4 ,6 -B is(d im eth yIam in o)th ien o[2 ,3 -b ]p yrid in es (40) have b een  synthesised^ 1 
v ia  a hexam ethylphosphoric triam ide induced ring closure o f  2 -acetam id o-3-  
th iophenecarboxylates (39).
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W hen R j= H  reaction y ie ld s w ere a m oderate 35-48%  but fe ll dram atically to  
10% i f  R \  w as a m ethyl or m ethylene group. The effect w as ev en  m ore  
pronoun ced  w h en  R j= P h  w hereupon no thienopyridine w as iso lated . It w as  
p r o p o s e d ^  that this w as caused by  steric hindrance at the 3 p o sitio n  w h ich  
w ou ld  inhib it cyclisation .
Furtherm ore, it w as found^82 that reaction o f  substituted 2 -a m in o -3 -  
cyanoth ioph en e (4 1 ) w ith  ethyl am inocrotonate in the presence o f  cata lytic  
am ounts o f  p -to lu en esu lfon ic  acid  afforded h igh  y ie ld s  o f  2 -[N -(3 '-  
ethoxycarbonyl-2 '-propenylam ino)]-3-cyanoth iop henes (42 ) w h ich  cou ld  be  
converted  in  h igh  y ie ld  to the corresponding thienopyridine (43) [S ch em e 7].
O
R CN
+
NH,
(4 3 )
[Schem e 7]
5 8
W hen studying the reactiv ities o f  4 ,6 -d ich loroth ien o[2 ,3-b ]p yrid in es, e th y l-4 ,6- 
d ich loroth ien o[2 ,3 -b]pyrid ine-5-carboxylate (4 6 ) w as synthesised^83 jn  three 
steps from  ethyl-2-am inoth iophene-3-carboxylate (44 ) v ia  the th ienopyridone  
(4 5 ) [Sch em e 8].
1.2.2.5 Gould-Jacobs synthesis of thieno[2,3-b]pyridines
T he first reported^84 application o f  the G ould-Jacobs syn th esis to 
th ienopyrid in es w as the treatm ent o f  the tin  salt o f  2-am inoth ioph en e (2 5 ) w ith  
eth oxym eth y len e derivatives o f  various active m ethylene com pound s. Therm al 
cy c lisa tio n  o f  the interm ediates afforded the th ien o[2 ,3-b ]p yrid in es (4 7 ) [Schem e
9].
[Schem e 9]
5 9
In an a tte m p t^ 5 to syn th esise  th ienopyridine isosteres o f  the antibacterial agent 
n alid ix ic  acid, a G ould-Jacobs condensation  o f  substituted 2 -am in oth iop h en es
(4 8 ) w ith  d ieth yleth oxym eth ylen e m alonate w as used to g iv e  the interm ediate
(4 9 ) w h ich  w as therm ally cy c lised  to the desired th ien o[2 ,3 -b ]p yrid in es (5 0 )  
[S ch em e 10].
[Schem e 10]
In a related cyclisa tion  step conducted  in  phosphoryl ch loride the 4 -  
ch loroth ienopyrid ine (5 1 ) w as form ed286 in  55%  yield .
Cl
■ Me
E nam ines have a lso  b een  cyclised^B? to th ienopyrid ines usin g  AICI3 .
1 .2 .2 .6  V ilsm e ie r  rea c tio n s
T he V ilsm eier-H aack  reaction has been  used ^88 jn the syn th esis o f  6- 
ch loroth ien o[2 ,3-b ]p yrid in es (53) and 5 -form yl-6-ch loroth ien o[2 ,3-b ]p yrid in es  
(5 4 ) from  2-acetam idoth iophenes (52).
6 0
T he con d ition s o f  th is reaction w ere studied in  order to op tim ise  the y ie ld s  o f  
(53) and (54)289. P rolonged  heating w ith  a 3:1 ratio o f  P O C h^D M F  gave  
com p ou n d s (53) optim ally  in  66-80% y ie ld  w hereas form ation o f  (54) w as  
m axim ised  usin g  a 7:3 ratio o f  PO C h^D M F . The pathw ays o f  form ation o f  both  
products have also been  proposed289,290 [Sch em e 11, S ch em e 12]. T he  
principal d ifference b etw een  the tw o routes is that in  the syn th esis o f  (54), the  
ring and the sidechain  both undergo form ylation prior to cyclisa tion  w hereas in  
the syn th esis o f  (53) o n ly  the th iophene ring is form ylated prior to cyclisa tion .
R
1
R,
R
H
R,
[Schem e 11]
6 1
R R
1 -Me2NH
2 H20
[Schem e 12]
1.2.3 Synthesis of thieno[2,3-b]pyridines from pyridine precursors
1.2.3.1 Early synthesis
T he first report o f  this type o f  syn th esis w as by  K oen igs and Geisler^^l in 1924  
w h o  cla im ed  that 3-h yd roxyth ieno[2 ,3-b]pyrid ine w as form ed from  treatm ent o f
2 -p yrid y lth ioacetic  acid w ith  acetic  anhydride. This w as q uestioned  by  
Chichibabin292 w ho sh ow ed  that the product obtained w as d ifferent from  an
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authentic sam ple o f  3 -h ydroxyth ieno[2 ,3-b]pyrid ine (56) prepared from  3- 
carbom ethoxy-2-ch loropyrid ine (55) [Sch em e 13].
.C 02Me
HSCH2C 02Me
NaOMe
N Cl
(55)
N
.C 02Me
SCH2C 02Me
NaOMe
T he true structure o f  K oen ig's product w as later identifled293 as (5 7 ),
1.2.3.2 Synthesis from 2-halo-3-cyanopyridine derivatives
It w as reported294,295 that reaction o f  2 -ch loro-3-cyan op yrid in e (58) w ith  ethyl 
m ercaptoacetate and base gave the th ieno[2 ,3-b]pyrid ine (59) [S ch em e 14]. T he  
reaction is thought to proceed  v ia  n u cleop h ilic  d isp lacem ent o f  the ch lorine by  
ethyl m ercaptoacetate fo llo w ed  by base prom oted intram olecular cyclisa tion . 
C om pound (59) has a lso  been  prepared^96 u sin g  a variation o f  this reaction. 
H igh ly  substituted derivatives have b een  synthesised^97-299 u sin g sim ilar  
m eth od ology .
6 3
(58)
1.2.3.3 Synthesis from substituted pyridine-2-thiols
T he syn th esis270  0 f  th ienopyridine (6 1 ) from  reaction o f  th io l (6 0 ) w ith  
ch loroacetic  acid  fo llo w ed  by cyclisa tion  and acetylation has b een  described  
[S ch em e 15].
.COOH
C1CH2C 00H
SH
COOH
SCH2COOH
(6 0 )
A c 2 0
, Q --C O M e
T he general reaction betw een  substituted p yrid ine-2-th io ls and h a logen  
com p ou n d s w ith  an activated m ethylene has been  used as a popular route to  
thieno[2,3-b]pyridines249,3 0 0 -3 0 6  [Schem e 16]. Initial n u cleop h ilic  attack by  
the sulfur affords the activated su lfid e  w h ich  cy c lise s  to the th ienopyrid ine in  
g o o d  y ie ld s.
6 4
z[Schem e 16]
A  variation o f  th is reaction w as u tilised ^ 07 w here 2 ,6 -d im eth y lth iop yrid in e-3-  
carboxaldehyde (6 2 ) w as reacted w ith  chloroacetic acid  to afford the  
th ien o[2 ,3 -b ]p yrid in e (63 ) as a potential antiviral agent.
1.2.3.4 Synthesis from pyridine thiones
There is probably m ore literature published  on this synthetic  route to  
th ien o[2 ,3 -b ]p yrid in es than any other. T he pyrid ine-2-th ione is a lkylated  by  
com pound s that contain  a h alogen  atom  adjacent to an active m eth y len e group, 
then  u ndergoes cyclisa tion  to g iv e  the th ieno[2 ,3-b]pyrid ine. R u ssian  
w orkers^0 8 -3 2 2  have published a num ber o f  papers on  the u se  o f  th is m ethod  to  
prepare substituted thienopyrid ines [Equation 4].
6 5
X = halogen
Z = COAr, C 02R3, C 02H, CONH2, CN 
[Equation 4]
T hiolate salts (64) have a lso  been  alkylated323,324 by active  m eth y len e  
com p ou n d s and cy c lised  to g iv e  substituted 3 -am in oth ien o[2 ,3-b ]p yrid in es (65) 
[S ch em e 17].
CN
SCH2Z
(64)
X = halogen
Z = C 02Et, CONH2, COAr, C 02H
[Schem e 17]
z
N u m erou s other publications on the preparation o f  th ien o[2 ,3 -b ]p yrid in es from  
pyrid ine th ion es are available325-332 p or exam ple, alkylation329 o f  3- 
cy a n o p y r id in -2 (lH )-th io n e  (66) w ith  phenacyl brom ide fo llo w ed  by spontaneous  
cy c lisa tio n  afforded the th ieno[2 ,3-b]pyrid ine (67) in  45-90% yield .
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In a variation^ 3 the th ione (68) w as reacted w ith  an a -b rom ocarb on yl 
com p ou n d  in the presence o f  potassium  hydroxide to g iv e  the S -a lkylated  
d erivatives w h ich  cy c lised  in  h igh  y ie ld s by intram olecular aldol condensation .
(68)
X = OEt, Ar
1.2.3.5 Synthesis from ortho halogenated pyridine derivatives containing an 
active methylene group
T h ien o[2 ,3 -b ]p yrid in es have been  prepared from  the reaction o f  
p h en yliso th iocyan ate  and carbon d isu lfide w ith  o r th o  halogenated  pyrid ine  
d erivatives contain ing a m ethylene group activated by a nitrile or ester^50,251  
R eaction  o f  (69a-c) w ith  carbon d isu lfide in the presence o f  base fo llo w e d  by  
q uenchin g w ith  m ethyl iod id e afforded the 2,3 substituted th ien o[2 ,3 -b ]p yrid in es  
(7 0 a -c) in  36-43%  yield .
a R=C02Et, b R^CC^Me, c R=CN
T he reaction is thought to proceed  v ia  base rem oval o f  the m eth y len e protons  
fo llo w ed  b y  form ation o f  a ketene dithioacetal dianion. O ne o f  the th iolate
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an ion s d isp laces the h a logen  and the other is  alkylated w ith  m ethyl iod id e  
[S ch em e 18].
A lk y la tion  o f  the th iolate anion has a lso  been  ach ieved  u sin g  ethyl 
chloroacetate^S 1. T he reaction o f  pyridines (69a-c) w ith  phen yliso th iocyan ate  
a lso  r e su lte d ^  1 in  the synthesis o f  th ien o[2 ,3-b ]p yrid in es in m oderate y ie ld s. 
T he th ienopyrid in es h ow ever w ere not alkylated  by the m ethyl iod id e present, 
but did protonate w h en  poured onto water.
R
NHPh
(6 9 a -c )
a R=C02Et, b R=C02Me, c R=CN
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1.2.4 Miscellaneous preparations
K lem m  and M c C o y ^ e  reported the reaction o f  3-v in ylp yrid in e (7 1 ) w ith  
h ydrogen  su lfid e at 630  °C  to g iv e  a lo w  y ie ld  o f  the parent 
th ien o[2 ,3 -b ]p yrid in e (19) and th ien o[3 ,2 -c]p yrid in e (23).
T he reaction  w ith  2 -m eth y l-5 -v in y l pyrid ine (72 ) also produced th ienopyrid in es  
in  lo w  y ie ld s. T he m echanism  o f  the reaction w as postulated to in v o lv e  a non- 
catalytic therm al process w hereby free radical substitution into the pyrid ine ring  
predom inates at the a  position .
T he sy n th e s is ^ S  o f  2 ,2-d ip h en yl-2 ,3 -d ih yd roth ien o[2 ,3-b ]p yrid in e (74 ) from  2-
m ercap to-3-(2-h yd roxy-2 ,2-d ip h en yleth yl)p yrid in e (73 ) w as a ch ieved  b y  the 
treatm ent o f  (7 3 ) w ith  co ld  concentrated sulfuric acid.
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T he pyrid in ium  salt (7 5 ) has been  cy c lised  to th ieno[2 ,3-b]pyrid ine derivative  
(7 6 ) from  reaction w ith  m ethylth ioglycollate^^^.
A fter refluxing  pyrid in -3-y lprop io lic  acid (77) in  th ionyl chloride a lo w  y ie ld  o f  
2-carb oeth oxy-3-ch loroth ien o[2 ,3-b ]p yrid in e (78) w as isolated^37> ft was 
proposed^ 7 that the reaction m ay take p lace by  the form ation o f  a pyridinium  
salt b etw een  (77) and th ionyl chloride w h ich  undergoes an addition  reaction on  
the triple bond to g iv e  a sulfur contain ing interm ediate w h ich  cy c lise s  v ia  
n u cleop h ilic  attack onto the pyridine ring.
C 0 2Et
Furtherm ore it w as discovered^ 8 that reaction o f  the p henylethyn ylpyrid ine  
(7 9 ) w ith  sod ium  hydrosulfide prepared in  s i tu  from  the saturation o f  a so lu tion  
o f  sod iu m  eth ox id e in  ethanol w ith  hydrogen su lfid e, afforded 2 - 
phenylth ien o[2 ,3-b ]p yrid in e (80) in  69%  y ield .
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A  m ost in teresting syn th esis o f  th ienopyrid ines from  an intram olecular D ie ls -  
A ld er reaction has been  described339,340 Substituted 3-th io  1 ,2 ,4-triazenes  
(8 1 ) reacted intram olecularly w ith  electron  rich d ien op h iles to g iv e  
th ienopyrid in es (8 2 ) [Sch em e 19]. W hen the starting triazene w as o x id ised  to  
the su lfox id e  (8 3 ) w ith  w -ch lorop eroxyb en zo ic  acid, cyclisa tion  to o k  p lace  
sp on tan eou sly  to g iv e  the th ien op yrid in e-S -oxid e derivatives w h ich  cou ld  be  
converted  to  the th ienopyrid ines (82) [S ch em e 20].
[Schem e 19]
[Schem e 20]
7 1
E lectrop h ilic  substitution o f  th ieno[2 ,3-b]pyrid ine (19) w as predicted267 to  
occu r at the C-3 p osition  rather than the C -2 position . The reaction o f  (19) w ith  
deuterated sulfuric acid  at 98.5 °C  gave  fastest exch an ge at the C-3  
position267,341 B rom ination o f  (19) w ith  brom ine in  carbon tetrachloride267 
led  to the 2 ,3-d ibrom o derivative (84) in  lo w  yield .
1.2.5 Reactions of thieno[2,3-b]pyridines
1.2.5.1 Electrophilic substitution
Br
M on oh alogen ated  thienopyridines (85a -c) have been  prepared^^2 in 27-40% 
y ie ld s  from  (19) by reaction w ith  elem enta l h a logen  and silver  su lfate in  the 
p resence o f  sulfuric acid. C om pound (85b ) cou ld  also be prepared342 [n 
im proved  y ie ld  (57% ) in  non-acid ic, non-aqueous conditions from  reaction o f  
(1 9 ) w ith  dry brom ine in  chloroform  in  the presence o f  a buffer. W hen  ch lorine  
gas w as bubbled  through a solu tion  o f  (19) in  a chloroform /w ater m ixture, tw o  
products w ere iso la ted  w h ich  w ere identified  as the m onoch loro (85a) and  
dichloro ( 86) th ieno[2 ,3-b]pyrid ines.
X
a X=C1, b X=Br, c X=I
7 2
N itration  o f  the halogenated thienopyrid ines (85a -c) gave^42 the 2-n itro-3-  
h aloth ien o[2 ,3-b ]p yrid in es (87a-c) in 22-47% y ield s. Nitration^^3 0 f  the parent 
com p ou n d  (19) and 5-ethylthieno[2,3-b]pyridine344 under m ixed  acid  
con d ition s have a lso  been  reported. N itration occurred at the C-3 p osition s in  
y ie ld s  o f  55 and 53%  respectively .
a X=C1, b X=Br, c X=I
It w as a lso  found that the nitration288 o f  2-b rom o-6-ch loroth ien o[2 ,3-b ]p yrid in e  
(88) g iv e s  the 3-nitro derivative (8 9 ) in  96%  yield .
E lectrophilic  substitution reactions o f  hydroxyth ienopyrid ines and  
th ienopyridon es have been  studied^^5 4-H yd roxyth ien o[2 ,3-b ]p yrid in e (9 0 )  
reacts w ith  brom ine in  acetic acid  and w ith  d iethylam ine/form aldehyde to g iv e  
substitution in  the pyridine ring but treatm ent w ith  nitric acid at 100 °C  afforded
2-n itro-4-hydroxyth ieno[2 ,3-b]pyrid ine (9 1 ) as the m ajor product [S ch em e 2 1 ].
7 3
O H  O H
7-m eth y lth ien o[2 ,3 -b ]p yrid in -4(7H )-on e (92 ) w as subjected to the sam e  
reactions^45 g iv in g  a sim ilar substitution pattern.
O
Me
(92)
R eaction  o f  the hydroxyth ieno[2 ,3-b]pyridone (9 3 ) w ith  brom ine in  acetic  acid  
ga v e  the 2-brom o com pound (9 4 ) but reaction w ith  other electrophiles resulted  
in  d ecom p osition  products on ly345 .
OH OH
7 4
1.2.5.2 Nucleophilic substitution
There is  n ot a great deal o f  literature on  the n u cleop h ilic  substitution reactions o f  
th ien o[2 ,3 -b ]p yrid in es. T he on ly  reactions published  for the unsubstituted parent 
com pound (1 9 ) are th ose  w ith  alkyl lith ium  reagents267. Treatm ent o f  (1 9 )  
w ith  rt-butyllithium  at 2 5 -3 5  °C  fo llo w ed  b y  lo ss  o f  lithium  hydride gave the 6- 
n-butyl derivative (9 5 ) in  47%  y ield . R eaction  o f  (19 ) w ith  m eth y llith iu m  at 
low er tem peratures h ow ever afforded o n ly  25%  o f  6 -m eth y lth ien o[2 ,3 -b ]  
pyrid ine and 75%  o f  starting m aterial. It w as proposed267 that the recovered  
starting m aterial w as the result o f  m etalation at the position  o r th o  to the sulfur  
atom  w h ich  com p etes w ith  the n u cleop h ilic  reaction and appears to be favoured  
at low er tem peratures.
R eaction  o f  both 3 -b rom oth ien o[2 ,3-b ]p yrid in e342  an<j 5-b rom oth ien o[2 ,3 -b ] 
pyridine^ 4 6  w fth copper (I) cyan ide in  refluxing D M F  gave 3-  
cyan oth ien o[2 ,3 -b ]p yrid in e (45% ) and 5-cyan oth ien o[2 ,3-b ]p yrid in e (29% ) 
resp ective ly . T he copper prom oted n u cleop h ilic  substitution o f  the 6-ch loro  
group o f  (9 6 ) has also been  in v e s tig a te d ^ ^ . H eating  6 - 
ch loroth ien o[2 ,3-b ]p yrid in e (96) w ith  ex c e ss  y -d iethylam inopropylam ine and a 
sm all am ount o f  copper pow der in  a sea led  tube at 168 °C  afforded the 6 - 
substituted th ienopyrid ine (97 ) in  58%  y ield .
75
Et2N(CH2)3NH2 ------------------- ».
Et2N(CH2)3HN N s'
(9 7 )
S im ilarly  n u cleop h ilic  substitution reactions o f  2 -b rom o-6- 
ch loroth ien o[2 ,3-b ]p yrid in e (88) have been  reported348# R eplacem ent o f  the 6- 
chloro group w as easily  ach ieved  w ith  th iophenol or piperidine.
N u c leo p h ilic  substitutions o f  som e h igh ly  substituted th ien o[2 ,3 -b ]p yrid on es  
h ave a lso  b een  described283 (see  section  1 .2 .2 .4 , S ch em e 8). Treatm ent o f  (4 6 )  
w ith  on e equ ivalent o f  ethoxide in ethanol gave n u cleop h ilic  substitution at the  
pyrid ine C -4  position . W hen ex cess  ethoxide w as used  substitution occurred at 
the C -4 and C -6 p osition s. A  sim ilar substitution pattern w as observed  for 4 ,6 -  
dich loroth ieno[2 ,3-b]pyrid ine. It w as concluded283 that un like their 2 ,4 -  
dich loroq u in olin e isosteres 4 ,6-d ich loroth ien o[2 ,3-b ]p yrid in es undergo  
n u cleo p h ilic  substitution a lm ost e x c lu s iv e ly  at the C -4 position .
It w as found  that so m e  nitrogen n u cleop h iles but not o x y g en  n u cleop h iles can  
displace^ 1 the th iom ethyl group o f  (70c).
CN
SMe
T he th iom eth yl group o f  com pound (70c) w a s oxidised^ 1 to the su lfo x id e  and  
su lfon e, and reactiv ities o f  the three com pounds w ith  the an ion  o f  
diethylm alonate w ere com pared. T he su lfid e  (7 0 c) did not undergo n u cleop h ilic
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substitution  but both the su lfox id e and the su lfon e did w ith  the latter b e in g  the  
m o st reactive.
1.2.5.3 Metalation of thieno[2,3-b]pyridines
It w as or ig in a lly  reported267 that reaction o f  th ieno[2 ,3-b]pyrid ine w ith  
m eth yllith iu m  at -25 °C  gave a m ixture o f  25%  o f  6-m eth ylth ien o[2 ,3 -b ]p yrid in e  
and 75%  o f  starting m aterial. The h igh  return o f  starting m aterial w as b e liev ed  
to  co m e from  the hyd rolysis during w ork-up o f  2 -lith io th ien o[2 ,3 -b ]p yrid in e. 
T h is w as further corroborated by repetition o f  the reaction and h yd ro lysis first 
w ith  deuterium  o x id e  and then w ater w h ich  gave approxim ately equal am ounts  
o f  the 2 -D  and 2-H  com pounds. Further reactions349 0 f  thieno[2,3-b]pyridine 
(19) w ith  /7-butyllith ium  and N ,N ,N ,A -tetram ethy lethy lened iam ine (T M E D A )  
a lso  gave 2-lith io th ien o[2 ,3 -b ]p yrid in e (98) w h ich  upon reaction w ith  D M F  
afforded the form yl derivative (99) in  6 6 %  y ie ld  [Sch em e 22].
N s'
nBuLi / TMEDA---------------------0
-70 °C
(19)
CHO
[Schem e 22]
3-L ithiated derivatives have been  prepared^49 from  lithium  - h a logen  exch an ge  
reactions b etw een  3-brom oth ieno[2 ,3-b]pyrid ine (85b ) and n-buty llith iu m  at 
-7 0  °C . R eaction s o f  3-lith ioth ien o[2 ,3-b ]p yrid in e (100 ) w ith  a num ber o f  
carbonyl com pound s have been  described  [S ch em e 23].
7 7
Br Li
T he lith iation  o f  2 -b rom o-6-ch loroth ieno[2 ,3-b ]p yrid ine ( 88) has b een  
studied288,348 R eaction  o f  (88) w ith  w-butyllithium  at -70  °C  gave 2 -lith io -6 -  
ch loroth ien o[2 ,3 -b]pyridine ( 10 1 ) w h ich  w as reacted w ith  several electrop h iles  
[S ch em e 24].
[Schem e 24]
7 8
1.2.5.4 Oxidation of thieno[2,3-b]pyridines
T he ox id ation  o f  thieno[2,3-b]pyridines to their respective N -o x id e  derivatives  
has b een  ach ieved  usin g  30% hydrogen peroxide in  g lacial acetic acid^O, m- 
ch lorop eroxyb en zo ic  acid^S 1 and m agnesium  monoperoxyphthalate352,353
T he attem pted^54 S -oxid ation  o f  th ieno[2 ,3-b:4 ,5-b ']d ipyrid ine (1 0 3 ) in  aqueous  
aceton itrile  w ith  an equim olar am ount o f  iod ob en zen e d ichloride ga v e  a lo w  
y ie ld  o f  the su lfox id e  (104 ). H ow ever the parent thieno[2,3-b]pyridine (1 9 ) gave  
a m ixture o f  chlorinated products. C om pound (103 ) w as converted  to the 
su lfo n e  in  41%  y ie ld 3 5 4  b y  bubbling chlorine gas through a so lu tion  o f  (1 0 3 ) in  
carbon tetrachloride, fo llo w ed  by hydrolysis. T h ien o [2 ,3 -b ]p y r id in e -l,l-d io x id e  
(1 0 5 ) w as synthesised^ 5 from  reaction o f  (1 9 ) w ith  sodium  h ypoch lorite  and  
dilute hydrochloric acid.
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1.2.5.5 Reactions of thieno[2,3-b]pyridine-7-oxides
T h ien o[2 ,3 -b ]p yrid in e-7 -ox id e  (1 0 2 ) has been  nitrated by tw o  m eth o d s^ O . 
R eaction  w ith  nitric acid  and sulfuric acid  at 9 0 -1 2 0  °C  gave 4 -  
n itroth ien o[2 ,3 -b ]p yrid in e-7-ox id e (106 ) but nitration w ith  nitric acid  and glacia l 
acetic  acid  gave 5 -n itroth ien o[2 ,3-b ]p yrid in e-7-oxid e (107 ) [Sch em e 25]. It w as  
p rop osed  that the m ech an ism  in v o lv ed  "normal" electrophilic attack o f  nitronium  
io n s onto unprotonated starting m aterial (1 0 2 ) to g iv e  (106). For the n itric/acetic  
acid  reaction the concentration o f  nitronium  ions w as thought to be greatly  
reduced  and a m echanism  in v o lv in g  cations obtained from  the protonation o f  
w ater, nitric acid  and acetic acid w as suggested .
[Schem e 25]
N u c leo p h ilic  substitution reactions o f  th ien o[2 ,3 -b ]p yrid in e-7-ox id es have a lso  
b een  described. R eaction  o f  (102 ) w ith  phosphoryl ch loride^ $ 6  gave tw o  
products (9 6 ) and (1 0 8 ) arising from  a  and y substitution o f  the pyrid ine ring.
8 0
Cl
(1 0 8 ) 54%
R eaction  o f  (1 0 2 ) w ith  acetic anhydride356 fo llo w ed  by h yd ro lysis afforded the  
th ienopyridon e (1 0 9 ) and 5-hydroxyth ieno[2 ,3-b]pyrid ine (110 ).
N u c leo p h ilic  substitution o f  4 -n itroth ien o[2 ,3-b ]p yrid in e-7-oxid e (1 0 6 ) w ith  
acety l ch loride afforded the 4-ch loro N -o x id e  (1 1 1 ) in 81%  y ie ld ^ O  w h ich  w as  
further substituted w ith  various nitrogen n u cleop h iles [Schem e 26].
(1 0 6 ) HO(CH2)5NH /^ / ( 111) ^ t 2N(CH2)2NH2
O' O'
[Schem e 26]
8 1
It w as fou n d 357 that th ien o[2 ,3 -b ]p yrid in e-7 -ox id es reacted under R eissert- 
H en ze  conditions to introduce a  cyan o  group at the pyridine a  p o sitio n  [Equation  
5], T he reaction w a s attem pted w ith  5 -n itroth ien o[2 ,3 -b ]p yrid in e-7-ox id e and  
ga v e  o n ly  a sm all am ount o f  6 -cyan oth ien o[2 ,3 -b ]p yrid in e but the 4-nitro isom er  
(1 0 6 ) reacted in  a refluxing chloroform /w ater m ixture to g iv e  6 - 
cyan oth ien o[2 ,3 -b ]p yrid in e (112 ) and 4 -ch loro-6-cyan oth ien o[2 ,3 -b ]p yrid in e  
(1 1 3 ).
R R
R=Me 60% 
R=CI 70%
[Equation 5]
(1 0 6 ) (112)51% (113)46%
A ttem pted  m od ifica tion  o f  this reaction^52 u sing potassium  th iocyanate and 
b en zo y l chloride gave  on ly  (114) in  2%  yield .
8 2
T h ien o  [2 ,3 -b]p yrid in e-7-ox id e (1 0 2 ) a lso  ga v e  y substitution  upon reaction  w ith  
b en zo y l ch loride and enam ines o f  cy c lo h ex a n o n e  fo llo w ed  b y  hydrolysis^ 8
O'
( 102)
Furtherm ore, reaction o f  (102 ) w ith  ethyl cyanoacetate in  the presen ce o f  a cetic  
anhydride^ 8 afforded a com pound w h ich  cou ld  be b est exp la in ed  b y  the  
resonance structures (1 1 5 ) and (1 1 6 ). T h is com pound has b een  u sed  as an  
acy la tin g  agent for amines351.
N C ^ C 0 2E t
Ac
( 102) (1 1 5 ) (1 1 6 )
1.2.5.6 Reactions of thieno[2,3-b]pyridine sulfones
T he o n ly  reported reactions o f  th ieno [2 ,3 -bjpyridine su lfo n es are D ie ls -A ld er  
reactions. S u lfon e (1 0 5 ) acts as a typ ica l d ien op h ile  and u ndergoes reaction  w ith  
anthracene and other dienes355,359t
8 3
1.2.5.7 Aminothieno[2,3-b]pyridines
5-A m in oth ien o[2 ,3 -b ]p yrid in e (117 ) w as reported^^6 to undergo d iazotisation  
reactions typ ical o f  primary aryl am ines to y ie ld  various 5 -substituted  
th ien o[2 ,3-b ]p yrid in es [Schem e 27].
[Schem e 27]
C om pound (1 1 7 ) a lso  reacts346 w ith  aldehydes to g iv e  S c h if f  s b ases w here the  
C = N  function  cou ld  be reduced to the secondary am ine. T his w ork w as  
extended350 to 4-am inoth ieno[2 ,3-b]pyrid ine (1 1 8 ) w h ich  cou ld  be prepared
8 4
from the reduction of 4-nitrothieno[2,3-b]pyridine-7-oxide (106) with iron and 
glacial acetic acid. No reaction of (118) with aldehydes was observed using the 
above conditions. This was attributed to the decreased nucleophilic character of  
the amino group due to resonance stability of (118) which is not possible for 
(117). Schiff s bases were only obtained from reaction in refluxing xylene with 
a molecular sieve [Scheme 28].
[Scheme 28]
Amino groups attached directly to the thiophene ring of thieno[2,3-b]pyridines 
generally yield unstable compounds as the free base. The N-acetyl derivatives 
however are stable and some have been prepared^[Equation  6, Equation 7].
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NHAc
[Equation 6]
It was f o u n d s  that diazotisation of ethyl 3-ammothieno[2,3-b]pyridine-2- 
carboxylate (59) followed by hypophosphorus acid-mediated reduction gave 
ethyl thieno[2,3-b]pyridine-2-carboxylate (119).
C02Et C02Et
1.2.5.8 Miscellaneous reactions
4,6-Dimethylthieno[2,3-b]pyridine (27) was characterised by preparing268 the 
dibenzylidene derivative (120) which was formed readily from reaction of (27) 
with two equivalents of benzaldehyde and a small amount of zinc chloride.
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Furthermore, reaction^^6 0f 5-bromothieno[2,3-b]pyridine (121) with potassium 
amide in liquid ammonia gave 40%  of 4-aminothieno[2,3-b]pyridine (118) and
0-13%  of the 5-amino isomer (117). It was proposed that the reaction involved 
an intermediate thienopyridyne.
Diazepines have been synthesised^ from 4 56-dimethylthieno[2,3-b]pyridine 
(27). For example, treatment of (27) with O-mesitylsulfonylhydroxylamine 
(H2N0 3 SMes) gave the N-amino compound (122) in 94% yield. This could be 
reacted with ethyl chloroformate in the presence of alkali to give the N- 
acylimide (123) which could be irradiated to afford diazepines (124) and (125) 
[Scheme 29].
C02Et
(124) (125)
[Scheme 29]
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There is also a great wealth of literature describing the synthesis of tricyclic 
compounds containing the thieno[2,3-b]pyridine moiety however this is well 
beyond the scope of this introduction.
1.2.6 Thienopyridines as pharmacological agents
Although there does not appear to be much literature on thieno[2,3-b]pyridines 
as pharmacological agents there are however several [2,3-c], [3,2-c] and [3,2-b] 
derivatives with known biological activity. The tetrahydrothieno[3,2-c]pyridines 
ticlopidine363,364 ( 126) and clopidogrel365 (127) are powerful inhibitors of 
platelet aggregation. The mechanism of action of these drugs is not entirely 
understood but they are believed to interfere with ADP induced platelet 
aggregation^66
The tetrahydrothieno[2,3-c]pyridine (128) and other tetrahydrothienopyridine 
derivatives have been identified as selective dopamine Dj receptor 
agonists^67,368
88
OH
A series of substituted 4-aryItetrahydrothieno[2,3-c]pyridines (129) have shown 
potential as antidepressants inhibiting the uptake of noradrenaline and 5-HT369.
Thienopyridine arylpiperazine derivatives e.g. (130) have exhibited high 
affinities for the 5-HTj and 5-HT2 subtypes but low dopamine D2 receptor 
a ff in ity ^ a n d  may be useful as antipsychotic agents.
Me
Me
(130)
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The fully aromatic thieno[3,2-b]pyridine (131) has been discovered as a 
leukotriene D4 receptor antagonist which was as equally potent as its quinoline
iso stere^ l.
(131)
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2 Molecular Modelling: Methods and Discussion
2.1 METHODS
2.1.1 Approach to modelling the 5-HT receptors
In 1993 when this project was initiated the rhodopsin projection m a p ^ l  was not 
available and only the coordinates of the transmembrane a-helices of 
bacteriorhodopsin 1 19 were obtainable. It was therefore assumed that the 5-HT 
receptors have a suitably similar overall topology to bacteriorhodopsin to 
warrant the use of the aforementioned coordinates as an initial, but not strict 
template to model the 5-HT receptors. Even today we still believe that the use of 
bacteriorhodopsin coordinates is a superior method to that based on the 
rhodopsin low resolution data and will continue to be so until high resolution 
coordinates of rhodopsin are published. If, or when, this happens the question 
will then be: are the 5-HT receptors similar enough to rhodopsin to warrant the 
use of the rhodopsin coordinates in a homology model of the 5-HT receptors?
The approach therefore adopted within this project was to use the 
bacteriorhodopsin coordinates as a template upon which the a-helices of the 
5-HT receptors could be arranged prior to any refinement. In the first instance, 
the human 5-HTj a  receptor was modelled as a prototype since there is a greater 
wealth of experimental data and binding affinity data available for the 5-H T j a  
receptor compared to all the remaining 5-HTi receptors. This prototype was 
used as the starting point for the models of the 5-H T ij)a  and 5-HTjp)p 
receptors which may be involved in migraine headache. There are some 
limitations to this approach and certain assumptions had to be made which will 
be discussed where appropriate.
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This study did not attempt to create the "perfect" GPCR model but instead to 
obtain experimentally relevant molecular models of the 5-HTi a > 5-HTip)a  and 
5-HTjDp agonist binding sites which are qualitatively useful.
2.1.2 Sequence alignment
The amino acid sequences of the cloned human 5-HT j a , 5 -H T u )a , 5-HTjp)p, 
5 -h tig , 5-htjp, 5-HT2A and 5 -H T 2 C ^ ,^ ^ , ^ ,' ^ “^ ®  receptors were 
extracted from the Swissprot database and read into the Insightll^l molecular 
modelling package. The bacteriorhodopsin^^ sequence was also obtained in a 
similar way. No satisfactory sequence alignment was observed between the 
5-HT receptors and bacteriorhodopsin due to the very low sequence similarity. 
The 5-HT receptors were then aligned using the multiple alignment option of the 
homology module of Insightll^l and the Dayhoff PAM 120 evolutionary 
scoring matrix^ This resulted in a sequence alignment showing seven 
distinct regions of high sequence homology undoubtedly corresponding to the 
seven a-helices of the receptors (Figure 4).
2.1.3 Hydrophobicity analysis
In addition to being comprised of conserved amino acids, the transmembrane 
domains are known to be hydrophobic in nature and hence an analysis of 
hydrophobicity should provide further evidence to assist in the identification of 
the a-helices.
Hydrophobicity profiles were calculated for each of the 5-HT receptors using the 
combined hydrophobicity scale of Kyte and Doolittle 127 with a window size of 
5 residues and a hydrophobicity threshold of 0. These parameters were found to 
be the optimal values based on hydrophobicity analysis of the bacteriorhodopsin
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A:
B:
C:
D:
E:
F:
G:
mdvlspgqgnnttsppapfetggnttgisdvtvsyqvitslllgtlifcavlg
msplnqsaeglpqeasnrslnatetseawdprtlqalkislawlsvitlatvls
meepgaqcappppagsetwvpqanlssapsqncsakdyiyqdsislpwkvllvmllalitlattls
mnitnctteasmairpktitekmlicmtlwittlttll 
mdflnssdqnltseellnrmpskilvsltlsglalmttti 
meilcedntslssttnslmqlnddtrlysndfnsgeantsdafnwtvdsenrtnlscegclspsclsllhlqeknwsalltawiiltiag 
mvnlrnavhsflvhligllvwqcdisvspvaaivtdifntsdggrfkfpdgvqnwpalsiviiiimtigg
A: nacwaaialerslqnvanyligslavtdlmvsvlvlpmaal-yqvlnkwtlgqvtcdlfialdvlcctssilhlcaialdrywaitdpid 
B: nafvlttilltrklhtpanyligslattdllvsilvmpisia-ytithtwnfgqilcdiwlssditcctasilhlcvialdrywaitdale 
C: nafviatvyrtrklhtpanyliaslavtdllvsilvmpistm-ytvtgrwtlgqwcdfwlssditcctasilhlcvialdrywaitdave 
D: nlavimaigttkklhqpanylicslavtdllvavlvmplsii-yivmdrwklgyflcevwlsvdmtcctcsilhlcvialdrywaitnaie 
E: nslviaaiivtrklhhpanylicslavtdflvavlvmpfsiv-yivreswimgqwcdiwlsvditcctcsilhlsaialdryraitdave 
F: nilvimavslekklqnatnyflmslaiadmllgflvmpvsmltilygyrwplpsklcavwiyldvlfstasimhlcaisldryvaiqnpih 
G: nilvimavsmekklhnatnyflmslaiadmlvgllvmplsllailydyvwplprylcpvwisldvlfstasimhlcaisldryvairnpie
A: yvnkrtprraaalisltwligflisip-pmlgwrtped-rsdpdactiskdh-gytiystfgafyiplllmlvlygrifraarfrirktvk 
B: yskrrtaghaatmiaivwaisicisip-plf-wrq-akaqeemsdclvntsqisytiystcgafyipsvlliilygriyraarn-rilnpp 
C: ysakrtpkraavmialvwvfsisislp-pff-wrq-akaeeevsecwntdhilytvystvgafyfptlllialygriyvearsrilkqtp
D: yarkrtakraalmiltvwtisifismp-plf-wrshrrlspppsqctiqhdhviytiystlgafyipltlililyyriyhaaks--lyqk
E: yarkrtpkhagimitivwiisvfismp-plf-wr— hqgtsrddeciikhdhivstiystfgafyiplalililyykiyraaktlyhkrqa
F: hsrfnsrtkaflkiiavwtisvgisinpipvfglq-ddskvfkegsclladdn— fvligsfvsffipltimvity---------------
G: hsrfnsrtkaimkiaivwaisigvsvpipviglrdeekvfvnnttcvlndp— nfvligsfvaffipltimvity---------------
A: kvektgadtrhgaspapqpkksvngesgsrnwrlgveskaggalcangavrqgddgaalevievhrvgnskehlplpseagptpcapasfe
B: slygkrfttahlitgsagss-lcslnsslheghshsagsplffnhvkikladsalerkri------------------------------
C: nrtgkrltraqlitdspgstssvtsinsrvpdvpsesgspvyvnqvkvrvsdallekkkl------------------------------
D: rgssrhlsnrstdsqnsfasckltqtf cvsdf stsdpttefekfhasir------------------------------------- ippf
E: sriakeevngqvllesgekstksvstsyvlekslsdpstdfdkihstvr------------------------------------- sirs
F: -------------------------------------------- fltikslqkeatlcvsdlgtraklasfsflpqsslsseklfqrsih
G: ------------------------------------ cltiyvlrrqalmllhghteeppglsldflkcckrntaeeensanpnqdqnarr
A: rknernaeakrkmalarerktvktlgiimgtfilcwlpffivalvlpfcessc— hmptllgaiinwlgysnsllnpviyayfnkdfqnaf
B: ------------ saarerkatkilgiilgafiicwlpffwslvlpicrdsc— wihpalfdfftwlgylnslinpiiytvfneefrqaf
C: ------------ maarerkatktlgiilgafivcwlpffiislvmpickdac— wfhlaifdfftwlgylnslinpiiytmsnedfkqaf
D: dndldhpgerqqisstrerkaarilglilgafilswlpffikelivgl--siytvssevadfltwlgyvnslinpllytsfnedfklaf
E: efkhekswrrqkisgtrerkaattlglilgafvicwlpffvkelwnv cdkckiseemsnflawlgylnslinpliytifnedfkkaf
F: repgsytgrrtmqsisneqkackvlgivfflfwmwcpffitnimavickescnedvigallnvfvwigylssavnplvytlfnktyrsaf 
G: rkkkerrprgtmqainnerkaskvlgivffvflimwcpffitnilsvlcekscnqklmekllnvfvwigyvcsginplvytlfnkiyrraf
A: kkiikckfcrq 
B: qkivpfrkas 
C: hklirfkcts 
D: kklircreht 
E: qklvrcrc
F: sryiqcqykenkkplqlilvntipalaykssqlqmgqkknskqdakttdndcsmvalgkqhseeaskdnsdgvnekvscv 
G: snylrcnykvekkppvrqiprvaatalsgrelnvniyrhtnepviekasdnepgiemqvenlelpvnpsswserissv
A human 5-HT iA, B human 5-HTjj)a , C human 5-HTjDp, D human 5-htip, E  human 5-htjp, 
F human 5-HT2A, G human 5-HT2C
Figure 4 Sequence alignment of the human 5-HT receptors
sequence and then cross-referencing the hydrophobic regions with the a-helices 
of the experimentally derived 3-dimensional structure 119
The hydrophobicity profiles of the 5-HT receptors readily indicated six distinct 
hydrophobic regions corresponding well with the first six regions of high 
sequence conservation. These motifs were identified as transmembrane helices 1 
to 6. Helix 7 was less well defined from the hydrophobicity profiles but the 
sequence alignment allowed the identification of helix 7 on the strength of its 
high sequence identity (Figure 5).
It is noted that there are sequence gaps in two of the identified transmembrane 
domains. Insertions and deletions are unlikely in structurally conserved regions. 
The gaps however occur towards the C-terminus of both helices and may result 
from an incorrect local alignment or overestimation of the lengths of the a -  
helices. Nevertheless these discrepancies will have very little bearing upon the 
agonist binding site of the 5-HTj receptors.
2.1.4 Helical wheel analysis
The identified a-helices were plotted around helical wheels at intervals of 100° 
using the GCG program HelicalwheeP83. The helical wheels for each receptor 
were arranged upon the template of bacteriorhodopsin. The rotational position 
of each helix was evaluated according to four factors.
1 Hydrophilic and charged groups were directed towards the central cleft away 
from the hydrophobic environment of the lipid membrane.
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HELIX 1 HELIX 2
A
B
C
D
E
F
G
VITSLLLGTLIFCAVLGNACWAAIA  
ISLAW LSVITLATVLSNAFVLTTIL  
VLLVMLLALITLATTLSNAFVIATVY 
MLICMTLWITTLTTLLNLAVIMAIG  
ILVSLTLSGLALMTTTINSLVIAAII 
NWSALLTAWIILTIAGNILVIMAVS 
NWPALSIVIIIIMTIGGNILVIMAVS
YLIGSLAVTDLMVSVLVLPMAAL- YQV 
YLIG SLATTDLLVSILVM PISIA-YTI 
YLIASLAVTDLLVSILVMPISTM-YTV  
YLICSLAVTDLLVAVLVMPLSII-YIV  
YLICSLAVTDFLVAVLVMPFSIV-YIV  
YFLMSLAIADMLLGFLVMPVSMLTILY 
YFLMSLAIADMLVGLLVMPLSLLAILY
HELIX 3 HELIX 4
A
B
C
D
E
F
G
VTCDLFIALDVLCCTSSILHLCAIAL 
ILCDIWLSSDITCCTASILHLCVIAL 
WCDFWLSSDITCCTASLIHLCVIAL 
FLCEVWLSVDMTCCTCSILHLCVIAL 
WCDIWLSVDITCCTCSILHLSAIAL 
KLCAVWIYLDVLFSTASIMHLCAISL 
YLCPVWISLDVLFSTASIMHLCAISL
AAALISLTW LIGFLISIP-PM L  
A A TM IA IV W A ISICISIP-PLF  
AAVMIALVWVFSISISLP- PFF  
AALM ILTVW TISIFISM P-PLF  
AG IM ITIV W IISV FISM P-PLF  
AFLKIIAVWTISVGISMPIPVF 
AIMKIAIVWAISIGVSVPIPVI
HELIX 5 HELIX 6
A YTIYSTFGAFYIPLLLMLVLY  
B YTIYSTCG A FYIPSV LLIILY  
C YTVYSTVGAFYFPTLLLIALY 
D Y T IY ST LG A FY IPLT LILILY  
E ST IY ST FG A FY IPLA LILILY  
F FVLIG SFV SFFIPLTIM VITY  
G FVLIG SFVAFFIPLTIM VITY
KTLGIIMGTFILC WL PFFIVALVL PF 
K ILG IILG A F11C W LPFFW SLV LPI 
KTLGIILGAFIVCW LPFF11S LVMPI 
RILG LILG AFILSW LPFFIKELIVG L  
TTLGLILGAFVIC WL PFFVKELWNV  
KVLGIVFFLFWMWCPFFITNIMAVI 
KVLGIVFFVFLIMWCPFFITNILSVL
HELIX 7
A LGAIINWLGYSNSLLNPVIYAY
B LFDFFTWLGYLNSLINPIIYTV
C IFDFFTWLGYLNSLINPIIYTM
D VADFLTWLGYVNSLINPLLYTS
E MSNFLAWLGYLNSLINPLIYTI
F LLNVFVWIGYLSSAVNPLVYTL
G LLNVFVWIGYVCSGINPLVYTL
A human 5-H T1A, B human 5-HT1Da, C human 5-HT1Dp, D human 5-ht1E, 
E human 5-ht1F, F human 5-FIT2A, G human 5-HT2c
Figure 5 The seven a-helices of the human 5-HT receptors
2 Highly conserved residues were directed towards the central cleft, these 
residues are likely to be involved in the receptor activation process or in 
maintaining the receptor structure.
3 Residues proposed to be involved in ligand binding from mutagenesis data 
(section 1.1.4.3) were directed towards the central cleft.
4 Proline residues in transmembrane helices prefer to pack against the protein 
interior or against other helices^ 84.
These rules were adhered to as strictly as possible, however, it became 
unavoidable that the criteria could not be met at all times. This resulted in 
several serine and threonine residues packing against other helices or the 
membrane. It is also appreciated that although the helical wheel arrangements 
give a good 2-dimensional representation of the receptors they cannot account 
for any distortions of the helical backbone caused by proline residues.
2.1.5 Modelling of the a-helices
The individual a-helices of the 5-HTj a , 5-H T ij)a  and 5-HTjDp receptors 
were constructed using the biopolymer module of Insightll as right-handed a -  
helices with dihedral angles of O =-650 , ¥ = - 4 0 °  and co=180°. As previously 
mentioned several of the helices contain proline residues which tend to induce 
kinking of the a-helical backbone. It is thought that this distortion may be an 
important structural feature of these receptors and thus should be incorporated 
into the models.
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Proline induced kinks were therefore introduced according to the work of 
Polinsky et a/. 385 who studied the minimum energy conformations of the cc- 
helical peptide ALAg-LEU-PRO-PHE-ALAg at a dielectric constant of 4.0.
The C-terminus of each helix was capped with an N-methyl group and the N- 
terminus of each helix with an acetyl group. Lysine, arginine, aspartic acid and 
glutamic acid residues were all assumed to be charged. The potential types and 
partial charges were all fixed using the set of rules accompanying the CVFF  
forcefield386 as supplied with Discover387> Each individual helix was 
subjected to 200 steps of steepest descent energy minimisation without using 
cross-terms followed by 1000 steps of conjugate gradient energy minimisation 
using cross-terms. All minimisations and subsequent minimisations were 
performed with a dielectric constant of 4.0 using the CVFF forcefield. The 
dielectric constant of 4.0 was chosen to simulate the hydrophobic environment 
of the receptor.
The mean RMS deviation of the helical backbones between minimised and non- 
minimised helices was 0.998 A. In all cases helix 4 was observed to deviate 
slightly more than the other helices and this was attributed to the PRO-PRO  
motif causing backbone conformational change.
2.1.6 Modelling the 5-HTi a  receptor
The seven energy minimised a-helices of the 5-HTj a  receptor were 
superimposed onto the bacteriorhodopsin template. The direction of the 
sidechain of the first residue of each 5-HTj a  receptor helix, as identified from 
the helical wheels (section 2.1.4), was matched with the first residue of the 
corresponding bacteriorhodopsin helix whose sidechain pointed in the same 
direction. This resulted in an initial alignment of the 5-HT \ a  receptor backbone
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with that of bacteriorhodopsin and allowed the superposition of the backbone 
atoms of the 5-HTj a  receptor onto the backbone atoms of bacteriorhodopsin.
This initial crude molecular model was then refined. Some of the helices were 
rotated about their helical axis to obtain a model that was totally consistent with 
the helical wheel projections. Translation of helices was also applied to improve 
interhelical sidechain interactions. The sidechain conformations of the residues 
were checked with reference to the standard rotamer library as supplied with the 
homology module of Insightll to ensure no sidechains existed in unlikely high 
energy conformations. The loop and terminal domains were not modelled due to 
the extreme uncertainty of their conformation. Additionally it is believed^ that 
the agonist binding site of the cationic amine neurotransmitter receptors is within 
the transmembrane core.
The receptor model was then energy minimised for 1000 iterations of steepest 
descent followed by 2000 iterations of conjugate gradient minimisation; all 
backbone atoms were fixed during the simulation. This was followed by a 
molecular dynamics simulation of 10 ps initialisation and 100 ps simulation at 
310 K with a time step of 1 fs; again with backbone atoms fixed. Non-bonded 
cutoffs were applied at 12 A for both the dynamics and minimisation steps. The 
simulation period was divided into 10 ps intervals and average conformations 
over these periods were calculated. Finally the average conformations were 
energy minimised for 1000 steps of steepest descent followed by 2000 steps of 
conjugate gradient again using 12 A cutoffs and fixed backbone atoms. The 
resulting minimum energy conformation was retained for the modelling of 
ligand receptor interactions.
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2.1.7 Modelling the 5-HTij)a  and 5-HTij)p receptors
There were at least three possible methods by which the 5-HTjp)a  and 
5-HTiDp receptors could be modelled.
1. The 5-HTip)a  and 5-H Tjj)p receptor helices could be superimposed onto 
the backbone of bacteriorhodopsin and the receptor models could be built in 
the same manner as the 5-HT \ a  receptor.
2. Homology models of the 5-HTip)a  and 5-HTj£)p receptors could be 
constructed using the exact backbone of the previously constructed 5-HT j a  
receptor model. The sequence alignment of the 5-HT receptors could be 
used to graphically mutate the 5-HT j a  receptor model into the required 
5-HTi d  receptor sequence.
3. The 5-HTj a  receptor model could be used as the template upon which the 
a-helices of the 5-H T id  receptors could be superimposed.
Method 1 could have possibly resulted in 5-HTjp) receptor models that were 
quite distant in terms of backbone atom deviation from the 5-HT j a  receptor 
model. Method 2 would give the impression of forcing the backbone of the 
5-HT jd  receptor models to adopt the exact conformation of the 5-H T\ a  
receptor model. Therefore the method of choice was option 3.
The transmembrane helices of the 5-HTjp)a  and 5-HTjp)p receptors were 
superimposed onto the corresponding helices of the 5-HT\ a  receptor model 
using their backbone atoms. Sidechain conformations were checked with the 
supplied rotamer library and the models were subjected to an identical 
minimisation and dynamics protocol as described for the 5-H T \a  receptor
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model in section 2.1.6. The RMS gradient of the minimised receptor models 
was less than 0.001 kcal/A. The RMS deviations in backbone structures were 
calculated (Table 2) and were found to be consistent with the sequence 
alignment, in that the 5-HTip)a  and 5-HTipjp receptors show greater similarity 
with each other rather than with the 5-HTj a  receptor.
Receptor Backbone RMS deviation (A)
5-HT1A /5 -H T 1Da 0.77
5-HT1 A /5 -H T 1DB 0.76
5-HT1D(x /5 -H T IDB 0.42
Table 2 Backbone RMS deviations between the 5-HT receptor models
2.1.8 Ligand - Receptor complexes
2.1.8.1 5-Hydroxytryptamine
5-HT (1) was assembled within Insightll, the ethylamine sidechain was 
protonated and CVFF forcefield potential types and partial charges were 
assigned. The molecule was then energy minimised to a gradient of less than
0.001 kcal/A to give the two global minimum energy conformations previously 
calculated^8_ These were named 5-HT(A) and 5-HT(B) (Figure 6).
The two conformations of the ligand were docked into the 5-HT j a  and 5-H T jt ) 
receptor models in a variety of positions allowing the protonated amine group to 
interact with the helix 3 aspartate residue which protrudes into the central cleft of 
the models. The hydroxyl group of 5-HT was positioned in such a way so it 
could potentially interact with a number of serine or threonine residues upon 
helices 4, 5 and 6. Sidechain conformations of the receptor model were again 
cross-referenced with the rotamer library to ensure no sidechains were trapped in
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unlikely high energy conformations. The ligand receptor complexes were then 
energy minimised for 1000 iterations of steepest descent followed by 2000  
iterations of conjugate gradient minimisation. Cutoffs were applied at 12 A and 
the receptor backbone atoms were fixed in position.
HO
D2 ^
ClfiC4
N
>
\H
Conformation D1 (C1-C2-C3-C4) D2 (C2-C3-C4-N)
5-HT (A) 80.33° -178.40°
5-HT (B) -80.33° 178.40°
Figure 6 The global minimum energy conformations of 5-HT
2.1.8.2 8-Hydroxy-2-(di-w-propylamino)tetralin
8-Hydroxy-2-(di-«-propylamino)tetralin (8-OH-DPAT, 12) is a selective 
5-HT j a  receptor agonist388,389 (Table 3). Although both enantiomers of (12) 
exhibit similar high affinity binding at the 5-HT\ a  receptor it is known that only 
the R enantiomer is a full agonist, the S enantiomer being a partial agonist^O. 
Therefore this study is concerned only with (R)-8-OH-DPAT (Figure 7).
The tetralin ring structure was built and energy minimised within Insightll 
yielding two distinct ring conformations. These conformations were found to be 
consistent with conformations found for the tetralin ring moiety within the 
CSSR database^93,394 The required substituents were added, the molecules
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were protonated and partial charges assigned. Conformational analysis was 
performed at 30° increments around the five rotatable bonds as illustrated in 
Figure 7.
Ligand Binding Affinity (pKj)
5-H T1A(») 5-H T1Da(b) 5-H TIDB(b)
5-HT 8.38 8.41 8.37
8-OH-DPAT 8.61 6.92 6.59
5-CT 9.53 9.15 8.80
5-OH-TMT 6.70(c) na na
Sumatriptan 6.62 8.47 8.11
(a) 5-HTj a  binding data from reference 391, (b) 5-HT jd  binding data from reference 27, 
(c) 5-OH-TMT data from reference 392, na no data available
Table 3 Binding affinity data for compounds to be docked into receptor models
Figure 7 The five rotatable bonds of (R)-8-OH-DPAT
Each conformer was energy minimised to an RMS gradient of less than 0.001 
kcal/A. The lowest energy conformation for each ring conformation was 
retained and named 8-OH-DPAT(I) and 8-OH-DPAT(II) (Figure 8) with the 
latter being the global minimum energy conformation by 3 kcal/mol. Both 
conformations were docked into the 5-HTj a  and 5-HTjp) receptor models by 
superposition of the phenol moiety of 8-OH-DPAT onto that of 5-HT in the final 
energy minimised 5-HT receptor complexes. The 8-OH-DPAT receptor
100
FIGURE 8
The tw o conform ations o f 8-OH-DPAT
complexes were energy minimised in exactly the same manner as for the 5-HT 
receptor complexes with the exception that 18 A cutoffs were used due to the 
increased size of the ligand.
2.1.8.3 5-Carboxamidotryptamine and 5-Hydroxy-7V,7V,./V- 
trimethyltryptamine
5-Carboxamidotryptamine (5-CT, 18) is a high affinity nonselective 5-HT 
receptor agonist^^l (Table 3). 5-Hy droxy-A,N,A-trimethy ltryptamine (5-OH- 
TMT, 132) binds at 5-HTj a  sites with an affinity several hundred fold lower 
than 5-HT39A Both molecules were constructed within Insightll, 5-CT was 
protonated, partial charges were assigned and both molecules were energy 
minimised as previously described for 5-HT. For each molecule two minimum 
energy conformations having the C-3 substituent in a similar position to that of 
the optimised conformations of 5-HT were obtained. These were named 
5-CT(A), 5-CT(B), 5-OH-TMT(A) and 5-OH-TMT(B).
The two conformations of 5-CT were docked into all the 5-HT receptor models 
while 5-OH-TMT was docked only into the 5-HTj ^  receptor model since there 
was no binding affinity data available for this compound at cloned 5-HTip)a  
and 5-H Tij)p receptors. All conformations were docked into the receptor 
models by superposition of the indole ring of the ligands onto the indole ring of
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5-HT in the final energy minimised 5-HT receptor complexes. All the ligand 
receptor complexes were then energy minimised using exactly the same criteria 
as described for 8-OH-DPAT.
2.1.8.4 Sumatriptan
Sumatriptan (4) was constructed within Insightll, the molecule was protonated, 
and partial charges were assigned. Energy minimisation afforded two 
conformations A and B similar to those described for 5-HT. The C-5 substituent 
of sumatriptan contains three rotatable bonds (Figure 9) which will dictate the 
position of the substituent.
H CH,
N ' - "  3CH,
H
Figure 9 The three rotatable bonds of the C-5 substituent of sumatriptan
A conformational analysis was performed about these bonds using a 3 0 °  
increment. Subsequent energy minimisation to an RMS gradient of less than
0.001 kcal/A yielded two sets of thirteen minimum energy conformations 
differing in energy by 6.8 kcal/mol. The twenty-six conformers were docked 
into the 5-HTip)a  and 5-HTjp)p receptor models by superposition of the indole 
ring of sumatriptan onto the indole ring of 5-HT in the final energy minimised 
5-HT receptor complexes. Only the most promising conformations of the ligand 
from the sumatriptan 5-H T j d  receptor complexes were docked into the 5-HT j a  
receptor model. All ligand receptor complexes were energy minimised as 
described previously for 8-OH-DPAT.
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2.1.9 Small molecule modelling of thieno[2,3-b]pyridines
The thieno[2,3-b]pyridine analog (133) of 5-HT was constructed within 
Insightll, protonated and CVFF forcefield potential types and partial charges 
were assigned. The molecule was energy minimised to an RMS gradient of less 
than 0.001 kcal/A. This resulted in two global minimum energy 
conformations^ 8 similar to 5-HT(A) and 5-HT(B), these were named THI(A) 
and THI(B) (Figure 10).
(133)
The thieno[2,3-b]pyridines were subjected to an RMS fitting procedure onto the 
respective conformation of 5-HT by means of superimposing the 6-membered 
rings, protonated amino groups, hydroxyl groups and a superposition of the 
thiophene sulfur of THI(A) and THI(B) onto the indole nitrogen of 5-HT. 
Additionally the technique of electrostatic fitting was also used. An electrostatic 
potential similarity function was calculated for the molecules under 
consideration using the Search_Compare module of Insightll. The 
thienopyridines THI(A) and THI(B) were aligned onto the 5-HT conformations 
5-HT(A) and 5-HT(B) respectively by optimisation of the electrostatic potential 
similarity function. Thus the two molecules under consideration are overlapped 
in such a way as to maximise the similarity function. This resulted in a 
molecular alignment and a similarity score between -1 (maximum dissimilarity) 
and 1 (maximum similarity). A molecular volume comparison was also 
performed.
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FIGURE 10
The tw o con form ation s o f the  
thieno[2,3-h] pyridine analog o f 5-HT
2.1.10 Thieno[2,3-b]pyridine receptor interactions
The two thieno[2,3-b]pyridine conformations THI(A) and THI(B) were docked 
into the 5-HT receptor models by superposition of the pyridine ring onto the 
phenyl ring of 5-HT in the final, energy minimised 5-HT receptor complexes. 
The resulting complexes were energy minimised following the same 
minimisation protocol as described for the 8-OH-DPAT receptor complexes.
2.1.11 Ligand design
In an attempt to identify possible regions within the 5-HT receptor models that 
may confer selectivity, use has been made of the ligand design program 
Ludp95> Ludi suggests how suitable molecular fragments from a fragment 
library may be positioned within an active site of a protein of interest. A 
receptor interaction score is calculated for each suggested fragment. 
Additionally Ludi can be used in link mode suggesting fragments which may be 
linked to existing ligands which are positioned within the binding site of the 
protein.
The energy minimised receptor complexes of 5-HT, 5-CT and THI were used as 
starting points for Ludi fragment searches. All searches were performed in link 
mode looking for potential fragments to add to the existing ligands. All 
suggestions were studied and checked for their viability. Some of the more 
interesting suggestions of ligands were docked into the final, energy minimised 
5-HT receptor complex and energy minimised as described previously for 8-OH- 
DPAT.
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2.2 DISCUSSION
2.2.1 The modelling procedure
A number of assumptions have been made during the modelling procedure, most 
notably the use of bacteriorhodopsin coordinates as a template. At present the 
bacteriorhodopsin coordinates are the only high resolution data available for any 
seven transmembrane helix protein ^ 9 .  Since it is known that the GPCRs are 
seven helical proteins it is a reasonable assumption that bacteriorhodopsin is a 
suitable starting place for modelling the 5-HT receptors. If, or when, full 
transmembrane coordinates of the GPCR rhodopsin become available the 5-HT 
receptors could be remodelled using a homology approach from a sequence 
alignment of the 5-HT receptors with rhodopsin. There is however no guarantee 
that the exact arrangement of a-helices in the 5-HT receptors is identical to that 
of rhodopsin.
The transmembrane helices of the 5-HT receptors were identified from the 
hydrophobicity analysis and sequence conservation data. The rotational position 
of each helix was determined from helical wheel projections which allowed the 
modelling of the 5-HTj a  receptor by superimposing the helices of the 5-H T i a  
receptor onto the template of bacteriorhodopsin. The 5-HT id  receptors were 
then modelled using the prototype 5-HTj a  receptor model as a template. The 
modelling procedure may seem a little crude but without high resolution 
coordinates of the 5-HT receptors or any homologous protein it is believed that 
the procedure utilised resulted in models that are as accurate as any that have 
been described in the literature. It was not the intention of this study to create 
the "perfect" 5-HT receptor model but merely to produce a model that is 
qualitatively useful and could be used as a guide in the rational design of novel 
drugs.
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The complexity and lack of knowledge of the entire 5-HT receptor system render 
the modelling procedure very difficult. Only the seven transmembrane helices 
of the 5-HT receptors were modelled (Figure 11). The loop and terminal regions 
were not modelled since there is too much uncertainty over the conformation of  
these domains, and in any case ligand binding of the cationic amine 
neurotransmitters is believed to involve the transmembrane helices only84. No 
lipid bilayer or internal water molecules were included in the models to save 
computational time and because it is still not entirely clear whether or not water 
molecules are present in the transmembrane cleft. All minimisations of the 
complete receptor models therefore have been performed with the backbone 
atoms fixed in position. This is obviously unrealistic but in the absence of the 
loop regions and the lipid bilayer the positions of the a-helices must be 
constrained to preserve the overall topology of the receptor models.
It is further believed that molecular dynamics simulations of GPCR models 
without modelling the loops, terminal domains, lipid bilayer and solvent are 
unrealistic. Any attempts to account quantitatively for ligand binding and signal 
transduction using models of this type must be viewed with scepticism.
2.2.2 Agonist receptor complexes
Amino acid residues of the 5-HT receptors will be referred to by their three letter 
code followed by the respective position of the residue in the helix followed 
finally by the helix number in parenthesis.
2.2.2.1 The 5-HT receptor complex
The results from the extensive docking studies of the 5-HT conformations were 
analysed in terms of ligand receptor interactions and relevance towards the
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experimental data available. Given the limitations of the modelling approach 
and the forcefield used, the overall topology of the receptor binding site was 
considered to be the most important aspect of the models. Hence the final 
results obtained and presented are not necessarily the most energetically 
favourable orientations of the ligand within the binding site but they did prove to 
be the most feasible in terms of the experimental data reported in the literature.
The observed 5-HT binding pocket was found to be in a similar position for both 
conformations of 5-HT at the 5 - H T ^  (Figure 12), 5-H T n )a  (Figure 13) and 
5-HTi£)p (Figure 14) receptor models. The 5-HT molecule is positioned 
approximately 15 A into the central cleft from the extracellular opening and is 
surrounded by helices 3, 4, 5 and 6. It is also conceivable that helix 7 may 
contribute to the binding of some agonists. The aromatic indole ring of 5-HT is 
anchored by two conserved aromatic residues TRP9(H4) and PHE18(H6) which 
lie below the plane (towards the cytoplasm) of the indole ring and create 
favourable perpendicular interactions with the ligand.
The protonated amine of 5-HT forms an ionic interaction with the carboxylate 
anion of the important aspartate residue of helix 3 ASP10(H3) with a mean 
NH--OC distance of 2.01 A. The ion pair is further stabilised from the 
interactions of the protonated amine function with three neighbouring aromatic 
residues PHE/TRP6(H3), PHE17(H6) and TRP14(H6). This type of 
stabilisation has been observed in the crystal structures of some globular 
proteins^96
The 5-hydroxyl group of 5-HT can accept a hydrogen bond from THR6(H5) 
with a mean OH—O distance of 1.93 A. This residue is mutated for a serine in 
the 5-HT2 subtype of receptors. In the case of the 5-HT^j) receptors it is also 
possible that the oxygen of the hydroxyl group of 5-HT can accept an additional
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FIGURE 11
The seven helices o f the 5-HT recep to r m odels 
view ed from  the extracellu lar su rface
A L A 21(H 6)
P H E 17(H 6)
P H E6(H 3)
FIGURE 12
5-HT(A) In the 5-HT1A receptor agonist binding site
PH EI 8 (H 6)
TH RPX *
A S P 10(H 3)
1
T R P 9(H 4)
TR P6(H 3)
S E R 2K H 6)
PH E17(H 6)
A SP10(H 3)
PHE18CH6)
TH R 6(H 5)
' V >
\
S E R 12(H 4)
T R P9(H 4)
FIGURE 13
5-HT(B) In the 5-HT1D receptor agonist binding site
T H R 6 (H 5 )
P H E 1 7 (H 6 )
T R P 6 (H 3 ) S E R 1 2 (H 4 )
S E R 2 1 (H 6 ) P H E 1 8 (H 6 )
A S P 1 0 (H 3 )
T R P 9 (H 4 )
FIGURE 14
5-HT(B) In the 5-HT1D(i receptor agonist binding site
hydrogen bond from SER21(H6) although the mean hydrogen bond angle ( 0 — 
H --0 ) of 114° is not ideal. This residue is mutated for an alanine residue in the 
5-HT j a  receptor.
An unusual interaction was discovered between the indole N-H group of 5-HT 
and SER12(H4) of the 5-HTjp) receptor models. The hydroxyl group of 
SER12(H4) is below the plane of the indole ring and directly underneath the 5- 
membered pyrrole moiety thus the serine residue cannot accept a hydrogen bond 
from the indole ring. The indole ring cannot act as a good hydrogen bond 
acceptor since the lone pair of electrons associated with the indole nitrogen is 
used in maintaining the aromaticity of the indole ring. This therefore prompts 
the hypothesis that the hydroxyl group of the serine residue interacts in a charge 
transfer complex with the ^-electrons of the indole ring. The mean distance 
from the hydroxyl group to the centroid of the 5-membered ring is 2.49 A. This 
type of interaction has previously been reported^ 6 in a model of the 
p2~adrenergic receptor. The alternatives to this hypothesis are that the indole N- 
H can donate a hydrogen bond to the backbone carbonyl of SER12(H4) or that 
the 5-HT binding site is inaccurate. In the 5-HT j a  receptor model the serine 
residue is mutated for glycine and the indole N-H of 5-HT can interact with the 
backbone of GLY12(H4). This interaction however is thought to be of minor 
importance for agonist binding at the 5-HT j a  receptor for reasons that will be 
discussed in section 2.2.2.2.
It has also become apparent that both conformations of the ligand 5-HT(A) and 
5-HT(B) can be accommodated within the binding site with minimum steric 
clashing between receptor and ligand. A closer inspection taking into account 
the relative ligand receptor interaction energies (Table 4) indicates that the 
5-HTj a  receptor model has a distinct preference for conformation A of 5-HT.
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T his is in d irect contrast to the 5 -H T jj)  receptor m odels w hich show  greater 
(less positive) in teraction  energies w ith  5-H T(B) i.e. conform ation B.
L igand R eceptor m odel In teraction  Energy
(kcal/m ol)
5-H T(A ) 5 -H T i a 0.0
5-H T(B) 5 -H T i a 17.3
5-H T(A ) 5 -H T 1Dtx 5.1
5-H T(B ) 5 -H T iD a 0.0
5-H T(A ) 5 -H T io p 3.3
5-H T(B) 5 -H T io p 0.0
Table 4 R elative interaction energies o f  5-H T(A ) and 5-H T(B) w ith  the
receptor m odels
2.2.2.2 The 8-OH-DPAT receptor complex
W ithin  the 5 -H T j a  receptor m odel both  conform ations o f  the ligand, 8-O H - 
D PA T(I) and 8-O H -D PA T(II) can be accom m odated in  the agonist b ind ing  site 
(F igure 15) w hich w as identified for 5-HT. The w-propyl substituents are 
surrounded by the hydrophobic residues PH E17(H 6) and PH E6(H 3) w hich 
appear to adjust their conform ations slightly  to allow  ligand binding. The 
residues T R P14(H 6), ILE7(H 3) and ILE5(H 7) also form  interactions w ith  the n- 
propyl substituents but are not show n in F igure 15.
The protonated  am ino group form s an ion pair w ith  A SP10(H 3) and the 
hydroxyl group can accept a  hydrogen bond from  TH R 6(H 5). C alculation  o f  the 
ligand  receptor in teraction  energies (Table 5) have dem onstrated  that 8-O H -
1 0 9
D PA T(II) form s a m ore energetically  favourable ligand receptor com plex. T his 
is consisten t w ith  8-O H -D PA T(II) being the global m in im um  energy 
conform ation  o f  the ligand.
L igand R eceptor m odel Interaction  Energy
(kcal/m ol)
8 -O H -D P A T ® 5 -H T i a 14.1
8-O H -D PA T(II) 5 -H T 1a 0.0
Table 5 R elative interaction energies o f  8-O H -D PA T(I) and 8-O H -D PA T(II) 
w ith  the 5-H T j a  receptor m odel
The results for the docking o f  8-O H -D PA T into the 5-H T jp) receptor m odels 
presented  quite a  d ifferent story (F igure 16). B oth  conform ations o f  8-O H - 
D PA T  in the 5 -H T u )a  and 5 -H T j£ )p  receptor m odels have m oved dow n the 
central cleft tow ards the cytoplasm  by 1-2 A. This has been  attributed  to steric 
repulsion  betw een  one o f  the bulky H-propyl groups w ith  the larger tryptophan  
residue, TR P6(H 3). This residue is conserved in all o f  the 5-H T receptors o f  the 
present study w ith  the exception o f  the 5-H T j a  receptor w hich  has a 
phenylalan ine residue w hich, w ith  a  slight adjustm ent o f  conform ation can 
accom m odate the ^-propyl substituent quite easily.
Steric bum ping  w as also observed betw een the am inotetralin  ring  o f  the ligand 
and SER 12(H 4) o f  the 5-H T i d  receptors. This residue is also conserved in  all 
the 5-H T receptors exam ined in this w ork  w ith  the exception o f  the 5 - H T j^  
receptor w here a glycine is found. M ovem ent o f  the ligand as a  resu lt o f  th is 
steric bum ping  at the 5-H T jp) receptors results in the hydrogen bond o f  the 
hydroxyl group o f  8-O H -D PA T to TH R 6(H 5) being altered. The hydroxyl
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FIGURE 158-OH-DPATQl) In the 5-HT1A receptor agonist
binding site
P IIE  18(116)
A L A 2 1 (H 6 )
+ T H R 6 (H 5 )
P H E 1 7 (H 6 )
7  G L Y 12 (H 4 )
P H E 6 (H 3 )
T R P 9 (H 4 )A S P 1 0 (H 3 )
FIGURE 16
8-OH-DPAT(I) In the 5-HT1D(/ receptor agonist
binding site
group o f  the ligand now  donates a hydrogen to the threonine residue instead  o f  
accepting  a  hydrogen as is observed for the 5-H T j a  receptor com plex.
It is therefore suggested tha t SER /G LY 12(H 4) and T R P/PH E6(H 3) p lay  an 
im portan t ro le in the fit and selectivity  o f  8-O H -D PA T at the 5-H T receptors. 
The steric bum ping and tightness o f  fit o f  8-O H -D PA T at the 5 -H T jp) receptor 
m odels has led to unfavourable interactions and has caused the m ovem ent o f  the 
ligand  w ith in  the agonist b inding site. This m ay account for the selectiv ity  o f  8- 
O H -D PA T  for the 5 -H T j ^  receptor.
G oing back  to the role o f  G LY /SER 12(H 4) it is clear that 8-O H -D PA T has no 
hydrogen  bond donating group w ith  the potential to interact w ith  the backbone 
o f  G LY 12(H 4). It is therefore proposed that the interaction betw een the indole 
N -H  o f  5-H T w hich w as observed in the com plex o f  5-H T w ith  the 5-H T  j a  
receptor is no t required for h igh  affinity binding to the 5-H T j a  receptor and is 
p robably  o f  m inim al im portance.
2.2.2.3 The 5-CT receptor complex
5-C arboxam idotryptam ine w as accom m odated in  the 5-H T j a , 5 -H T ij)a  and 
5 -H T jD p  receptor m odels in a  sim ilar position  to that observed for 5-H T (no 
figure show n). In  all the receptor m odels the ion  pair w as form ed betw een  the 
p ro tonated  am ine and A SP10(H 3). The arom atic indole ring o f  the ligand  w as 
held  in position  by T R P9(H 4) and PH E18(H 6) and the carbonyl group o f  5-C T 
w as w ell positioned  to accept a  hydrogen bond from  TH R 6(H 5). A dditionally , 
in the 5 -H T jj)  receptor m odels the carbonyl oxygen could accept a further 
hydrogen  bond from  SER21(H 6).
I l l
The indole ring form ed an interaction w ith  SER 12(H 4) for the 5-H T j q  receptor 
com plexes as previously  described for 5-HT. The hydroxyl group o f  
SER 12(H 4) is directly  below  the 5-m em bered pyrrole ring  o f  the ligand, 
allow ing  the hydroxyl group to interact w ith  the arom atic ring  o f  the ligand. The 
indole N -H  is also in  a position  to form  a hydrogen bond w ith  the backbone 
carbonyl o f  SER 12(H 4). A gain, sim ilar to the results for 5-H T, the 5 -H T j a  
receptor m odel exhibited  greater interaction energy w ith  5-C T(A ) and the 
5 -H T jj)  receptor m odels show ed a preference for 5-CT(B) (Table 6).
L igand R eceptor m odel Interaction E nergy
(kcal/m ol)
5-CT(A ) 5-H T! A 0.0
5-C T(B ) 5 -H T 1A 30.7
5-C T(A ) 5 -H T m a 5.1
5-C T(B ) 5 -H T iD a 0.0
5-C T(A ) 5 -H T io p 3.7
5-C T(B ) 5 -H T io p 0.0
T able 6 R elative interaction energies o f  5-C T(A ) and 5-C T(B ) w ith  the receptor
m odels
2.2.2.4 The 5-OH-TMT receptor complex
In itial analysis o f  these com plexes show s that both  conform ations o f  the ligand 
w ere accom m odated in a sim ilar position  to that o f  5-H T w ith in  the proposed 
b inding  site o f  the 5 -H T j a  receptor m odel. A  hydrogen bond w as form ed 
betw een  T H R 6(H 5) and the hydroxyl group o f  5-O H -TM T but a  closer 
inspection  o f  the ligand binding site unearthed som e additional findings.
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F or 5-O H -T M T (A ), steric bum ping betw een the m ethyl groups o f  the quaternary  
am ine and  the arom atic residues PH E17(H 6) and PH E18(H 6) causes the 
conform ation  o f  the C-3 sidechain o f  the ligand to becom e extended. In  the case 
o f  5-O H -T M T (B ) steric bum ping o f  the sidechain m ethyl groups w ith  
P H E 17(H 6) and A SP10(H 3) w as observed. This bum ping results in  a 
conform ational change o f  the h ighly  im portant aspartate residue causing the 
carboxylate  anion to be directed aw ay from  the agonist b ind ing  site tow ards 
transm em brane helices 2 and 7.
The conform ational changes described above result in the cationic am ine group 
being positioned  further aw ay from  the carboxylate anion o f  A SP10(H 3) 
com pared to the corresponding distance in the 5-H T - 5 -H T j a  receptor m odel 
com plexes (Table 7).
L igand D istance ligand-N +— O -A SP 10(H3)
(A)
5-O H -TM T(A ) 5.18
5-O H -TM T(B ) 4.38
5-H T(A ) 3.01
5-H T(B ) 2.93
Table 7 P rotonated  am ine-A SP10(H 3) distances for the 5-O H -TM T and 5-H T 
com plexes w ith  the 5-H T j a  receptor
T his w ill undoubted ly  lead to a  significant decrease in  the electrostatic  
in teraction  energy betw een 5-O H -T M T  and A SP10(H 3). In  conclusion  the 
results h igh ligh t the tightness o f  fit betw een 5-O H -TM T and the 5-H T j a  
receptor. T his tightness o f  fit has induced conform ational changes in either the
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ligand  or the receptor leading to  an increased distance and decreased electrostatic  
in teraction  energy betw een the ligand and the im portant aspartate residue o f  
helix  3. T his m ay explain  the reduced binding affinity  o f  5-O H -T M T  for the 
5 -H T j a  receptor w hen com pared to 5-HT.
2.2.2.5 The sumatriptan receptor complex
M ajor conform ational changes in bo th  ligand and 5-H T jp) receptor m odels w ere 
observed for all but one o f  the sum atriptan C-5 substituent conform ations. The 
exception  occurred w hen the C-5 substituent w as folded back across the indole 
ring  m oiety , thus enabling sum atriptan  to be accom m odated. This resu lted  in 
tw o conform ations o f  sum atriptan, sum atriptan(A ) and sum atriptan(B ) 
dependant upon the conform ation o f  the C-3 sidechain  and sim ilar to 5-H T(A ) 
and 5-H T (B ) respectively.
B oth  conform ations o f  sum atriptan fit into the 5 -H T jp )a  and 5 -H T jD p  receptor 
m odels allow ing  the protonated  am ine group o f  sum atriptan to form  an ion  pair 
w ith  A SP 10(H 3) (F igure 17). The indole ring is again anchored by  the arom atic 
residues T R P9(H 4) and PH E18(H 6). There is how ever a m inor reorganisation  
o f  the arom atic  residues surrounding the protonated am ine - A SP10(H 3) ion pair. 
The sidechains o f  PH E17(H 6), PH E2(H 7) and PH E5(H 7) all undergo a  slight 
change in  conform ation to avoid steric bum ping w ith  the d im ethylam ino group 
o f  the ligand. The hydroxyl group o f  SER12(H 4) is positioned  directly  below  
the 5-m em bered pyrrole ring o f  sum atriptan thus allow ing the hydrogen  o f  the 
hydroxyl to interact w ith  the 71-electrons o f  the arom atic system . A n  additional 
hydrogen  bonding  interaction is p roposed betw een the indole N -H  and  the 
hydroxyl oxygen o f  SER 16(H 4) w hich is conserved in all the 5-H T receptors 
studied. O ne o f  the oxygens o f  the  sulfone group can accept hydrogen  bonds 
from  bo th  T H R 6(H 5) and SER 21(H 6).
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S E R 2 K H 6 )
T H R 6 (H 5 )
P H E 1 7 (H 6 )
T R P 6 (H 3 ) S E R 12(H 4)
P H E 1 8 (H 6 )
i) 5N l
T R P 9 (H 4 )
FIGURE 17
Sumatriptan(B) In the 5-HT1D i receptor agonist
binding site
E xam ination  o f  the interaction energies betw een the two conform ations o f  
sum atriptan  and the 5-H T jp) receptor m odels show ed resu lts that w ere 
consisten t w ith  those for 5-HT and 5-CT. The 5 -H T jp)a  and 5 -H T jD p  receptor 
m odels have a  p reference for the sum atriptan(B ) conform ation (Table 8).
L igand R eceptor m odel Interaction E nergy
(kcal/m ol)
Sum atriptan(A ) 5-H T lD a 12.2
Sum atriptan(B ) 5 -H T iD a 0.0
Sum atriptan(A ) 5 -H T io p 20.2
Sum atriptan(B ) 5 -H T io p 0.0
Table 8 R elative interaction  energies o f  sum atriptan(A ) and sum atriptan(B ) w ith
the 5-H T j d  receptor m odels
The 5 -H T i a  receptor m odel and sum atriptan  com plex show ed quite contrasting  
results. The ion  pair betw een the protonated  am ine and A SP10(H 3) is form ed 
and one o f  the sulfone oxygen atom s can m aintain  the hydrogen  bond w ith  
TH R 6(H 5). The 5-H T i a  receptor has an alanine residue at position  21 o f  helix  
6 (serine in  the case o f  5 -H T ij)) , but th is residue does no t allow  the C-5 
substituent o f  sum atriptan  to be held in position  and thus stabilise  the 
conform ation o f  the  ligand. The nonpolar alanine residue A L A 21(H 6) does no t 
in teract favourably  w ith  the polar sidechain  o f  sum atriptan. A s a  resu lt the 
ligand  has repositioned  itse lf w ithin  the central cleft causing som e 
conform ational changes in the arom atic residues TR P14(H 6) and P H E 17(H 6) 
w hich  are in  the v icinity  o f  the cationic am ine. The inability o f  A LA 21(H 6) o f  
the 5-H T i a  receptor to  hold sum atriptan  in the folded conform ation  and to
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stabilise the "active" conform ation o f  the ligand m ay contribute to the decreased 
affin ity  o f  sum atriptan  for the 5-H T j a  receptor.
2.2.3 Evaluation of the binding site
2.2.3.1 Consistency with mutagenesis data
The agonist b ind ing  site presented  w ith in  this study for the three 5-H T receptor 
m odels is consisten t w ith  the lim ited m utagenesis data available. A SP10(H 3) is 
k n o w n t o  be crucial in the binding o f  high affinity agonists at the 5-H T j a  
receptor. M utation  o f  TH R 6(H 5) has also been shown! 04 to have a critical 
effect on the b inding o f  agonists to the 5-H T j a  receptor. In the m odels 
developed both  o f  these residues have been show n to have essential roles. The 
aspartate residue form s an ion pair w ith  the cationic am ine group w hich is 
characteristic o f  all 5-H T receptor agonists and the threonine residue donates a 
hydrogen bond  to the agonist.
M utagenesis studies 104 have aiso im plicated the serine residue SER 5(H 5) in the 
b inding o f  agonists to the 5-H T j a  receptor. The 5-H T receptor m odels how ever 
show  no d irect interaction betw een any o f  the studied agonists and SER5(H 5). 
M utation  o f  the equivalent residue^ 97 jn  the P2 -adrenergic receptor, SER 203- 
A LA  resu lted  in the absence o f  norm ally  processed receptor protein^4. i t  is 
therefore possib le  that the SER 5(H 5) residue o f  the 5-H T j a  and 5-H T j d  
receptors m ay play  a sim ilar role or be involved in m aintain ing the  conform ation 
o f  the receptor.
The conserved phenylalanine residue PH E18(H 6) is one o f  the arom atic residues 
in  the m odels w hich  anchors the arom atic ring m oiety  p resent in  all 5-H T 
receptor agonists and has been show n for the 5-H T2A  receptor to be im portan t in 
agonist b in d in g !08 ft js therefore p lausible that since this residue is conserved
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in  all the  5-H T receptors studied it w ill p lay a sim ilar im portan t role in the 
b ind ing  o f  agonists to the 5-H T \ a  and 5-H T jp) receptors.
O f  the rem aining  residues that have been show n from  the m odels to participate 
d irectly  in agonist b inding there is no available m utagenesis data  for the 5-H T ] 
subtype o f  receptors. These am ino acid residues such as A LA /SE R 21(H 6) and 
the residues o f  helix  4 m ay w ell be w orthy o f  m utation  studies. N evertheless the 
p resented  m odels do seem  highly  feasible because o f  their com patib ility  w ith  the 
lim ited  m utagenesis data.
2.23.2 The binding of 5-HT, 5-CT, 5-OH-TMT and 8-OH-DPAT
The receptor m odels can account for the h igh  affinity binding o f  5-C T and 5-H T 
as a  resu lt o f  the com fortable accom m odation o f  these ligands w ith in  the central 
c left o f  the 5-H T ] a  and 5-HT]p> receptor m odels. The decreased affin ity  o f  5- 
O H -T M T  for the 5 -H T j a  receptor is explained by steric bum ping  betw een the 
ligand and the 5-H T j a  receptor m odel. This causes conform ational changes 
w hich  increase the distance betw een the cationic nitrogen o f  5 -O H -T M T  and the 
im portan t aspartate residue o f  helix 3, A SP10(H 3). The increase in interatom ic 
d istance is accom panied by a decrease in the electrostatic energy betw een the 
ligand  and A SP10(H 3) thus explaining the decreased affinity o f  5-O H -TM T for 
the 5 -H T ] a  receptor.
T he 5 -H T ] a  selective agonist 8-O H -D PA T is one o f  the few  5-H T receptor full 
agonists that does no t contain  an indole ring. The 5-H T ] a  receptor how ever has 
no residue w ith  the potential to interact w ith  the pyrrole m oiety  o f  the indole 
ring  since a  glycine residue is found at position  12 on helix  4 (G LY 12(H 4)). A ll 
the o ther 5-H T receptors in this study have a serine residue at th is position  w hich 
can cause steric bum ping w ith  the tetra lin  ring  structure o f  8-O H -D PA T. The
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5 -H T j a  receptor m odel also has a phenylalanine residue PH E6(H 3) w hich  is 
d irectly  above (tow ards the extracellu lar space) the aspartate residue 
A SP10(H 3). PH E6(H 3) can adjust its conform ation slightly  to tolerate one o f  
the bu lky  «-propyl groups o f  8-O H -D PA T. The phenylalanine residue is only 
present in  the 5-H T j a  receptor and occupies a lesser volum e than  the tryptophan 
residue T R P6(H 3) observed for the o ther 5-H T receptors. Therefore the fact that 
the 5 -H T j a  receptor is the only 5-H T receptor o f  the present study that has the 
G LY 12(H 4) and PH E6(H 3) residues w hereas the others have SER 12(H 4) and 
T R P6(H 3) m ay explain  w hy 8-O H -D PA T is one o f  the few  selective 5-H T 
receptor agonists.
2.2.3.3 The role of THR6(H5)
O ne o f  the  m any interesting questions encountered in  this study w as the role o f  
the hydroxy l group o f  5-HT. The hydroxyl group alm ost certainly  participates in 
a  hydrogen  bond w ith  the receptor, but does it accept or donate a hydrogen  
bond?
It has b een  demonstrated^98 that the hydroxyl group o f  5-H T m ay be replaced 
by a  m ethoxy  group w ithout any significant loss o f  b inding affinity  for the 
5-H T i a  receptor. The 8-hydroxy group o f  8-O H -D PA T has also been  replaced 
by a m ethoxy, th iom ethyl or carboxam ido group w ithout loss o f  5-H T i a  
receptor b inding  affinity^98#
The 5 -H T jp ) receptors show  a sim ilar pattern. R eplacem ent o f  the hydroxyl 
group o f  5-H T for m ethoxy resulted  in a  slight decrease in binding affin ity  for 
bovine 5-H T i d  sites65 (5-H T K ;=2.2 nM , 5-M eO T K;=4.1 nM ). O -A lkyl 
derivatives o f  5-H T are also know n to bind w ith  h igh  affinity to the 5-HT]p>p
re c e p to r ^ .
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T herefore the replacem ent o f  the hydrogen  atom  o f  the hydroxyl group o f  
5 -H T j a  and 5 -H T i d  receptor agonists by o ther functional g roups appears to 
have very  little effect upon the binding affinities o f  the com pounds. This 
suggests that the C-5 substituent o f  5-H T and equivalent substituent o f  other 
5-H T  receptor agonists norm ally  acts as a hydrogen bond acceptor during 
agonist b inding at the 5 -H T j and 5 -H T j d  receptors. The p resented  m odels are 
entirely  consisten t w ith  this hypothesis since all the m odelled  agonists can 
accept a hydrogen bond from  TH R 6(H 5). It is noted that an  assum ption  has 
been  m ade that all the 5-H T receptor agonists occupy the sam e binding pocket 
and bind in a  sim ilar m anner.
2.2.3 A The binding of sumatriptan
T he b inding o f  sum atriptan  to the 5-H T receptor m odels has som e im portant 
im plications. Sum atriptan can fit into the agonist binding site o f  the 5-H T j d  
receptor m odels w hen the C-5 substituent is folded back across the indole ring 
m oiety . It appears likely that the am ino acid residues SER 21(H 6) and 
T H R 6(H 5) can hold the am ino-sulfone group in position  by  hydrogen  bonding. 
M utation  o f  SER 21(H 6) to alanine as observed for the 5-H T j a  receptor m odel 
can create unfavourable interactions betw een the sm all nonpolar alanine residue 
and the po lar C-5 substituent o f  sum atriptan. This m ay contribute to the reduced 
affin ity  o f  sum atriptan  for the 5-H T j a  receptor.
A lthough there is no m utagenesis data available for residue 21 o f  helix  6 there 
are tw o literature reports 1^2,207 0 f  the participation o f  th is residue in  ligand 
binding at the 5-H T receptor m odels. The equivalent residue o f  the 5-H T2C 
receptor, A SN 21(H 6) has been reported to form  a hydrogen bond w ith  the 
hydroxyl group o f  5-H T in a sim ilar m anner to the results p resented  in  this
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study. The sam e residue has also been im p lic a te d ^ ?  from  sequence analysis in  
the b inding o f  5-C T to the 5 -H T \ receptor subtype. Therefore it does appear to 
be possib le  that residue 21  o f  helix  6 is a  m ajor p layer in the binding o f  som e 
com pounds at the 5-H T receptors and w ould be a  suitable candidate for 
m utagenesis experim ents.
W hen d iscussing  the b inding o f  sum atriptan to the 5 -H T jj)  receptors the 
involvem ent o f  TH R 6(H 7) cannot be ignored. It has been show n by a num ber o f  
independent research  groups that the m utation o f  TH R 6(H 7)-A SN  (asparagine is 
found in  the 5 -H T j a  and rodent 5-H T j 3  receptors) decreases the affin ity  for 
sum atriptan  by  5-15 fold 1 1  T his could im ply a d irect ro le for T H R 6(H 7) 
in sum atrip tan  binding.
A nalysing the m odels developed during this study, the threonine residue w as 
found to be a  distance o f  8-10  A  aw ay from  the ligand. The threonine can 
how ever form  a hydrogen bond to the backbone carbonyl o f  P H E 2(H 7) b u t the 
asparagine residue o f  the 5-H T j a  receptor cannot. Furtherm ore it is particularly  
interesting  that the threonine residue is directly above the glycine residue 
G LY 9(H 7) w hich  is conserved in the serotonergic, adrenergic, dopam inergic and 
histam ine r e c e p t o r s ^ T h e  glycine residue m ay act as a  helical h inge allow ing  
the helix  to k ink  during ligand binding bu t unfortunately  this cannot be show n in 
the p resent m odel since the backbone atom s w ere fixed during m inim isations. 
T herefore the conform ational changes o f  PH E17(H 6), PH E2(H 7) and PH E 5(H 7) 
that accom pany sum atriptan binding to the 5-H T 1 3  receptors m ay affect the 
conform ation  o f  helix  7. A ny induced m ovem ent o f  helix  7 can be stabilised  by  
a hydrogen  bond betw een TH R 6(H 7) and the backbone o f  PH E2(H 7). T here is 
no equivalent hydrogen bond observed for the 5-H T i a  receptor m odel thus any 
changes in  the conform ation o f  the helix  around TH R 6(H 7) w ill n o t be 
stabilised.
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T his proposal o f  the function  o f  TH R 6(H 7) is supported by  S m olyar and 
O s m a n s  w ho studied the interactions o f  sum atriptan w ith  the 5 -H T jp )(X 
receptor, a lthough the sum atriptan b inding site o f  these w orkers differs 
considerab ly  from  that o f  the present study.
It can be postu lated  tha t TH R 6(H 7) plays a d irect role in sum atrip tan  b inding 
either by hydrogen bonding or in a  steric capacity. H ow ever at p resen t there is 
not enough  experim ental data available to prove any o f  these hypotheses. The 
possib ility  o f  a direct role for TH R 6(H 7) has arisen from  the rhodopsin^l 
derived m odels o f  the G PC R s. In  these m odels it is believed tha t helix  7 is 
c loser to the agonist b ind ing  site and helix 4 plays a less prom inent role. It has 
been further stated 152 that bacteriorhodopsin  based m odels ignore the 
im portance o f  residues upon  helix  7.
To tes t th is hypothesis helix  7 o f  the 5-H T j d  receptor m odels developed in this 
study w as translated into the central cleft in closer proxim ity  to helices 2 and  3 
and in  a position  sim ilar to that o f  the helix  in rhodopsin  derived m odels. 
A lthough  the calculated distance betw een TH R 6(H 7) and sum atriptan  decreased, 
it w as still in the reg ion  o f  4-5 A. This renders the possib ility  o f  a d irect 
hydrogen  bond unlikely. It is also w orth  noting  that o f  all the transm em brane 
helices o f  the 5-H T receptors the seventh helix  is undoubtedly  the m ost 
conserved  and therefore is less likely to be im portant in the selectiv ity  o f  ligands 
a t the 5-H T receptors. T hus the findings o f  th is study appear to support the  
hypo thesis that TH R 6(H 7) plays an indirect role in  the binding and selectiv ity  o f  
sum atriptan.
In  sum m ary, two am ino acid residues have been  identified from  the receptor 
m odels as having a  m ajor effect upon sum atriptan  selectivity  at the  5 -H T jp)
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receptors. The polar SER 21(H 6) residue form s favourable interactions w ith  the 
am ino-sulfone group o f  sum atriptan and TH R 6(H 7) can p lay  an ind irect role 
stabilising  any agonist induced conform ational changes o f  the receptor.
2.2.3.5 The receptor bound conformation of 5-HT, 5-CT and sumatriptan
The results o f  energy m inim isation  dem onstrated that both  global m in im um  
energy conform ations o f  5-H T and sim ilar conform ations o f  5-C T and 
sum atriptan  can occupy the proposed agonist binding site. This suggests two 
possib le explanations.
The ligand b inding process m ay allow  the conform ation o f  the flexib le C-3 
substituent o f  the ligand to fluctuate betw een m inim um  energy conform ations 
during ligand b inding  and receptor activation. O bviously the static nature o f  the 
receptor m odels m ake this im possible to dem onstrate how ever the calculated  in 
vacuo energy barrier betw een the tw o global m inim um  energy conform ations o f  
5-H T is low  and o f  the order o f  6 kcal/m ol.
A lternatively  the d ifferent conform ations A  and B m ay in teract p referentially  
w ith  the 5-H T \ a  and 5-H T jp) receptors respectively. The in teraction  energies 
o f  the 5-HT, 5-C T and sum atriptan com plexes have consistently  show n that 
conform ation  B is p referred  at the 5-H T jp) receptor m odels and conform ation  A  
is preferred  at the 5 - H T j^  receptor m odel. A  sim ilar hypothesis has been  
proposed*^ w here, i f  the orientation  o f  the ethylam ine substituent o f  5-H T 
receptor agonists w as in an "easterly" d irection  relative to the indole ring  this 
w ould  confer h igh  affinity  binding for the 5-H T jp) receptors. I f  the sidechain  
w as orientated  in a  "northerly" direction, h igh  affinity for the 5 -H T j a  receptor 
w ould  be observed. A lthough these conform ations are d ifferent from
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conform ations A  and B presented  in this study, the feasibility  o f  the situation  is 
highlighted.
The tw o explanations g iven above w ould have very different consequences upon 
the design o f  selective drugs for the 5-H T j subtype o f  receptors. I f  the 5 -H T j 
receptors have a  preference for d ifferent conform ations o f  the characteristic C-3 
sidechain  o f  agonists th is w ould  allow  the design o f  conform ationally  restricted  
m olecules w hich m ay have im proved 5-H T receptor selectivity. O n the o ther 
hand  the alternative hypothesis w ould be o f  no significant help in  the  design o f  
n ew  drugs.
2.23.6 Comparison with published models
The identified  agonist b inding site for the 5-H T receptor m odels has a  certain  
degree o f  sim ilarity  to the m odels o f  H ibert's groups53-163 Berth m odels
incorporate the aspartate o f  helix  3 and TH R 6(H 5) but the arom atic residues 
anchoring the arom atic ring  o f  the agonists differ and no m ention has been  m ade 
by this group o f  A LA /SER 21(H 6).
The 5-H T j a  receptor m odel w as also com pared to the m odel o f  the 5-H T j a  
receptor from  the 7TM  database at EM B L in Heidelberg214. A lthough the exact 
lengths o f  the a -h e lices  d iffer by a few  residues the relative positions o f  the 
im portan t am ino acid residues are sim ilar.
In  sum m ary although the presented  m odels have a degree o f  sim ilarity  to som e 
o f  the published  5-H T receptor m odels, this is the first w ork w hich correlates the 
m odelling  procedure and detailed ligand receptor interactions o f  agonists at the 
hum an  5 -H T j a > 5 -H T ij)a  and 5 -H T ip jp  receptors.
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2.2.3.7 Extrapolation of the models to other 5-HT receptors
M olecular m odels o f  the 5 - h t ^ ,  5-h t^p , 5-H T2A  and 5-H T2C  receptors have 
no t been  constructed  in this study but the m odels o f  the 5-H T j a  and 5-H T j d  
receptors can be used in conjunction w ith  the sequence alignm ent (F igure 4) to 
d iscuss possib le agonist binding to these receptors. The g lu tam ate residue 
G LU 21(H 6) o f  the 5 - h t |£  and 5 -h tjp  receptors m ay form  unfavourable 
interactions w ith  the am ide group o f  5-C T but not the hydroxyl group o f  5-HT. 
T his could  account for the low  affinity o f  5-CT at the cloned 5 -h t^ p  and 5 -h t]p  
receptors^^. This assum es that tryptam ine com pounds such as 5-H T bind  to 
these  receptors in  a sim ilar m anner to ligand binding at the 5 -H T \ a  and 5-H T jp) 
receptors.
The b inding o f  sum atriptan results in an intriguing anom aly. The 5 -h t jg  
receptor has a  threonine residue at position  6 o f  helix  7 and the 5 -h tjp  receptor 
has an alanine residue at this position. One w ould consequently  expect that the 
5 -h t ip  receptor w ould exhibit h igh  affinity  for sum atriptan and the 5 -h tjp  
receptor low  affinity for the ligand. H ow ever this is not the case and the exact 
opposite  is true, sum atriptan binds w ith  h igh  affinity to the 5 -h tjp  receptor and 
low  affin ity  to the 5 -h t jp  receptor379 This suggests that there are o ther 
un identified  factors contributing to the binding o f  sum atriptan at these receptors 
possib ly  a  d ifferent m ode o f  binding or the involvem ent o f  additional, as yet 
un identified  am ino acid  residues. F rom  the sequence a lignm ent the only 
residues tha t the  5-H T jp) and 5 -h tjp  receptors have in com m on that are absent 
from  the 5 -H T j a  and 5 -h tjp  receptors are ILE11(H 3) and LEU 11(H 7). O ne or 
bo th  o f  these residues m ay have an effect upon the binding o f  sum atrip tan  to the 
5 -h tjE  and 5 -h tjp  receptors.
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F or the 5-H T2 subtype o f  receptors, residue 21 o f  helix  6 is asparagine and  th is 
residue m ay force the nearby serine residue o f  helix  5 SER 6(H 5) to adop t a 
certain  conform ation w ith  the hydroxyl group in a d ifferent position  to the 
hydroxyl group o f  the  threonine residue in the 5 -H T j subtype o f  receptors. T his 
w ould  change the directionality  o f  the hydrogen bond accepted by the ligand, 
thus creating a slightly  different binding site. This issue o f  hydrogen  bond 
directionality  betw een the 5 -H T j and 5-H T2 subtypes has already been  
suggested^ 99,400 from  tpe synthesis and pharm acological evaluation  o f  
conform ationally  constrained analogs o f  the natural neurotransm itter w here the 
C-5 hydrogen bond acceptor function is constrained in a 6-m em bered ring. The 
slight changes in ligand binding site could perhaps allow  5-H T and o ther 
agonists to be orientated  further into the cleft aw ay from  A SN 21(H 6) possib ly  
allow ing the indole N -H  group to be in the v icinity  o f  G LY 5(H 5) or 
SER /A LA 9(H 5). The latter residue is know n to be im portant in the b inding o f  
som e agonists to the 5-H T2A  an<3 5-H T2C receptors 106,107,190
T herefore although the 5 -h tip , 5 -h tjp , 5-H T2A  and 5-H T2C receptors have not 
been  m odelled  a picture o f  the probable agonist b inding sites can be proposed  
based on the m odels developed during this study w hich appear to be consisten t 
w ith  som e o f  the available experim ental data.
2.2.3.8 Antagonists, partial agonists and signal transduction
The b inding o f  antagonists and partial agonists has not been investigated  during 
th is study but it is p robable that the p-adrenoceptor antagonists such as 
(-)-propranolol (11) could interact w ith  the 5 -H T \ a  receptor m odel by 
occupying the pocket betw een helices 1, 2, 3 and 7. The am ino group could  
form  an ion  pair w ith  A SP10(H 3) and the hydroxyl group and ether oxygen  can
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partic ipate  in hydrogen bonds w ith  A SN 6(H 7) in a  sim ilar m anner to that 
recently  d e s c r ib e d ^ .
T he 5 -H T j a  partial agonists such as buspirone398 (134) can  conceivably  
occupy b o th  the agonist and P-adrenoceptor antagonist binding pockets w ith  one 
o f  the p iperazine n itrogens form ing an ion pair w ith  A SP10(H 3). These 
hypo theses are sheer speculation and unlike the agonists, partial agonists and 
antagon ists are structurally  diverse and m ay occupy different regions o f  the 
receptor and interact w ith  different am ino acid residues.
(134)
N o attem pt w hatsoever has been  m ade to rationalise the signal transduction  
process. In  order to study this, one w ould need to analyse the  dynam ics 
tra jectories o f  receptor m odels w ith  bound agonists, partial agonists and 
antagonists. It is thought that w ithout the explicit inclusion o f  the loops, 
term inal dom ains, lipid b ilayer and any solvent into the m odels tha t any attem pt 
to rationalise signal transduction  w ould be very crude and  potentially  
m isleading.
2.2.4 Thienopyridine small molecule modelling
A s anticipated  there w as a h igh  degree o f  sim ilarity  betw een  the 
thieno[2 ,3-b]pyrid ine analogs o f  5-HT, TH I(A ) and T H I(B ) w ith  the 
neuro transm itter conform ations 5-H T(A ) and 5-H T(B ) (Table 9).
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Thienopyridine 5-HT R M S F it (A) Electrostatic F it (score)
TH I(A ) 5-H T(A ) 0.182 0.999
TH I(B ) 5-HT(B) 0.182 0.999
Table 9 R M S and electrostatic sim ilarity  com parisons o f  5-H T and TH I
The RM S fit (F igure 18) indicated an excellent superposition betw een  the tw o 
m olecules w ith  bo th  the hydroxyl oxygen and protonated n itrogen  in identical 
positions. The only m inor difference being the position  o f  the su lfur atom  o f  the 
th ieno[2 ,3-b]pyridine as com pared w ith  the indole N -H  group o f  5-HT. 
M olecular volum es w ere calculated (Table 10) and it w as observed  that they 
w ere sim ilar for the 5-H T and thieno[2 ,3-b]pyridine conform ations how ever the 
thiophene ring o f  the thieno[2 ,3-b]pyridine occupies a slightly  g reater volum e 
than  the pyrrole ring  o f  5-HT.
Ligand V olum e (A 3)
5-HT(A) 142.51
5-HT(B) 143.26
THI(A) 149.66
THI(B) 149.07
Table 10 M olecular volum es o f  5-H T and THI
Furtherm ore, m olecular volum e differences using the RM S superposition  w ere 
calculated (Table 11). The difference in  volum es accounted for approxim ately  
10% o f  the volum e occupied  by the thieno[2 ,3-b]pyridine and this w as attributed  
to the overlap around the indole N -H  and thiophene sulfur.
1 2 7
T hienopyridine 5-H T A lignm ent V olum e difference (A ^)
TH I(A ) 5-HT(A) RM S 14.96
TH I(B ) 5-HT(B) RM S 15.03
TH I(A ) 5-HT(A) Electrostatic 20.06
TH I(B ) 5-HT(B) Electrostatic 15.74
T able 11 A ligned m olecular volum e differences betw een TH I and 5-H T
The electrostatic sim ilarity scores (Table 9) indicate v irtually  identical 
electrostatic potentials. The m olecular alignm ent (F igure 19) how ever is 
certain ly  no t as good as that observed in the RM S fitting. The C-3 ethylam ino 
sidechains o f  the m olecules are superim posed very w ell but th is is at the expense 
o f  the arom atic rings. It appears that the electrostatic fitting  procedure is 
dom inated  by the large positive electrostatic potential associated  w ith  the 
protonated  am ino groups. This has resulted  in an excellent alignm ent o f  the  C-3 
substituents but a poorer alignm ent o f  the arom atic rings and hydroxyl groups. 
M olecular volum e difference analysis using the electrostatic alignm ent (Table 
11) has show n that the difference in volum es has increased for conform ation A  
and is essentially  unchanged for conform ation B in com parison to the volum e 
differences from  the RM S alignm ent. The m ain  areas o f  difference are 
surrounding the hydroxyl groups and the sulfur atom s o f  the 
thieno [2,3 -b]pyrid ine conform ations.
T his sm all m olecule m odelling has therefore acted as an initial guide and has 
h ighlighted  the sim ilarities betw een the thieno [2,3-b jpyridine analog o f  5-H T 
and 5-HT. There are how ever sm all differences in  occupied volum e, m ainly  
surrounding the 5-m em bered rings w hich m ay or m ay not be o f  im portance.
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5 - H T ( A )  G R E E N  
T H I(A ) R E D
FIGURE 18
RMS Superposition o f  5-HT(A) and THI(A)
FIGURE 19
E lectrostatic superp osition  o f 5-HT(B) and THI(B)
N evertheless due to the sim ilarity  w ith  5-HT, the thieno[2 ,3-b]pyridine analog o f  
5-H T  is a  suitable candidate for ligand receptor m odelling studies and synthesis.
2.2.5 Thieno[2,3-b]pyridine receptor interactions
T he tw o conform ations o f  the thieno [2,3-b jpyridine analog o f  5-H T  can be 
accom m odated  easily  w ithin  the agonist b inding site o f  all the 5-H T  receptor 
m odels (F igure 20). The th ieno[2,3-b]pyrid ine ring can occupy the sam e 
position  as the indole ring  o f  5-H T interacting w ith  PH E18(H 6) and  TR P9(H 4). 
T he protonated  am ine can form  an ion pair w ith  A SP10(H 3) and the hydroxyl 
group  can accept a  hydrogen bond from  TH R 6(H 5). In the 5 -H T i d  receptor 
com plexes, the ligand can form  an additional interaction betw een  the hydroxyl 
group and SER 21(H 6). The serine residue SER 12(H 4) o f  the 5 -H T jj)  receptors 
can  interact w ith  the electron rich thiophene ring in the sam e m anner as the 
residue can interact w ith  the 5-m em bered pyrrole ring o f  5-HT. O bviously  the 
th iophene ring cannot participate in a  hydrogen bond to the backbone carbonyl 
o f  SER 12(H 4) but it is not know n how  im portant this in teraction  is. I f  the 
in teraction  is unim portant, the thieno [2,3-b jpyrid ine w ould be expected  to have 
equal affinity  for the 5-H T j a  and 5-H T i d  receptors. On the o ther hand i f  the 
in teraction  is indeed im portant one w ould  expect a h igher affin ity  o f  the 
com pound for the 5-H T j a  receptor since a hydrogen bond donating  group at 
th is position  is defin itely  not essential for high affinity 5 -H T j a  receptor 
binding.
Looking at the ligand receptor interaction energies (Table 12) it is again apparent 
that the 5-HT j a  receptor has a preference for THI(A) which is the equivalent o f  
conformation A o f 5-HT. The 5-HTj d  receptor models have a preference for 
conformation B i.e. THI(B).
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P H E 1 8 ( H 6 )
PHE17(H6)
TH R 6(H 5)
TR P6(H 3) p
SER12(H 4)
SER21(H6)
ASP10(H3)
TRP9(H 4)
FIGURE 20
THI(B) In the 5 HT1D receptor agonist b in d in g  site
L igand R eceptor m odel In teraction  Energy
(kcal/m ol)
TH I(A ) 5-H T i a 0.0
TH I(B ) 5-HT1a 16.3
TH I(A ) 5-HTiDa 4.3
TH I(B ) 5-HTiDa 0.0
TH I(A ) 5 -H T io p 0.8
TH I(B ) 5 -H T io p 0.0
T able 12 R elative interaction energies o f  TH I(A ) and TH I(B ) w ith  the
receptor m odels
T hese resu lts further dem onstrate that the thieno[2,3-b]pyridine analog o f  5-H T 
can occupy the proposed agonist b inding sites o f  the 5 -H T j^ , 5 -H T ip )a  and 
5 -H T iD p  receptor m odels. It therefore seem s appropriate that th is m olecule be 
considered as an initial target for synthesis. B iological evaluation  o f  th is 
com pound could then  aid a better understanding o f  the requirem ents for agonist 
b ind ing  a t the 5 - H T ^  and 5-H T i d  receptors.
2.2.6 Ligand design and receptor selectivity
2.2.6.1 Suggestions of ligands
M any fragm ents that could be added to 5-HT, 5-C T or the th ienopyrid ine analog 
o f  5-H T w ere suggested using Ludi395 (for a b rie f overview  o f  Ludi see section  
2.1 .11). O nly the fragm ents that occurred exclusively for one receptor m odel or 
those w hich  w ere suggested m any tim es for different ligands are d iscussed  in  the 
fo llow ing sections. The m ost intriguing results w ere obtained exclusively  for 
the 5 -H T u )a  receptor w here in m any cases arom atic or alkyl groups w ere
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suggested  either at the C-5 or C-6 position  o f  the arom atic rings o f  the ligand. 
O ne such suggestion  w as structure (135). It is proposed tha t the pyrid ine ring 
can occupy a  sim ilar reg ion  o f  the receptor m odel to the C-5 sidechain  o f  
sum atriptan.
Suggestions that w ere com m on for all three receptor m odels included 
substitu tions o f  the ethylam ino sidechain w ith  an (R )-hydroxyl group e.g. (136) 
w ith  the  hydroxyl group potentially  form ing interactions w ith  either A SP10(H 3) 
o r SER 12(H 4).
NH.
The incorporation  o f  the C-5 hydrogen bonding acceptor into a  5 or 6 m em bered  
ring  as observed in the structure (137) w as another frequent suggestion  allow ing 
the  new  ring to be positioned  betw een transm em brane helices 5 and 6. S im ilarly  
the constrained structure (138) allow s the ring em bedded n itrogen to in teract 
w ith  SER 21(H 6) o f  the 5-HT^p) receptors.
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T here w as no significant difference betw een the fragm ents suggested  for the 
indole com pounds 5-H T and 5-CT com pared to the fragm ents suggested  for the 
thieno[2 ,3-b]pyridine. The new  potential ligands described above are all show n 
as indole com pounds but could have equally been show n as the 
th ieno[2 ,3-b]pyrid ine analogs.
2.2.6.2 Discussion and validation of the structures devised via Ludi
T he fragm ents suggested  by Ludi w ere com pared to the vast experim ental 
b ind ing  affin ity  data available for the 5-H T j a  and 5 -H T jj)  receptor sites. This 
perm itted  the feasibility  o f  the suggestions to be assessed and also proved  useful 
in  the validation  o f  the b inding site.
S im ilar com pounds to (135) have previously  been exam ined for 5-H T  receptor 
b inding  affinity. It w as discovered^ that the conform ationally  restricted  
com pound (139) exhibited a 21 fold  selectivity  for 5-HTjp> sites over the
5-HT t a  site.
/C H 3
(139)
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The sam e authors^OO have also studied com pounds w here the hydrogen  bond 
acceptor is part o f  a 6-m em bered ring. The dihydropyrano[2 ,3-f]indole (140) 
how ever d id  no t have an appreciable affinity  for 5 - H T ^  or 5-H T i d  receptor 
sites. Thus thieno[2 ,3-b]pyridine analogs o f  (137) w ould not appear to be 
suitable candidates to pursue.
H
(140)
L Y 197206 (141) is a h igh  affinity  5-HTja  receptor ligand^Ol w hich is sim ilar 
to structure (138). Therefore com pounds that are sim ilar to the  structures 
devised  using Ludi are know n 5-H T receptor agonists. This further validates the 
agonist b inding sites proposed in this study.
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2.2.6.3 Receptor ligand interactions of compound (135)
C learly , due to tim e constraints, all the suggested fragm ents could  not be 
evaluated  for ligand receptor interactions. A s (135) w as the only  ligand 
suggested  for one specific subtype o f  receptor, it w as decided to  study the 
receptor interactions o f  th is m olecule.
C om pound (135) w as constructed w ith in  Insigh tll, atom  potential types and 
partial charges w ere assigned according to the CV FF forcefield  and the am ino 
nitrogen  w as protonated. Energy m inim isation  afforded tw o m inim um  energy 
conform ations o f  (135) sim ilar to conform ations A  and B o f  5-HT. A  
conform ational analysis w as perform ed around the three rotatable bonds (F igure 
21) at 3 0 °  increm ents. Subsequent energy m inim isation  to an  R M S gradient o f  
less than  0.001 kcal/A  yielded tw o sets o f  four suitable m in im um  energy 
structures differing  in energy by 5.9 kcal/m ol. These w ere docked  into the 
5-H T i a > 5 -H T ip )a  and 5-H T ]jyp  receptor m odels in  a position  equivalen t to 
5-H T at the respective receptor m odels. The ligand receptor com plexes w ere 
energy m inim ised  as described previously  for the 8-O H -D PA T  receptor 
com plex.
n h 2
Figure 21 The three rotatable bonds o f  (135)
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Compound (135) was found to be accommodated at the 5-HTn)a  receptor 
model occupying a position similar to sumatriptan at the same receptor model 
(Figure 22). The protonated amine could interact with ASP10(H3) and the 
indole nucleus was anchored by TRP9(H4) and PHE18(H6). Interaction with 
SER12(H4) was also possible. The hydroxyl group accepted a hydrogen bond 
from THR6(H5) and interacted with SER21(H6). Additionally the nitrogen of 
the pyridine ring could accept a hydrogen bond from THR2(H5) however this 
residue is conserved in all the 5-HTj subtype of receptors.
More interestingly when the same molecule was docked into the 5-HTjj)p 
receptor model and energy minimised all the interactions described for the 
5-HTjjya  receptor were maintained except the hydrogen bond between the 
pyridine ring of (135) and THR2(H5). The pyridine ring bumped with 
PHE20(H4) (LEU for 5-HTjd o ) causing a reorientation of the pyridine ring 
and a conformational change in PHE20(H4) resulting in no hydrogen bond 
formation.
Similarly at the 5-HTja  receptor model, (135) can interact with ASP10(H3), 
THR6(H5), TRP9(H4) and PHE18(H6) but due to steric hindrance between the 
pyridine ring and MET20(H4) both the ligand and the residue have to change 
their positions. Thus no interaction is observed between (135) and THR2(H5). 
The pyridine ring can therefore cause steric bumping with residue 20 of helix 4 
of the 5-HT \ a  and 5-HT ip>p receptor models causing both the pyridine ring and 
the offending residue to change conformation preventing hydrogen bond 
formation. If this change in conformation is unfavourable (135) may have a 
higher affinity for the 5-HTjp)a  subtype over the remaining 5-HTj receptors.
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FIGURE 22
Com pound (135)(B) In the 5-HT1D(/ receptor agonist
binding site
2.2.7 Receptor selectivity
The preceding section has highlighted one of the few amino acid residues within 
the vicinity of the agonist binding pocket that is different for the 5 -H T ^ 5 
5-HTiDa  and 5-HTjp)p receptors i.e. MET/LEU/PHE20(H4). In the design of 
more selective agonists, residues which differ between receptors must be 
identified and used to suggest ligands that might increase receptor selectivity. It 
is therefore possible that ligands which may interact with the various amino 
acids positioned at residue 20 helix 4 can improve the selectivity for one of the 
5-HTje) receptors.
From analysis of the sequence alignment, several alternative residues which 
differ between the 5-HTjd  receptors can be proposed. Possible candidates 
include ILE/VAL1(H3), LEU/VAL2(H3), ILE/PHE5(H3), ILE/LEU18(H3) and 
LEU/ILE19(H3). Of these helix 3 residues only LEU/VAL2(H3) and 
ILE/LEU18(H3) are within the central cleft but both are conserved mutations 
that are too far away from the proposed agonist binding site to have an effect.
THR/VAL3(H4), ILE/LEU7(H4), ALA/VAL10(H4), ILE/PHE11(H4), 
CYS/SER14(H4), ILE/LEU17(H4) and LEU/PHE20(H4) are the residues that 
differ between the 5-HTjp) receptors on helix 4 but only the previously 
identified LEU/PHE20(H4) is within the central cleft close to the agonist 
binding site. The potential effects of this residue on selectivity have already 
been discussed. No suitable helix 5 residues were found but LEU/MET24(H6) 
is directed towards the central cleft above the important SER21(H6) residue. 
However the distance between LEU/MET24(H6) and the protonated amine of 
5-HT in the energy minimised 5-HTjp) receptor complexes is approximately 10 
A and is probably too distant from the agonist binding site. Helix 7 is almost 
identical for the 5-HTjp)a  and 5-HTjp)p receptors except for the first and last
1 3 6
residues. The former being a conserved LEU/ILE substitution and the latter is 
too distant from the binding site.
Thus from a consideration of the sequence alignment and correlating this with 
the 3-dimensional receptor models, volumes of the surrounding agonist binding 
site which may confer selectivity can be identified. In the case of the 5-HTip)a  
and 5-HTjDp receptors the most promising volume of difference is that above 
the aromatic ring of 5-HT in the region of LEU/PHE20(H4). It may be possible 
that agonists can be designed and synthesised with larger C-5 or C-6 substituents 
which demonstrate a higher binding affinity for the 5-HTjp)a  receptor over the 
5-HTip)p receptor. These agonists would certainly be desirable in the 
determination of the exact mode of action of antimigraine drugs.
It has also been observed from the models developed in this study that the 
5-HTid  receptors may prefer one conformation of the ligand and the 5-HT j a  
receptor a different conformation of the ligand. Agonists could then be designed 
and synthesised that incorporate these features by conformationally constraining 
the ethylamine sidechain of 5-HT which then may exhibit 5-HTia /5-HT;h) 
receptor selectivity.
Many research groups have studied extensively the effect of substitution of the 
indole ring, in particular at the C-5 position^,56-58 mainly addressing the issue 
of 5-HTip)/5-HTiA. receptor selectivity. All the known indole agonists which 
have high affinity for the cloned 5-HTjDp receptor also have a high affinity for 
the cloned 5-HTjp)a  receptor. The question therefore to be answered is that, 
given the high degree of sequence homology between the 5-HTjj)a  and 
5-HTip)p receptors, are selective agonists possible? Selective antagonists can 
probably be found since antagonists tend to interact with the receptors in 
different manners, interacting with different residues, but agonists all appear to
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interact with the same residues thus questioning the whole possibility of 
selective agonists.
2.2.8 Conclusions
The agonist binding site of the human 5-HT] a , 5-HT]p)a  and 5-HT]p>p 
receptors has been identified with a high degree of certainty from the 
bacteriorhodopsin derived molecular models of these receptors. The agonist 
binding site has been studied not in terms of energies, but in a more qualitative 
sense, accounting for the binding of some known agonists.
The thieno[2,3-b]pyridine (133) analog of 5-HT has been identified from both 
small molecule modelling and ligand receptor modelling as a potential bio- 
isostere for 5-HT (the attempted synthesis of this compound is dealt with in 
chapter 3).
The entire concept of receptor selectivity has been considered using sequence 
analysis and the ligand design program Ludi to identify features of the models 
and ligand receptor interactions which may confer selectivity. Two such 
features have been identified which may help the design and synthesis of 5-HT 
receptor agonists with selectivity for one of the 5-HT ]p> receptor subtypes.
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3 SYNTHETIC CHEMISTRY DISCUSSION
3.1 SYNTHESIS AND REACTIONS OF 3-CARBOETHOXY-2-METHYL- 
THIOTHIEN O [2,3-B] PYRIDINE
From modelling of the analogs of 5-HT (133) within the agonist binding site, the 
thieno[2,3-b]pyridine (133) was identified as an initial synthetic target. 
Methodology for the synthesis of thieno[2,3-b]pyridines has already been 
developed at the University of Abertay, Dundee^9-251,402 and it was therefore 
decided to use this route to prepare 3-carboethoxy-2-methylthiothieno[2,3-b] 
pyridine251,402 (70a). It was the intention of this work to reduce the 3- 
carboethoxy group to the hydroxymethyl derivative which could be substituted 
by a nitrile function increasing the chain length by one carbon atom. Reduction 
of the nitrile would afford the amine and the methylthio group could be removed 
and functionality would then be introduced into the C-5 position in an 
electrophilic substitution reaction [Scheme 30].
Alternatively, the methylthio group could be removed prior to conversion of the 
C-3 carboethoxy substituent of (70a) to the hydroxymethyl derivative. 
Thieno[2,3-b]pyridine compounds with a hydrogen bond acceptor at the C-5 
position such as (133) could then be evaluated for biological activity at the 5-HT 
receptors. If these compounds are active the implications upon receptor 
selectivity studied in section 2.2.7 would be used to suggest additional synthetic 
targets.
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(70a)
[H]
c h 2c h 2n h 2
0‘
[Scheme 30]
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Ethyl 3-pyridylacetate-l-oxide (143) had originally been p r ep a red ^  1 in 55% 
yield from the reaction of ethyl 3-pyridylacetate (142) with hydrogen peroxide 
and glacial acetic acid. In an attempt to improve this moderate yield (142) was 
stirred at room temperature with magnesium monoperoxyphthalate (MMPP). 
MMPP is a newer reagent which is stable at ambient temperatures and has been 
shown to oxidise alkenes, ketones, sulfides, sulfoxides and pyridines in high 
yields^O^. p>ue to the solubility of the product (143) in water an aqueous work­
up procedure to remove the phthalic acid by-product had to be avoided. Thus a 
work-up procedure was developed where solid reagents were added directly to 
the reaction mixture, solid sodium metabisulfite to destroy any excess oxidising 
agent and solid potassium carbonate to neutralise the acid by-product. Removal 
of the solids by filtration followed by evaporation of the filtrate afforded the 
required product (143) also in 55% yield (identified from its ir spectrum and 
melting point^04)
,CH2C 02Et
N
>
MMPP 55% 
/w-CPBA 94%
CH2C 02Et
(142) (143)
Due to the failure to improve the yield of (143) using MMPP an alternative 
oxidising agent was sought. The oxidation was thus attempted at room 
temperature using w-chloroperoxybenzoic acid (m-CPBA) in dichloromethane. 
A similar solid reagent work-up procedure was used and ethyl 3-pyridylacetate-
l-oxide (143) was isolated in a much improved 94% yield.
When ethyl 3-pyridylacetate-l-oxide (143) was refluxed in phosphoryl chloride 
tic indicated that three major products had formed. Column chromatography
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however only allowed the exclusive separation of the most polar component 
which was identified as ethyl 4-chloro-3-pyridylacetate (144) (20% yield) on the 
comparison of its ir spectrum with that of an authentic sample^ 1.
(143) (144)
.CH2C 02Et
+
(145) 61% (69a)
The two less polar compounds were obtained substantially as a mixture (61% 
yield) presumably consisting of ethyl 2-chloro-5-pyridylacetate (145) and ethyl
2-chloro-3-pyridylacetate (69a). Further attempts to separate these compounds 
by column chromatography with a variety of solvent mixtures also failed. 
Therefore the mixture was stirred at room temperature with MMPP for 24 h and 
after work-up the resulting oil was chromatographed on silica to afford firstly 
47% of the unoxidised mixture of (145) and (69a). Also isolated was ethyl 2- 
chloro-5-pyridylacetate-l-oxide (146) in 6% yield. The Iff nmr spectrum 
showed a double doublet at 6.97 6 corresponding to the C-4 proton of the 
pyridine ring coupling with the C-3 and C-6 protons. The C-3 and C-6 protons 
were both observed as doublets at 7.25 5 and 8.07 5 respectively, coupling with 
the C-4 proton only. The ir spectrum indicated the presence of the N-oxide 
function (1275 cm~l) thus confirming that the product was the 2,5-disubstituted 
pyridine-1-oxide (146).
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Ethyl 2-chloro-3-pyridylacetate-l -oxide (147) was also isolated in 9% yield. 
The infrared spectrum of (147) again confirmed the presence of the N-oxide 
function (1250 cm‘l) and the nmr spectrum showed a multiplet at 7.11 5 
characteristic of the C-5 and C-4 protons of a pyridine-1-oxide and a multiplet at 
8.18 5 which was assigned to the C-6 proton. All of which is consistent with the 
proposed structure (147).
O
(147)
Reagent (146) % (147) % (145) + (69a) %
MMPP 6 9 47
m-CPBA 42 56 0
Oxidation with MMPP was obviously unsatisfactory, therefore the remaining 
mixture of (145) and (69a) was oxidised with the stronger oxidising agent m- 
CPBA. Room temperature oxidation of (145) and (69a) with m-CPBA followed 
by solid reagent work-up and column chromatography afforded (146) in 42% 
yield and (147) in 56% yield. The low yields observed with using MMPP can be
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attributed to a combination of steric hindrance caused by the chloro group a  to 
the nitrogen and the -I effect of the chloro group rendering the pyridine nitrogen 
less nucleophilic. Thus to effect the oxidation reaction a stronger oxidising 
agent had to be used.
Ethyl 2-chloro-3-pyridylacetate-l -oxide (147) was then treated with base and 
heated with carbon disulfide at 70 °C for 1.5 h [Scheme 31]. After cooling to 
room temperature the reaction was quenched with methyl iodide, stirred for a 
further 1.5 h at room temperature then poured onto ice/water and extracted with 
ethyl acetate. The resulting solid was chromatographed to afford a white solid in 
17% yield. The ir spectrum of the product showed the presence of an ester (1690 
cm"l) and N-oxide (1240 cm“l) functional groups. The nmr spectrum 
showed no singlet corresponding to the methylene protons of the acetate ester as 
observed for the starting material (147), but the presence of a two proton quartet 
and a three proton triplet at 4.38 5 and 1.44 8 respectively suggested an ethyl 
ester. A three proton singlet was observed at 2.72 8 which was assigned to a 
methylthio group and the downfield protons were indicative of a 2,3- 
disubstituted pyridine-1-oxide. The compound was assigned the structure of 3- 
carboethoxy-2-methylthiothieno[2,3-b]pyridine-7-oxide (148) and the molecular 
ions of 270 (M+H) and 254 [(M+H)-0] further corroborated this finding. The 
mechanism of this reac tion ^  has already been discussed in section 1.2.3.5.
Deoxygenation of compound (148) at ice temperature with phosphorus 
tribromide in DMF afforded 3-carboethoxy-2-methylthiothieno[2,3-b]pyridine 
(70a) in 80% yield [Scheme 31]. The ir spectrum showed no peak associated 
with the N-0 stretch of a pyridine-N-oxide and the nmr spectrum was 
identical to that of an authentic sample of (70a) as described in the literature^ 1.
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Furthermore, ethyl 2-chloro-3-pyridylacetate402 (69a) was cyclised under the 
same conditions as described for ethyl 2-chloro-3-pyridylacetate-l-oxide (147) 
to afford compound (70a) directly in 67% yield. This is a significant 
improvement on the literature reported yield^S 1 of 36%.
The ester group of 3-carboethoxy-2-methylthiothieno[2,3-b]pyridine (70a) was 
reduced to the primary alcohol (149) with lithium aluminium hydride in diethyl 
ether. Excess lithium aluminium hydride was destroyed by the careful addition 
of water and 2N sulfuric acid in a 5:2 volumetric ratio. This allowed the 
extraction of the product into diethyl ether. Subsequent removal of solvent and 
column chromatography gave 3-hydroxymethyl-2-methylthiothieno[2,3-b] 
pyridine (149) in 50% yield. The product was identified from the absence of a 
carbonyl stretch and the presence of a broad O-H stretch peak in the ir spectrum. 
The 'H  nmr spectrum showed no evidence of the characteristic quartet and 
triplet of an ethyl ester however a broad one proton singlet at 3.05 5 and a two 
proton singlet at 4.89 5 were observed and accounted for the hydroxyl and C-3 
methylene protons respectively. The three proton singlet at 2.50 5 was assigned 
to the methylthio protons. Three double doublets were observed downfield
(70a)
[Scheme 31]
145
corresponding to the pyridine ring protons which is typical of a 2,3-disubstituted 
pyridine. The C-6 proton is the furthest downfield resonating at 8.38 5 and 
coupling with the C-4 proton (J=1.7 Hz) and the C-5 proton (J=4.5 Hz). The C-4 
proton is observed at 8.06 6 and couples with the C-5 (J=8.1 Hz) and the C-6 
proton. This is further downfield than is normally associated with a pyridine y 
proton due to the deshielding effect of the thiophene ring. The C-5 proton is the 
least downfield of the aromatic protons at 7.20 6. The LC mass spectrum gave 
molecular ions of 212 (M+H) and 197 [(M+H)-CH3] and the microanalytical 
figures were consistent with the structure of (149).
When the reaction was attempted in THF the yields of (149) were inconsistent 
ranging from 20-70% possibly due to the poorer solubility of lithium aluminium 
hydride in THF.
Classical methods for the conversion of an alcohol to a nitrile^OS involve a two 
step procedure where the hydroxyl group is converted to a good leaving group 
such as a halide or sulfonate ester. This is followed by nucleophilic 
displacement of that group by the cyanide anion, however some undesirable side 
reactions can occur. A direct one step method for the conversion of alcohols to 
nitriles in high yields has been published406# The alcohol is treated with two 
equivalents of sodium cyanide and chlorotrimethylsilane and a catalytic amount 
of sodium iodide in a DMF/acetonitrile mixture. For example406 benzyl alcohol 
was converted to benzylcyanide in 98% yield [Equation 8].
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c h 2o h
Me3SiCl / CH-^CN / DMF / NaCN / Nal 
[Equation 8]
3-Hydroxymethyl-2-methylthiothieno[2,3-b]pyridine (149) was therefore heated 
at 60 °C with chlorotrimethylsilane, sodium cyanide and a catalytic amount of 
sodium iodide in a 1:1 mixture of DMF/acetonitrile. After 5 h tic indicated that 
only starting material and baseline material was present so heating was 
continued for a further 14 h. Subsequent work-up yielded a small return of what 
was identified as unreacted starting material and the reaction was therefore 
abandoned. At this stage it was envisaged that the methylthio group may be 
interfering with the reaction and preventing the formation of the crucial 
intermediate (150) by steric hindrance or by reaction with chlorotrimethylsilane. 
It was therefore decided to look at possible methods of removing the methylthio 
group.
SiMe, /  3
(150)
There are many methods available for the cleavage of carbon-sulfur 
bonds407,408 m0st common being the use of Raney nickel. There are
however known problems associated with the use of Raney nickel; it is 
pyrophoric and must be kept wet; the reactivity of Raney nickel varies from one 
batch to another; and reactions using it may not be reproducible. In a typical 
laboratory procedure the compound of interest is treated with a 5-10 fold excess 
of Raney nickel in ethanol at 20-80 °C. With respect to this work the overriding
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problem is that the Raney nickel would also desulfurise the thiophene ring of the 
thieno[2,3-b]pyridines so an alternative method was sought.
Alkali metal liquid ammonia reductions are also well known and reactions with 
thienyl sulfides have been described^OB but instead of yielding the unsubstituted 
thiophene, the bond between the sulfur atom and the sp3 hybridised carbon is 
cleaved408 [Equation 9]. A subsequent literature search unearthed a publication 
on the synthesis of thiasteroids where a methylthio group was removed in the 
presence of a thiophene ring [Equation 10] using Raney nickel in acetone^09# 
The acetone will react with the catalyst to give isopropyl alcohol, deactivating 
the catalyst prior to reaction with the thiophene compound. This method was 
thus used in an attempt to remove the methylthio group from the 
thieno[2,3-b]pyridines (70a) and (149).
M = Alkali Metal 
R = Alkyl group
[Equation 9]
3-Hydroxy-2-methylthiothieno[2,3-b]pyridine (149) was refluxed with an excess 
of Raney nickel in acetone for 1 h. The Raney nickel was removed by gravity 
filtration, the solvent was dried and removed to give an oil which tic showed to 
be a complex mixture of five components. Column chromatography afforded the
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two major components but in very low yields. The nmr spectrum of the least 
polar compound (2% yield) was identical to that of unreacted (149). The more 
polar compound was obtained as only a trace but the nmr spectrum showed 
the presence of the three double doublets at 8.54 8, 8.14 5 and 7.29 8 which are 
consistent with a thieno[2,3-b]pyridine ring. A two proton singlet at 4.89 8 
corresponded to the methylene protons of the C-3 substituent but no singlet was 
observed at 2.50 8 for the methylthio group, instead a downfield one proton 
singlet at 7.69 8 appeared which is typical of a C-2 proton of a thiophene ring. 
Although due to the low yield of the compound no ir spectrum, mass spectrum or 
microanalysis was obtained the compound was believed to be 3- 
hydroxymethylthieno[2,3-b]pyridine (151) on the strength of the nmr 
spectrum. Any attempts to repeat this reaction in the hope of obtaining an 
improved yield of (151) gave low yields of complex mixtures.
The same reaction conditions were applied to 3-carboethoxy-2- 
methylthiothieno[2,3-b]pyridine (70a) and again only a trace amount of a 
mixture of products was isolated. The nmr spectrum of the mixture indicated 
that the major component was a thieno[2,3-b]pyridine but the low yield 
prevented the reaction being taken any further.
Instead of using deactivated Raney nickel, 3-hydroxy-2-methylthiothieno[2,3-b] 
pyridine (149) was stirred with an excess of Raney nickel in ethanol at -10 °C, 
tic indicated that no reaction had taken place thus the reaction mixture was 
allowed to warm to room temperature and stirred for a further 2 h. Work-up
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afforded 30 mg of an oil but tic and nmr indicated a complex mixture of 
products so the reaction was not pursued any further due to the low yield.
Interestingly, however, 3-cyano-2-methylthiothieno[2,3-b]pyridine250,251 (70c) 
did undergo reaction with Raney nickel in acetone to give the required product 3- 
cyanothieno[2,3-b]pyridine (152) in 98% yield. Compound (152) was identified 
from the nmr spectrum showing the three double doublets of a 2,3- 
substituted pyridine and a one proton singlet at 8.19 5 caused by the C-2 proton 
of the thieno[2,3-b]pyridine ring. No upfield signals corresponding to methyl 
protons were observed. The liquid chromatography mass spectrum gave a 
molecular ion of 161 (M+H) and microanalysis figures were consistent with the 
proposed structure (152).
CN
SMe
When this reaction was repeated the 98% yield was not reproducible and a 
mixture of products was obtained. It became apparent during the reactions of the 
thieno[2,3-b]pyridines with deactivated Raney nickel that large excesses of the 
reagent were required and the reactions only proceeded when there was very 
little solvent in the reaction vessel. When the reactions did take place complex 
mixtures were obtained which contained unreacted starting material and required 
product in yields that were too low to allow the isolation and purification of 
these compounds. The reaction of (70c) with deactivated Raney nickel did 
produce the required product (152) in almost quantitative yield. It was therefore 
thought that the smaller nitrile group may allow reaction to take place however it 
was subsequently proved that this was a one-off and the reaction was certainly
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not reproducible. In conclusion the attempted removal of the methylthio group 
with Raney nickel was not reproducible thus it was decided to take this approach 
no further.
3.2 SYNTHESIS AND REACTIONS OF 3-CARBOMETHOXY-5- 
C Y AN OTHIEN O [2,3 -B] PYRIDINE AND (E)-ETHYL-3-(5-CYANO-
THIENO[2,3-B]PYRIDIN-3-YL)PROP-2-ENOATE
Due to the failure in removing the methylthio group from the 
thieno[2,3-b]pyridine (149) synthesised using CS2 methodology a new synthetic 
route to thieno[2,3-b]pyridines was sought. In general, the majority of methods 
to thieno[2,3-b]pyridines from preformed pyridine rings lead to 2,3-disubstituted 
thieno[2,3-b]pyridines (section 1.2.3) but as we have already seen in the 
preceding section substitution at the C-2 position is undesirable. The synthesis 
of thieno[2,3-b]pyridines from preformed thiophene rings in a Skraup type 
reaction and its variations on the other hand can afford non highly substituted 
thieno[2,3-b]pyridines in variable yields. The general reaction involves the 
cyclisation of a 2-aminothiophene salt with a 1,3-dicarbonyl, a,p-unsaturated 
carbonyl compound or an equivalent compound with two electrophilic carbon 
atoms separated by a methylene spacer which can be substituted if desired. The 
thiophene compound contributes two carbon atoms and the nitrogen of the 
pyridine ring and the carbonyl compound provides the three remaining carbon 
atoms of the ring.
Such an approach has been reported^? 1,272 (see section 1.2.2.2) for the 
synthesis of 3,5-disubstituted thieno[2,3-b]pyridines in good yields from 
reduction of 2-nitrothiophenes followed by cyclisation with 3,3-dimethoxy-2- 
formylpropionitrile sodium salt.
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It was therefore envisaged that this approach could be used to prepare 
thieno[2,3-b]pyridine analogs of 5-HT [Scheme 32]. Thieno[2,3-b]pyridine 
(153) could be hydrogenated and hydrolysed to the saturated carboxylic acid. 
Conversion to the /-BOC protected amine would then allow the C-5 substituent 
to be converted into many other functional groups.
3,3-Dimethoxy-2-formylpropionitrile sodium salt (155) was prepared according 
to the literature procedure272 from reaction of 3,3-dimethoxypropionitrile (154) 
with sodium hydride and methyl formate in dry diethyl ether at room 
temperature.
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The required [Bis(4-carboxythienyl-2-ammonium)]hexachlorostannate(IV) (157) 
was prepared from the reduction of 2-nitrothiophene-4-carboxylic acid (156) 
with powdered tin metal at 40 °C in concentrated hydrochloric acid [Scheme 
33]. If the reaction temperature is allowed to rise to over 50 °C no (157) is 
isolated and only decomposition products are obtained. Compound (157) was 
characterised from the nmr spectrum showing the presence of the two 
thiophene protons as one proton singlets at 6.59 5 and 7.46 5.
SnClg
2
[Scheme 33]
The cyclisation of (157) with 3,3-dimethoxy-2-formylpropionitrile sodium salt 
(155) and concentrated hydrochloric acid in methanol proceeded smoothly over
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24 h [Scheme 33]. Subsequent work-up afforded a mixture of two components 
which were separated by column chromatography. The ir spectrum of the least 
polar compound (8% yield) indicated the presence of a nitrile group at 2233 
cm"l and an ester group at 1727 c m 'l  The nmr spectrum exhibited the 
expected pattern for the pyridine ring protons, two doublets at 8.77 8 and 8.96 8 
each integrating to one proton and corresponding to the C-4 and C-6 protons 
respectively. The small coupling constant of J=1.8 Hz is characteristic of 
coupling between the a  and y protons of a pyridine ring. A three proton singlet 
at 4.06 8 suggested a methyl ester attached directly to the thiophene ring at the 
C-3 position however there was no downfield singlet corresponding to a proton 
attached to the thiophene ring. The proton decoupled nmr spectrum showed 
three carbon atoms with bonded hydrogen of which the carbon of the methyl 
ester was assigned the most upfield peak at 52.4 8. The C-4 carbon was 
observed at 136.0 8 and the C-6 carbon at 148.7 8. There were additionally 
seven other peaks of a lesser magnitude which could not be assigned 
unambiguously. The compound was obviously not the required 3- 
carbomethoxy-5-cyanothieno[2,3-b]pyridine (159) but a 2-substituted derivative 
of (159). The mass spectrum gave a molecular ion of 253 which is consistent 
with the C-2 substituent being a chloro group and the compound was therefore 
identified as 3-carbomethoxy-2-chloro-5-cyanothieno[2,3-b]pyridine (158). The 
microanalytical data was consistent with structure (158).
The more polar compound isolated in 40% yield also showed the presence of a 
nitrile and an ester group in the ir spectrum. The nmr spectrum was almost 
identical to that of (158) except a one proton singlet was seen at 8.56 8 which 
was assigned to the C-2 proton of the thiophene ring. Therefore the compound 
was identified as the expected product 3-carbomethoxy-5- 
cyanothieno[2,3-b]pyridine (159). The mass spectrum and microanalysis data 
were also consistent with this compound.
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Although the yield of (159) is lower than that reported in the literature^? 1,272 
the presence of 3-carbomethoxy-2-chloro-5-cyanothieno[2,3-b]pyridine (158) 
had previously not been reported. The mechanism of formation of (159) 
probably proceeds by hydrolysis of 3,3-dimethoxy-2-formylpropionitrile sodium 
salt (155) to the 1,3-dialdehyde (160) followed by nucleophilic attack of the 
amino group of the thiophene. Cyclisation can then occur with the loss of water. 
It is not known when the esterification of the carboxylic acid takes place 
[Scheme 34].
The formation of (158) probably results from electrophilic attack of chlorine 
onto the formed 3-carbomethoxy-5-cyanothieno[2,3-b]pyridine (159). Similar 
chlorinations have been observed in the synthesis of quinolines and in the 
tin/hydrochloric acid reduction o f  3-n itroth ieno[3 ,2-b]pyrid ine343 [Equation 11]. 
There was no evidence from the 1h  nmr spectrum of any chlorinated by-product 
in the tin/hydrochloric acid reduction of (156) to (157) therefore the mechanism 
of the reaction probably proceeds from Lewis acid catalysed electrophilic 
substitution of chlorine into the C-2 position of the thieno[2,3-b]pyridine ring of 
(159). Typical chlorinations are effected by chlorine gas which may or may not 
be present but reactions of this type are known to proceed in the presence of 
Lewis acid catalyst alone^lO . This reaction could be investigated further by 
subjecting (159) to the same reaction conditions used in the cyclisation step.
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[Scheme 34]
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Sn / HC1 Cl
[Equation 11]
The Homer-Wadsworth-Emmons reaction is an important variation of the well 
known Wittig reaction and is frequently used because of its versatility and mild 
reaction conditions. A phosphonate ester deprotonated by base, attacks the 
carbonyl group of an aldehyde or ketone. Syn-elimination of the intermediate 
betaine affords alkenes in good yields [Equation 12].
O
II(EtO)2P —  CH2R3
[Equation 12] E / Z Alkenes
When R.3=C02Et, a, p-unsaturated esters are formed with the E isomer 
predominating. It has been reported^!! that the reaction between 
triethylphosphonoacetate and benzaldehyde in a two phase system using phase 
transfer catalysis results in the exclusive formation of the E isomer of ethyl 
cinnamate^ll [Equation 13].
o
II(EtO),P — CH,C02Et +
H NaOH / H20  / CH2C12
PTC
C 02Et
[Equation 13]
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2-Nitrothiophene-4-carboxaldehyde (161) and triethylphosphonoacetate were 
stirred for 7 days in a two phase system of toluene and aqueous potassium 
carbonate in the presence of a phase transfer catalyst (Method A).
Method (162) % Unreacted (161) %
A 34 6
B 71 20
C 62 20
Separation of the two phases of the resulting dark emulsion proved almost 
impossible thus a 10% solution of hydrochloric acid was added. The toluene 
layer could then be separated and the aqueous phase was extracted with ethyl 
acetate. Even after the addition of the hydrochloric acid the separation and 
extraction still proved tedious due to the dark colouration of the mixture and 
involved the use of large volumes. Combination of the organic washings and 
removal of solvent afforded a dark solid which tic showed to consist of two 
components and a considerable amount of baseline material which were 
separated by column chromatography. The ir spectrum of the major, less polar 
component showed peaks at 1700 and 1639 cm"l which correspond to the 
carbonyl group of a conjugated ester and a carbon-carbon double bond 
respectively. Furthermore, the two absorbances at 1509 and 1337 cm"l were 
representative of a nitro group. The nmr spectrum indicated the presence of 
an ethyl ester from the mutually coupling three proton triplet at 1.32 5 and the
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two proton quartet at 4.25 8 (J=7.2 Hz). The two doublets at 8.04 8 and 7.58 8 
each integrating to one proton and coupling with each other (J=1.9 Hz) are 
typical of the C-5 and C-3 protons of a 2,4-disubstituted thiophene ring. The one 
proton doublets at 6.31 8 and 7.51 8 accounted for the hydrogens of a carbon- 
carbon double bond. The large vinylic coupling constant of J=16.2 Hz implied 
that the geometry of the double bond is trans (E). Of the two doublets the most 
downfield signal at 7.51 8 was assigned to the ArCH=CHC02Et proton due to 
the strong deshielding effect from the aromatic thiophene ring and the doublet at 
6.31 8 was assigned to the ArCH=CHC02Et proton. Therefore the ^H nmr and 
ir spectra confirmed that the product was the expected (E)-ethyl-3-(2-nitro-4- 
thienyl)prop-2-enoate (162) obtained in 34% yield. The mass spectrum shows 
no molecular ion but the most abundant peak at 198 is consistent with the loss of 
an ethyl group from the molecular ion. The microanalysis data is consistent with 
structure (162).
Unreacted 2-nitrothiophene-4-carboxaldehyde (161) was also isolated in 6% 
yield but there was no evidence of the formation of the Z isomer of (162). The 
low yield of the required product (162) and the problems encountered during the 
tedious extraction of the product prompted an investigation into the use of other 
methods for the preparation of (162).
The Homer-Wadsworth-Emmons variation of the Wittig reaction using 
triethylphosphonoacetate has also been reported^l^ using just aqueous 
potassium carbonate without organic solvent or phase transfer catalyst to give 
high yields and E stereoselectivity of the alkene. A two phase solid-liquid 
reaction of aldehydes with triethylphosphonoacetate and potassium carbonate in 
THF has also been reported413 again giving almost exclusively the E alkene.
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Thus, in method B, a mixture of (161) and triethylphosphonoacetate was stirred 
at room temperature for 3 h in an aqueous solution of potassium carbonate. 
Ethyl acetate extraction of the reaction mixture proved less troublesome than in 
method A and subsequent column chromatography afforded (162) in a much 
improved 71% yield and unreacted starting material (161) in 20% yield. Again 
there was no evidence for the presence of the Z isomer from the nmr 
spectrum of the isolated compound.
In method C a mixture of (161), triethylphosphonoacetate and solid potassium 
carbonate was stirred in THF for 24 h at room temperature in the absence of a 
phase transfer catalyst. No extraction was required as the insoluble by-products 
were removed by filtration. Removal of the solvent and column chromatography 
of the crude solid afforded (162) in 62% yield and unreacted (161) in 20% yield. 
Again there was no evidence of the Z isomer of (162).
Thus method B was used in subsequent synthesis of (162). Although the work­
up still involves an extraction, the extraction is more facile than that of method A 
and the yield of (162) is better than both methods A and C. The higher yields of 
(162) in methods B and C may be attributed to the product being contaminated 
with less of the dark baseline material which was observed in method A and 
rendered the isolation of (162) very difficult. This and the use of a phase transfer 
catalyst could have been detrimental to the isolated yield in method A. Attempts 
to force the reaction to completion (method B) using longer reaction times only 
made the extraction step more tedious due to the formation of more baseline 
material.
(E)-Ethyl-3-(2-nitro-4-thienyl)prop-2-enoate (162) was then reduced carefully at 
40 °C with tin in concentrated hydrochloric acid to the tin double salt [bis((E)- 
ethyl-3-(2-ammonium-4-thienyl)prop-2-enoate)]hexachlorostannate(IV)
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(163). The ir spectrum confirmed the presence of an amine from the absorbance 
bands at 3568, 3472 and 3288 cm"l. The peaks at 1706 and 1638 cm“l are 
typical of a conjugated ester. No nmr was obtained due to decomposition of 
the product in hexadeuterodimethylsulfoxide.
SnCl^'
2
Compound (163) was refluxed with 3,3-dimethoxy-2-formylpropionitrile sodium 
salt (155) and concentrated hydrochloric acid in ethanol. The reaction was 
monitored by tic and after 4 h no more product appeared to be formed thus the 
solvent was removed from the deep blue reaction mixture and replaced by water. 
Extraction into ethyl acetate and removal of the solvent gave a dark oil which 
consisted of two major products, several minor components and a large amount 
of coloured baseline material (by tic). Column chromatography afforded a white 
solid in 12% overall yield from (162). The ir spectrum showed peaks at 2234, 
1731 and 1636 cm"l confirming the presence of a nitrile, ester and carbon- 
carbon double bond respectively. The nmr spectrum looked quite similar to 
that of compound (162). A quartet at 4.33 8 and a triplet at 1.40 8 indicated an 
ethyl ester. The two single proton doublets at 6.65 8 and 7.85 8 with a coupling 
constant of J=16 Hz correspond to the vinylic protons. The aromatic protons 
were observed further downfield than in (162) at 8.48 8 and 8.80 8 and these 
represent the C-4 and C-6 protons of a substituted thieno[2,3-b]pyridine ring. 
There was no evidence of the C-2 proton of the thiophene ring suggesting that 
the compound was a 2,3,5-substituted thieno[2,3-b]pyridine. The mass spectrum 
gave a molecular ion at 293 (M+H) which confirmed that the C-2 substituent
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was a chloro group and the compound was (E)-ethyl-3-(2-chloro-5- 
cyanothieno[2,3-b]pyridin-3-yl)prop-2-enoate (164). The microanalysis figures 
are consistent with this structure.
The more polar compound isolated in 18% yield from (162) showed almost 
identical ir and nmr spectra to that of (164). However a one proton singlet
appears in the nmr spectrum at 7.93 6 suggesting that the thieno[2,3-b]
pyridine ring is unsubstituted at the C-2 position and the compound is the 
required product (E)-ethyl-3-(5-cyanothieno[2,3-b]pyridin-3-yl)prop-2-enoate 
(153). The molecular ion of 259 (M+H) and microanalysis figures were 
consistent with structure (153).
The low yield of (153) compared to the yield of 3-carbomethoxy-5- 
cyanothieno[2,3-b]pyridine (159) is particularly disappointing. Throughout the 
synthesis of (153) large amounts of a blue polymeric tar formed which hampered 
the work-up procedure. It was therefore hoped that the cyclisation reaction could 
be modified to reduce the production of the tar and increase the yield of (153). It 
was originally thought that the ester function of (163) may be more susceptible 
to nucleophilic attack by the amine group of another molecule of (163) leading
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to tar formation. To investigate this (E)-ethyl-3-(2-nitro-4-thienyl)prop-2-enoate 
(162) was hydrolysed at room temperature with 4.8M sodium hydroxide solution 
in ethanol. Acidic work-up afforded (E)-3-(2-nitro-4-thienyl)prop-2-enoic acid 
(165) in 82% yield [Scheme 35]. The product was confirmed as (165) from the 
spectral data. The ir spectrum shows a broad O-H stretch at 3110 cm"l and a 
C=0 stretch at 1686 cm~l. The Iff nmr spectrum also showed no protons 
corresponding to an ethyl ester but did show the expected aromatic and vinylic 
protons.
SnCIg
2
[Scheme 35]
Reduction of (165) with tin and hydrochloric acid afforded a crude solid which 
was reacted immediately with 3,3-dimethoxy-2-formylpropionitrile sodium salt 
(155) and concentrated hydrochloric acid in methanol. Subsequent work-up 
yielded a solid which tic indicated to consist of one major product and several 
minor components. Only the major product was isolated by column 
chromatography in 10% overall yield from (165). The ir spectrum of the product 
exhibited peaks corresponding to a nitrile and conjugated ester. The nmr
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spectrum was similar to that of (153) but showed no protons indicative of an 
ethyl ester, however a three proton singlet at 3.86 5 was consistent with the 
compound being the methyl ester. The compound was identified as (E)-methyl- 
3-(5-cyanothieno[2,3-b]pyridin-3-yl)prop-2-enoate (166) and confirmed by the 
molecular ion of 245.1 (M+H) from the liquid chromatography mass spectrum 
[Scheme 35].
The low yield of this reaction implies that the ester group of (163) is probably 
not reacting with the amino group of the same compound to give polymers and 
that this hypothesis is not the reason for the low yield of (153) from (163). 
Therefore attempts were made to selectively hydrogenate the carbon-carbon 
double bond of (E)-ethyl-3-(2-nitro-4-thienyl)prop-2-enoate (162) prior to 
cyclisation.
The catalytic hydrogenation of olefins is well known^l^ but for thiophene 
compounds high pressures are generally required. Catalytic hydrogenation has 
also been reported^lS using a hydrogen source such as ammonium formate with 
a palladium on carbon catalyst. For example ethyl cinnamate was converted to 
ethyl 3-phenylpropionate in 92% yield^lS [Equation 14].
,C 02Et .C 0 2Et
Pd/C / HCOONH4-
[Equation 14]
Sodium borohydride - cuprous chloride in methanol has also been utilised^l^ in 
the conjugate reduction of a,p-unsaturated esters. Optimised reaction conditions 
using ten equivalents of borohydride gave a quantitative yield of ethyl 3- 
phenylpropionate from ethyl cinnamate^l^.
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The attempted hydrogenation of (E)-ethyl-3-(2-nitro-4-thienyl)prop-2-enoate 
(162) with palladium on carbon and ammonium formate in refluxing glacial 
acetic acid failed and only unreacted starting material was recovered. 
Compound (162) was then stirred with cuprous chloride in methanol. An excess 
of sodium borohydride was added portionwise over 30 minutes, the mixture was 
stirred for a further 30 minutes then partitioned between diethyl ether and water. 
Evaporation of the solvent from the organic phase afforded a brown solid which 
turned red on exposure to the atmosphere. It was postulated that the nitro group 
had been reduced to the primary amine giving the 2-aminothiophene which is 
notoriously unstable. The attempted hydrogenation of (162) was therefore not 
pursued any further.
In a further effort to improve the overall yield of (153) the cyclisation of (163) 
was attempted in concentrated sulfuric acid. The work-up procedure was altered 
and after removal of the ethanol the residue was basified with concentrated 
ammonia solution. The extraction stage with diethyl ether was cleaner and any 
of the insoluble blue baseline material was removed by filtration through a bed 
of Celite. The required product (153) was isolated after column chromatography 
in 14% yield. Additionally isolated was (162) in 17% yield arising from 
contamination of the hexachlorostannate salt (163) with compound (162).
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It is also very interesting that there was no evidence o f (E)-ethyl-3-(2-chloro-5- 
cyanothieno[2,3-b]pyridin-3-yl)prop-2-enoate (164) being formed in this 
reaction. This could suggest that the concentrated hydrochloric acid plays a 
crucial role in the formation o f (164) from (163) and confirms that the 
chlorinated derivative (164) is synthesised in the cyclisation step. By changing 
the acid from hydrochloric acid to sulfuric acid the yield o f (153) from (162) was 
not improved. Likewise hydrolysis o f the ester group o f (162) to the carboxylic 
acid (165) prior to reduction and cyclisation also offered no improvement. It 
therefore seems plausible that the introduction o f an a,p~unsaturated ester 
sidechain at the C-4 position o f 2-nitrothiophene renders the tin salt o f the amino 
compound to be highly unstable in the harsh reaction conditions used for 
cyclisation. This probably leads to decomposition and/or polymerisation o f  
(163) producing large amounts o f the blue tar.
One final attempt to improve the yield o f (153) also failed. Compound (162) 
was heated at 40 °C in ethanol with tin(II) chloride.2 H2 0 . When tic had 
indicated that all the starting material had reacted a suspension o f 3,3- 
dimethoxy-2-formylpropionitrile sodium salt (155) and concentrated
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hydrochloric acid were added and the reaction mixture was refluxed for 48 h. 
Work-up afforded an oil which was chromatographed to give only 3% o f (153).
Summarising, although the desired compound (153) has been synthesised the 
yields were much lower than expected. This has been accounted for by the 
instability o f the crucial tin salt intermediate (163) which decomposes and/or 
polymerises in the harsh cyclisation conditions.
The hydrogenation o f (E)-ethyl-3-(5-cyanothieno[2,3-b]pyridin-3-yl)prop-2- 
enoate (153) was then studied. Attempted catalytic hydrogenation at 
atmospheric pressure under a hydrogen atmosphere failed and only unreacted 
(153) was recovered in 89% yield.
When ten equivalents o f sodium borohydride was added portionwise over a 
period o f 30 minutes to a suspension o f (153) and cuprous chloride (1.5 
equivalents) at ice temperature followed by stirring for a further 1 h a dark 
brown suspension formed. Ethyl acetate was added and the reaction mixture was 
washed with water and brine. Evaporation o f the solvent gave a solid which was 
chromatographed upon silica gel to give a single product. The ir spectrum 
confirmed the presence o f the nitrile and ester groups but no peak at around 1640 
cm"l was observed suggesting that the olefinic bond had indeed been 
hydrogenated. This was confirmed from the nmr spectrum when the two 
doublets at 6.49 8  and 7.81 8  seen in the nmr spectrum o f (153) were 
missing and replaced by two proton triplets at 2.77 8  and 3.20 8  coupling with 
each other (J=7.2 Hz). The mass spectrum gave a molecular ion o f 261 (M+H) 
and the product was identified as ethyl-3-(5-cyanothieno[2,3-b]pyridin-3- 
yl)propanoate (167) (55% yield). The microanalytical data was also consistent 
with the molecular formula o f C 1 3 H 1 2 N 2 O2 S.
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The moderate yield o f (167) prompted a decrease in the amount o f sodium 
borohydride used in the reaction. When six equivalents o f sodium borohydride 
was used under exactly the same reaction conditions tic indicated the reaction 
mixture contained one component with the same R f value as that o f the starting 
material, and some baseline material. Chromatography afforded 72% o f a white 
solid however the nmr spectrum demonstrated that the solid was in fact a 
mixture o f (153) and (167) in almost equal proportions. All attempts to separate 
(153) and (167) by column chromatography were unsuccessful due to the two 
compounds having very similar Rf values on silica gel.
The conjugate reduction o f (153) was further attempted using a 10% palladium 
on carbon catalyst and ammonium formate as a hydrogen donor. Refluxing the 
reaction mixture in glacial acetic acid followed by work-up and column 
chromatography gave the required product (167) in 30% yield. There was no 
evidence o f any unreacted starting material (153) in the ir and Iff nmr spectra o f  
the product.
To study the conversion o f the C-3 sidechain o f ethyl-3-(5-
cyanothieno[2,3-b]pyridin-3-yl)propanoate (167) to a protected ethylamine, 3- 
carbomethoxy-5-cyanothieno[2,3-b]pyridine (159) was used as a test compound 
prior to attempting the reactions with (167) [Scheme 36].
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The hydrolysis o f esters is normally a straight forward procedure carried out 
using acid or base catalysis with the latter normally being the method o f choice. 
In this instance a problem arises due to the presence o f a nitrile group which 
could possibly also be hydrolysed to the amide or carboxylic acid, however the 
reaction normally requires higher temperatures than that required for ester 
hydrolysis.
A mild and efficient method for the cleavage o f carboxylic esters has been 
reported417 in the literature using iodotrimethylsilane prepared in situ from 
chlorotrimethylsilane and sodium iodide in acetonitrile. Alkyl and aryl esters 
were shown^l7 to undergo facile cleavage to the intermediate 
trimethylsilylcarboxylate which can be hydrolysed to the carboxylic acid 
[Scheme 37].
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A solution o f chlorotrimethylsilane, sodium iodide and 3-carbomethoxy-5- 
cyanothieno[2,3-b]pyridine (159) in dry acetonitrile was refluxed for 48 h but tic 
indicated that only starting material was present. Subsequent work-up afforded 
only unreacted (159) in 60% yield.
The hydrolysis was then attempted using a slight excess o f 2M sodium 
hydroxide solution at room temperature in methanol. After stirring for 24 h tic 
showed no starting material was present so the methanol was removed, the 
residue was acidified to pH=3 and the resulting white precipitate was filtered. 
The ir spectrum o f the product confirmed the presence o f a carboxylic acid from 
the C =0 stretch at 1706 cm~l and the characteristic broad O-H stretch at around 
3000 cm"l. Furthermore the sharp peak at 2235 cm~l confirmed that the nitrile 
group was intact. The nmr spectrum showed no upfield protons whatsoever. 
The one proton singlet at 8.90 6  is further downfield than is normally expected 
for the C-2 proton o f a thieno[2,3-b]pyridine but this could be attributed to the 
strong deshielding effect o f a C-3 carboxylic acid group and the use o f  
hexadeuterodimethylsulfoxide as solvent for the recording o f the spectrum. An 
unresolved signal at 9.05 8  integrating to two protons is evidence o f the C-4 and 
C- 6  protons o f the ring. The LC-mass spectrum showed a molecular ion o f  203 
(M -l) and the most abundant peak at 159 is attributed to the loss o f the 
carboxylic acid group from the molecular ion. The product was therefore
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confirmed as 5-cyanothieno[2,3-b]pyridine-3-carboxylic acid (168) obtained in 
6 8 % yield. Due to the low solubility o f (168) in almost all common solvents a 
sample o f sufficient purity for microanalysis was not obtained.
The pyrolysis o f acyl azides to isocyanates is the Curtius rearrangement. If the 
reaction is performed in water or alcohol the products formed are amines and 
urethanes respectively. The reaction is therefore an extremely valuable method 
for the preparation o f amines and their protected derivatives.
Acyl azides can be prepared relatively easily from carboxylic acids by the 
formation o f an acid chloride^lS or mixed anhydride^ 19-425 followed by 
nucleophilic substitution by an azide anion. Problems often occur due to the 
high reactivity o f the acid chloride and the preferred method is usually via the 
mixed anhydride intermediate.
The conversion o f carboxylic acids to urethanes can be alternatively 
accomplished directly using the reagent diphenylphosphorylazide (DPPA)426- 
428 [Equation 15].
l l . O P h  R 1O H /E t3N
RCOOH +  N , —  P .  -------------------- ►  RNHCOORi
OPh
[Equation 15]
1 7 1
The reaction is thought to proceed by the transfer o f the azide group o f DPPA to 
the carbonyl carbon o f  the carboxylic acid. Typically an equimolar mixture o f  
the carboxylic acid, DPPA and triethylamine is heated in the presence o f t- 
butanol to afford the t-BOC protected amine in high yield.
5-Cyanothieno[2,3-b]pyridine-3-carboxylic acid (168) was refluxed with DPPA 
and triethylamine in ^-butanol for 18 h. The solvent was removed and the 
residue was dissolved in ethyl acetate and washed with saturated sodium 
hydrogen carbonate solution then brine. Evaporation o f the ethyl acetate 
afforded a low yield o f a complex mixture o f products which were inseparable 
by column chromatography. When the aqueous washings were acidified and 
extracted with ethyl acetate unreacted (168) was obtained almost quantitatively 
thus proving the reaction was unsuccessful.
Thieno[2,3-b]pyridine (168) was however converted to the acyl azide using the 
mixed anhydride route [Scheme 38]. After stirring (168) with triethylamine and 
ethyl chloroformate in acetone for 3 h sodium azide was added and the reaction 
mixture stirred for a further 2.5 h. Work-up and purification by column 
chromatography gave a quantitative yield o f 3-azidocarbonyl-5- 
cyanothieno[2,3-b]pyridine (169). The ir spectrum showed two sharp peaks at 
2232 and 2181 cm 'l corresponding to nitrile and azide groups respectively; a 
carbonyl stretch was also observed at 1694 cm~l. The nmr spectrum was 
very similar to that o f the starting material (168), with three downfield signals. 
A one proton singlet at 8.65 5 was assigned to the C-2 proton and the two single 
proton doublets at 8.84 8  and 9.18 5 are typical o f the C-4 and C- 6  protons o f a 
thieno[2,3-b]pyridine ring respectively. The microanalysis figures are also 
consistent with (169) for carbon, hydrogen and sulfur, however the figure for 
nitrogen is lower than the expected figure; this is quite common in acyl azides 
due to decomposition through loss o f nitrogen gas.
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Compound (169) was then refluxed in /-butanol until tic had indicated that no 
unreacted (169) remained. Evaporation o f the solvent and purification by 
column chromatography afforded a white solid in 68% yield. The ir spectrum 
showed peaks at 3276 and 3174 cm 'l consistent with the N-H stretch o f a 
urethane. Furthermore the peak at 2231 cm~l confirmed the nitrile group was 
still present but there was no evidence o f any azide. The nmr spectrum 
showed a large singlet at 1.61 6 integrating to nine protons which can only be 
indicative o f a /-butyl group. A broad singlet at 6.83 5 was caused by the 
exchangeable urethane proton. The three signals for the aromatic protons were 
most interesting, as expected the C-6 proton was the furthest downfield and was 
observed as a clear doublet with a coupling constant o f J=1.85 Hz typical o f the 
coupling between the C-6 and C-4 protons o f a thieno[2,3-b]pyridine. The C-4 
and C-2 protons were observed as broad one proton singlets at 8.26 6 and 7.75 5 
respectively. This unexpected line broadening in the nmr spectrum can 
possibly be explained by the presence o f the urethane N-H group which may 
interfere with the relaxation mechanism429 The mass spectrum gave a
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molecular ion at 276 (M+H) and the microanalytical data is consistent with the 
assigned structure o f 3-[(/-butoxycarbonyl)amino]-5-cyanothieno[2,3-b]pyridine 
(170) [Scheme 38].
Hydrolysis o f the nitrile function o f (170) was effected by stirring with 
concentrated ammonia and hydrogen peroxide in ethanol at room temperature for 
24 h. Removal o f solvent and recrystallisation o f the resulting solid gave a 
quantitative yield o f a product which according to tic was pure. The most 
notable feature o f the ir spectrum o f the compound was the disappearance o f the 
sharp peak associated with the nitrile function. A  carbonyl C =0 stretch was 
observed at 1668 cm‘ l. Peaks at 3418, 3211 and 3060 cm'* imply an amide and 
urethane function. The product was thus identified as 3-[(/- 
butoxycarbonyl)amino]-5-carboxamidothieno[2,3-b]pyridine (171). The nmr 
spectrum was consistent with the structure (171).
It has therefore proved possible to convert 3-carbomethoxy-5- 
cyanothieno[2,3-b]pyridine (159) to the t-BOC protected amines (170) and (171) 
in good yield. The experience gained in studying these reactions was used for 
similar reactions o f ethyl-3-(5-cyanothieno[2,3-b]pyridin-3-yl)propanoate (167) 
in an attempt to synthesise potential bio-isosteres o f 5-HT.
As an aside the chlorinated thieno[2,3-b]pyridine (158) was refluxed with 
guanidine hydrochloride and sodium hydride in DMF in an effort to prepare the 
tricyclic thieno[2,3-b]pyridine (172) which has an amino function in a similar
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region to that o f the amino group o f 5-HT. The reaction mixture was poured 
onto ice/water and extracted with ethyl acetate affording only unreacted starting 
material (158).
The base catalysed hydrolysis o f ethyl-3-(5-cyanothieno [2,3-b]pyridin-3- 
yl)propanoate (167) afforded an excellent yield o f a yellow solid. Purification o f 
the substance however proved to be very difficult due to the poor solubility o f  
the solid in almost all solvents. When the product was dissolved in aqueous base 
and precipitation induced by the addition o f acid the purity was not improved. 
The ir spectrum showed a broad absorption band at 3439 cm 'l and a carbonyl 
C =0 stretch at 1717 cm"l which is consistent with a non-conjugated carboxylic 
acid. Furthermore the sharp peak at 2232 cm 'l confirms that the nitrile group is 
still intact. No nmr spectrum was obtained due to the poor solubility o f the 
compound but from the ir spectrum the product was assumed to consist o f 
mainly 3-(5-cyanothieno[2,3-b]pyridin-3-yl)propanoic acid (173).
COOH
(167) (173)
When (173) was stirred with triethylamine and ethyl chloroformate in acetone 
followed by the addition o f sodium azide the ir o f the isolated crude product
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indicated the presence o f an azide group from the strong absorption at around 
2100 cm"l. Purification o f the crude product by column chromatography 
however afforded a solid (37% yield) which was confirmed as ethyl-3-(5- 
cyanothieno[2,3-b]pyridin-3-yl)propanoate (167).
The formation o f (167) from (173) was unexpected but tic o f the starting material 
(173) showed that there were no nonpolar components present therefore 
formation o f (167) cannot be accounted for by the presence o f unreacted (167) 
from the hydrolysis reaction. It is possible however that in the reaction the 
mixed anhydride formed undergoes nucleophilic attack by the azide anion to 
give the required acyl azide, carbon dioxide and the ethoxide anion. The 
ethoxide anion could subsequently displace the azide group from the acyl azide 
to afford the isolated product (167) [Scheme 39].
Since the ir spectrum o f the crude solid exhibited a strong azide peak it was 
postulated that the required azide is present in the reaction mixture either as a 
minor product or as an intermediate in the reaction to form the ester (167). 
Therefore the crude solid o f the reaction was taken up directly in /-butanol and 
refluxed. However, tic indicated that no reaction was taking place so the solvent 
was removed and the crude solid was refluxed in o-xylene in the presence o f t- 
butanol. When the o-xylene was removed tic indicated a complex mixture o f  
components and the ir spectrum suggested possibly a urethane but the nmr 
spectrum confirmed that the major component was (167).
The attempted synthesis o f the intermediate azide via the acid chloride also 
failed. Thieno[2,3-b]pyridine (173) was refluxed with thionyl chloride for 24 h, 
the thionyl chloride was removed and the crude product was stirred in acetone 
with sodium azide for 5 h. Work-up and column chromatography afforded low
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yields o f two components but the ir spectra o f both indicated the absence o f the 
nitrile function and the reaction was abandoned.
(167)
[Scheme 39]
1 7 7
The conversion o f (173) to the /-BOC protected amine (174) was also attempted 
in one step by refluxing (173) with DPPA and triethylamine in /-butanol but the 
ir spectrum o f the crude product suggested that the nitrile group was no longer 
present and the nmr spectrum indicated that no protons corresponding to a 
thieno[2,3-b]pyridine ring were present.
The problems encountered in the attempted synthesis o f the t-BOC protected 
amine derivative have prompted an investigation into alternative methods for the 
synthesis o f the required compound.
The Gabriel reaction is a widely used method for the synthesis o f amines430 
The reaction o f an alkyl halide with potassium phthalimide forms a protected 
amine which upon treatment with potassium hydroxide solution or hydrazine can 
be converted to the primary amine [Scheme 40].
[Scheme 40]
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Thus if  the carboxylic acid (173) could be chain shortened by the Hunsdiecker 
reaction to the halide (175) the Gabriel reaction would afford one o f the synthetic 
target compounds.
Using a modified p roced ure^  for the Hunsdiecker reaction lead tetraacetate 
and lithium chloride were heated at 80 °C for 3 h with a suspension o f crude 3- 
(5-cyanothieno[2,3-b]pyridine)propanoic acid (173) in dry toluene. The reaction 
mixture was partitioned between diethyl ether and sodium hydrogen carbonate. 
The organic phase was dried and solvent removed to afford a low yield o f  a solid 
which lH  nmr indicated to be a complex mixture o f components. Thus the 
reaction was pursued no further due to the low yield and complex mixture. 
Acidification and extraction o f the aqueous phase into ethyl acetate yielded 
unreacted (173). The low solubility o f the starting material (173) in toluene may 
have prevented the reaction from proceeding.
C O O H  C l
A further alternative synthetic route to amines is the Hofmann 
rearrangement^2 a  primary amide is treated with sodium hydroxide and 
bromine to afford an isocyanate which upon hydrolysis would give a primary 
amine [Scheme 41].
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The ester (167) was refluxed with concentrated ammonia in ethanol until tic 
indicated that no unreacted (167) remained. The ir spectrum o f the isolated 
crude product suggested that the nitrile function was still present and a carbonyl 
C =0 stretch at 1684 cm"l suggested an amide. A mixture o f sodium hydroxide 
solution and bromine was added to the crude product and the reaction mixture 
was heated at 90 °C for 3 h. After work-up the crude product was dissolved in 
dry diethyl ether and hydrogen chloride gas was bubbled through the ether 
solution. The precipitated solid darkened probably due to decomposition on 
exposure to air. The nmr spectrum provided no evidence whatsoever o f any
thieno[2,3-b]pyridine. Thus if  the required product was formed it had
decomposed prior to the recording o f the nmr spectrum.
In a final effort (E)-3-(2-nitro-4-thienyl)prop-2-enoic acid (165) was stirred with 
triethylamine, ethyl chloroformate and sodium azide. The ir spectrum o f the 
intermediate product indicated a peak corresponding to an azide group. This 
crude product was refluxed in /-butanol; removal o f solvent and purification by
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column chromatography afforded (E)-l-[(/-butoxycarbonyl)amino]-2-(2-nitro-4- 
thienyl)ethene (176) in 28% yield. The ir spectrum exhibited an amide N-H  
stretch at 3354 cm"l and C =0 stretch at 1700 c m 'l  The peak at 1654 cm"  ^ was 
attributed to the carbon-carbon double bond and the nitro group caused peaks at 
1499 and 1326 cm 'l. The nmr spectrum was consistent with a 2,4-substituted 
thiophene. The nine proton singlet at 1.25 6  confirmed the r-butyl group and the 
vinylic protons were observed as two doublets at 6.61 8  and 5.82 8  (J=14.6 Hz). 
The molecular ion o f 269 (M -l) is consistent with the assigned structure (176).
Attempted tin hydrochloric acid reduction o f (176) followed by cyclisation with
3,3-dimethoxy-2-formylpropionitrile sodium salt (155) afforded a low yield o f a 
complex mixture possibly containing a thieno[2,3-b]pyridine but inseparable by 
column chromatography. The failure o f this reaction is probably due to the 
cleavage o f the amine protecting group in the harsh reaction conditions followed 
by reaction o f the resulting enamine.
Unfortunately time constraints did not allow the synthesis o f the required 
thieno[2,3-b]pyridine analogs o f 5-HT. Although 3-carbomethoxy-5- 
cyanothieno[2,3-b]pyridine (159) could however be converted to the protected 
amine derivatives (170) and (171) the attempted route from (E)-ethyl-3-(5- 
cyanothieno[2,3-b]pyridin-3-yl)prop-2-enoate (153) has proved to be 
unsuccessful. This may be due to the carbonyl function o f (153) not being 
directly attached to the aromatic rings. The synthesis o f (153) from the 
thiophene precursor is low yielding and involves a tedious work-up and
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purification routine. Although (153) could be converted to the hydrogenated 
compound (167) any further attempts at reactions have generally afforded low  
yields, mixed products and decomposition. Therefore it has been concluded that 
this route is definitely not the best method for the synthesis o f the desired 
compounds and alternative methods must be investigated.
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4 CONCLUSIONS AND FUTURE WORK
4.1 CONCLUSIONS
Molecular models o f the human 5-HTj a , 5 -H T u)a  and 5-HTip)p receptors 
have been constructed using the heptahelical structure o f bacteriorhodopsin as an 
initial template. The probable agonist binding site o f the receptor models has 
been identified and validated by the docking o f several known agonists. The 
models account for the high affinity o f 5-HT and 5-CT, the 5-HTj a  receptor 
selectivity o f (R)-8 -OH-DPAT, the 5-HTjp) receptor selectivity o f sumatriptan 
and the low 5-HT j a  receptor affinity o f 5-OH-TMT.
The possibility o f a thieno[2,3-b]pyridine analog o f 5-HT acting as a bio-isostere 
for 5-HT has been investigated. Small molecule similarity studies and ligand 
receptor modelling have confirmed this possibility. Therefore compound (133) 
and similar thieno[2,3-b]pyridine derivatives which can accept a hydrogen bond 
at the C-5 position were identified as synthetic target compounds.
The ligand design program Ludi was used to provide further suggestions o f  
possible synthetic targets and proved valuable in the identification o f  a receptor 
volume that may confer selectivity between the 5-HTjj)a  and 5-HTiDp  
receptors.
The models are consistent with most o f the available experimental data for the 
5-HT receptors. Even so, as with all GPCR models, the models must be treated 
with caution. They are qualitatively useful in studying the requirements for 
ligand binding and in the design o f new ligands but they are certainly not "real". 
One o f the major dangers o f GPCR modelling is that the modellers actually 
believe that their models are true. There will be inaccuracies in the models
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which may only be eliminated or minimised upon the availability o f further 
experimental data.
The major disappointment o f this work was that a thieno[2,3-b]pyridine analog 
o f 5-HT could not be synthesised and isolated. Nevertheless in the attempts to 
synthesise compounds o f this type a number o f novel thieno[2,3-b]pyridines 
were prepared en route. Using methodology developed at the University o f  
Abertay Dundee 3-carboethoxy-2-methylthiothieno[2,3-b]pyridine (70a) was 
synthesised and reduced to the hydroxymethyl derivative however the removal 
o f the methylthio group in the presence o f a thiophene ring proved troublesome. 
The attempted synthesis o f (174) via (E)-ethyl-3-(5-cyanothieno[2,3-b]pyridin-3- 
yl)prop-2-enoate (153) likewise proved problematic due to low yields, tedious 
work-ups and complex reaction mixtures. The key intermediate azide could not 
be synthesised from the carboxylic acid so alternative routes to (174) were 
attempted without success.
The unfortunate consequence o f this work is that no biological activity data for 
the synthetic targets was obtained. This would have been used as feedback in an 
effort to improve the models and to provide a greater understanding o f the 
requirements for 5-HT receptor binding.
4.2 SUGGESTIONS OF FUTURE W ORK
On the modelling front it would be relatively easy to model many more agonists, 
partial agonists and antagonists in order to study how these compounds might 
interact with the receptor models. However it has been said^33 "m0re 
calculations do not validate calculations" and thus studying more compounds is 
probably not worthwhile investigating.
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One o f the more interesting points to arise from the models was the possible role 
o f SER12(H4) interacting with the electron rich indole ring o f some compounds 
in the 5-HTjp) receptor models. This could be further investigated. The 
preference o f different conformations o f the ethylamine sidechain o f tryptamines 
for different 5-HT receptors could also be investigated further, studying the 
synthesis and 5-HT receptor affinities o f conformationally constrained 
compounds similar to known 5-HT receptor agonists. The 5-htjE and 5-ht^p 
receptors could also be modelled but again these models would only act as a 
potentially useful guide in the rational design o f novel drugs.
The main thrust must therefore be on the synthetic chemistry. 
Thieno[2,3-b]pyridine analogs o f  5-HT need to be synthesised and isolated. A  
more in depth investigation into the removal o f the methylthio group o f (70a) 
could be studied. Alternatively a possible synthetic route is described below  
[Scheme 42].
In scheme 42 the hexachlorostannate salt (25) o f 2-aminothiophene is reacted 
with 3,3-dimethoxy-2-formylpropionitrile sodium salt (155) to give the 
thieno[2,3-b]pyridine (177). Monohalogenation as described in the literature^^2 
should occur at the C-3 position. Displacement o f the halogen in a lithium - 
halogen exchange reaction and reaction o f the lithiated compound with 2 - 
bromoethylamine (the amine function o f 2 -bromoethylamine may need to be 
protected) should afford the desired thieno[2,3-b]pyridine (178). Subsequent 
manipulation o f the nitrile group could then take place and the 
thieno[2,3-b]pyridine analogs o f 5-HT could be evaluated for biological activity 
at the 5-HT receptors.
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[Scheme 42]
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5 EXPERIMENTAL
Infrared spectra were recorded on a Perkin-Elmer 1600 FT-IR 
spectrophotometer. NMR spectra were recorded using tetramethylsilane as 
reference on a Jeol PMX 60si or a Bruker AMX 360 spectrometer. Melting 
points were determined with an Electrothermal melting point apparatus and are 
uncorrected. Column chromatography was performed using the method o f  
Still434 silica gel 60, 220-440 mesh, particle size 0.035-0.070 mm, 
purchased from Fluka. Reactions were monitored by thin layer chromatography 
on Merck DC-Alufolien Kieselgel 60 F2 5 4  (Merck #5554) plates which were 
visualised under ultraviolet irradiation. Mass spectra, LC-mass spectra and 
microanalysis were provided by Glaxo-Wellcome Medicines Research, 
Stevenage. Reagent quality solvents were used unless otherwise stated. 
Petroleum ether refers to the fraction o f petroleum boiling in the range 60-80 °C. 
Raney nickel was purchased ready to use from Fluka.
Ethyl 3-pyridvlacetate-l-oxide H43")
a) Oxidation o f ethyl 3-pyridylacetate (142) with magnesium monoperoxy- 
phthalate.
Ethyl 3-pyridylacetate (142) (1.0 g, 6.05 mmol) was added dropwise to a 
solution o f magnesium monoperoxyphthalate (3.02 g, 6.10 mmol) in ethanol (25 
ml). The reaction mixture was stirred at room temperature for 2.5 h. Excess 
oxidising agent was destroyed by the addition o f solid sodium metabisulfite (wet 
starch/iodide paper). Solid potassium carbonate was then added and any 
insoluble solids were removed by filtration. The solvent was removed in vacuo 
to afford a solid which was recrystallised from toluene to give ethyl 3-
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pyridylacetate-1-oxide (143) as a white solid (0.60 g, 55%), mp 94-96 °C  
(litera tu re^  9 7 . 9 8  oC); v ^ C K E ^ /c n r 1 1733, 1271.
b) Oxidation o f ethyl 3-pyridylacetate (142) with m-chloroperoxybenzoic acid.
m-Chloroperoxybenzoic acid (70%) (16.41 g, 95 mmol) was added to a solution 
o f ethyl 3-pyridylacetate (142) (10.0 g, 60 mmol) in dichloromethane (70 ml). 
The mixture was stirred at room temperature for 7 days. When no oxidising 
agent remained (wet starch/iodide paper) solid potassium carbonate was added 
and any insoluble solids were removed by filtration. The solvent was removed 
in vacuo to give a solid which was recrystallised from toluene affording ethyl 3 - 
pyridylacetate-1-oxide (143) (10.27 g, 94%) as a white solid identical (tic, ir) to 
a sample prepared in (a).
Reaction o f ethvl 3-pyridvlacetate-l-oxide (443^ with phosphorvl chloride^  1
Ethyl 3-pyridylacetate-1-oxide (143) (12.67 g, 69.9 mmol) was refluxed in 
phosphoryl chloride (150 ml) for 3 h. The phosphoryl chloride was removed in 
vacuo and the residue poured onto ice/water (150 ml), neutralised with 2M  
ammonium chloride solution and extracted with ethyl acetate (3 x  150 ml). The 
combined organic extracts were dried over magnesium sulfate and the solvent 
removed in vacuo to afford an oil. The oil was dissolved in a little 
dichloromethane and chromatographed on silica gel. Gradient elution with 
petroleum ether/ethyl acetate (5-50%) afforded a mixture o f ethyl 2-chloro-5- 
pyridylacetate (145) and ethyl 2-chloro-3-pyridylacetate (69a) (8.54 g, 61%). 
Also isolated was ethyl 4-chloro-3-pyridylacetate251 (144) (2.82 g, 20%) as an 
oil; vmax/cm"l 1737. No boiling point was obtained due to decomposition.
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Oxidation o f the mixture o f ethyl 2-chloro-5-pyridylacetate H 45") and ethvl 2 - 
chloro-3-pvridylacetate (69a)
(a) Oxidation with magnesium monoperoxyphthalate.
Magnesium monoperoxyphthalate (13.54 g, 24.6 mmol) was added to a mixture 
o f ethyl 2-chloro-5-pyridylacetate (145) and ethyl 2-chloro-3-pyridylacetate 
(69a) (8.94 g, 44.8 mmol) in ethanol (50 ml). The reaction mixture was stirred 
at room temperature for 24 h. Solid sodium metabisulfite was added to destroy 
any excess oxidising agent. The ethanol was removed in vacuo and replaced 
with dichloromethane (100 ml). The dichloromethane solution was washed with 
saturated sodium hydrogen carbonate solution, dried over magnesium sulfate and 
the solvent removed in vacuo to give an oil which was chromatographed on 
silica gel. Gradient elution with petroleum ether/ethyl acetate (10-100%) 
afforded the unoxidised mixture o f (145) and (69a) as an oil (4.20 g, 47%). Also 
isolated was ethyl 2-chloro-5-pyridylacetate-l-oxide402 (146) (0.59 g, 6 %) as a 
white solid, mp 104-105 °C; vmax(KBr)/cm-l 1710, 1275; 5H(CDC13) 1.20 (t, 
3H, J= 6  Hz, CH3), 3.47 (s, 2H, CH2 C 0 2), 4.03 (q, 2H, J= 6  Hz, C 0 2 CH2), 6.97 
(dd, 1H, J=2 & 8  Hz, H-4), 7.25 (d, 1H, J= 8  Hz, H-3) and 8.07 (d, 1H, J=2 Hz, 
H-6 ); MS m/z 216 (M+H), 200 [(M+H)-0]. Further elution afforded ethyl 2-
chloro-3-pyridylacetate-l-oxide402 (147) (0.86 g, 9%) as a white solid, mp
59-60 OC; vmax(KBr)/cm-l 1700, 1250; 5H(CDC13) 1.24 (t, 3H, J= 6  Hz, CH3), 
3.74 (s, 2H, CH2 C 0 2), 4.14 (q, 2H, J= 6  Hz, C 0 2 CH2), 7.11 (m , 2H, H-4 & H- 
5) and 8.18 (m, 1H, H-6 ); MS m/z 216 (M+H), 200 [(M+H)-0].
(b) Oxidation with w-chloroperoxybenzoic acid402
m-Chloroperoxybenzoic acid (70%) (14.49 g, 62.7 mmol) was added to a 
mixture o f ethyl 2-chloro-5-pyridylacetate (145) and ethyl 2-chloro-3-
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pyridylacetate (69a) (4.20 g, 21 mmol) in dichloromethane (80 ml). The 
reaction mixture was stirred at room temperature for 3 days. Excess oxidising 
agent was destroyed by the addition o f solid sodium metabisulfite. Solid 
potassium carbonate was then added and any insoluble solids were removed by 
filtration. The filtrate was dried over magnesium sulfate and the solvent 
removed in vacuo to give a brown oil which was chromatographed on silica gel. 
Gradient elution with petroleum ether/ethyl acetate (75-100%) gave ethyl 2- 
chloro-5-pyridylacetate-1-oxide (146) (1.91 g 42%) as a white solid which was 
identical (tic, ir, mp) to an authentic sample o f (146) prepared in (a). Further 
elution afforded ethyl 2-chloro-3-pyridylacetate-1-oxide (147) (2.54 g, 56%) as a 
white solid which was identical (tic, ir, mp) to an authentic sample o f (147) 
prepared in (a).
3-Carboethoxy-2-methylthiothieno[2.3-b]pyridine-7-oxide (T48l402
Sodium hydride (0.6 g, 25 mmol) was added portionwise to a stirred solution o f  
ethyl 2-chloro-3-pyridylacetate-1-oxide (147) (2.39 g, 11 mmol) and carbon 
disulfide (0.93 g, 12.2 mmol) in DMSO (30 ml) under nitrogen. The reaction 
mixture was stirred at room temperature for 1 h then at 70 °C for 1.5 h, cooled 
and methyl iodide (3.5 g, 25 mmol) was added and stirring continued at room 
temperature for a further 1.5 h. The reaction mixture was poured onto ice/water 
(200 ml) and extracted with ethyl acetate (3 x 100 ml). The combined extracts 
were dried over magnesium sulfate and the solvent removed in vacuo to yield a 
solid which was then dissolved in a little dichloromethane and chromatographed 
on silica gel. Gradient elution with petroleum ether/ethyl acetate (50-100%) 
afforded 3-carboethoxy-2-methylthiothieno[2,3-b]pyridine-7-oxide (148) (0.5 g, 
17%) as a white solid, mp 158-159 °C; v ^ C K B ry cm - 1 3025, 2950, 1690, 
1240; 8H(CDC13) 1.44 (t, 3H, J=7.2 Hz, CH3), 2.72 (s, 3H, SCH3), 4.38 (q, 2H,
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J=7.2 Hz, C 0 2 CH2), 7.22 (dd, 1H, J=6 . 2  & 7.6 Hz, H-5) and 8.20 (m, 2 H, H-4 
& H-6 ); MS m/z 270 (M+H), 254 [(M+H)-0].
3-Carboethoxv-2-methvlthiothieno[2.3-b]pyridine (TOa"!
a) Deoxygenation o f 3-carboethoxy-2-methylthiothieno[2,3-b]pyridine-7-oxide 
(148).
Phosphorus tribromide (0.8 ml, 8.42 mmol) was added dropwise at ice 
temperature to a solution o f 3-carboethoxy-2-methylthiothieno[2,3-b]pyridine-7- 
oxide (148) (0.4 g, 1.5 mmol) in DMF (15 ml). The reaction mixture was stirred 
for 5 minutes, saturated sodium hydrogen carbonate solution (20 ml) was added 
and the aqueous phase was extracted with ethyl acetate (3 x 35 ml). The 
combined organic extracts were washed with brine then dried over magnesium 
sulfate. The solvent was removed in vacuo to give a solid which was 
recrystallised from ethyl acetate to afford 3-carboethoxy-2- 
methylthiothieno[2,3-b]pyridine251 (70a) (0.3 g, 80%) as a white solid, mp 108- 
110 °C; vmax(KBr)/cm~ 1 1695; 5H(CDC13) 1.46 (t, 3H, J=7.1 Hz, CH3), 2.66 
(s, 3H, SCH3), 4.44 (q, 2H, J=7.1 Hz, C 02CH2), 7.29 (dd, 1H, J=4.65 & 8.26 
Hz, H-5), 8.41 (dd, 1H, J=1.65 & 4.65 Hz, H-4) and 8.51 (dd, 1H, J=1.65 & 8.26 
Hz, H-6 ).
(b) Cyclisation o f ethyl 2-chloro-3-pyridylacetate (69a)251.
Sodium hydride (0.53 g, 22 mmol) was added portionwise to a stirred solution o f
ethyl 2-chloro-3-pyridylacetate402 (69a) (2.02 g, 10.1 mmol) and carbon
disulfide (0.85 g, 11 mmol) in DMSO (25 ml) under nitrogen. The reaction 
mixture was stirred at room temperature for 1 h then at 70 °C for 1.5 h, cooled 
and methyl iodide (3.15 g, 22 mmol) was added and stirring continued at room
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temperature for a further 1.5 h. The reaction mixture was poured onto ice/water 
(150 ml) and extracted with ethyl acetate (3 x 75 ml). The combined extracts 
were dried over magnesium sulfate and the solvent removed in vacuo to yield a 
yellow solid. The solid was dissolved in a little dichloromethane and 
chromatographed on silica gel. Gradient elution with petroleum ether/ethyl 
acetate (0-50%) afforded 3-carboethoxy-2-methylthiothieno[2,3-b]pyridine (70a) 
(1.72 g, 67%) as a white solid which was identical (tic, ir, *H nmr) to an 
authentic sam ple^ 1 .
3-Hydroxymethyl-2-methvlthiothieno[2.3-b]pyridine ("1491
3-Carboethoxy-2-methylthiothieno[2,3-b]pyridine (70a) (1.16 g, 4.57 mmol) in 
diethyl ether ( 2 0  ml) was added dropwise under nitrogen to a suspension o f  
lithium aluminium hydride (0.22 g, 5.95 mmol) in diethyl ether (60 ml). The 
reaction mixture was refluxed for 48 h. Water (10 ml) and 2N sulfuric acid (4 
ml) was added and the diethyl ether phase was separated. The aqueous phase 
was extracted with a further 2 x 50 ml o f diethyl ether. The combined extracts 
were dried over sodium sulfate and the solvent removed in vacuo to give a 
yellow oil which was dissolved in dichloromethane and chromatographed on 
silica gel. Elution with cyclohexane/ethyl acetate (40%) afforded 3- 
hydroxymethyl-2-methylthiothieno[2,3-b]pyridine (149) (0.48 g, 50%), a white 
solid, mp 92-93 °C (Found: C, 50.94; H, 4.27; N, 6.52. C9 H9 NOS2  requires C, 
51.16; H, 4.29; N, 6.63%); vmax(KBr)/cm-l 3197, 1380; 5H(CDC13) 2.50 (s, 
3H, CH3 ), 3.05 (br s, 1H, OH), 4.89 (s, 2H, CH2), 7.20 (dd, 1 H, J=4.5 & 8.1 Hz, 
H-5), 8.06 (dd, 1H, J=1.7 & 8.1 Hz, H-4) and 8.38 (dd, 1H, J=1.7 & 4.5 Hz, H-
6 ); LC-MS m/z 212 (M+H), 197 [(M+H)-CH3].
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Attempted reaction o f  3-hydroxymethvl-2-methylthiothieno[2.3-b]pvridine (449"! 
with chlorotrimethvlsilane. sodium iodide and sodium cyanide
3-Hydroxymethyl-2-methylthiothieno[2,3-b]pyridine (149) (0.30 g, 1.4 mmol) 
was added to a mixture o f chlorotrimethylsilane (0.31 g, 2.8 mmol), sodium 
cyanide (0.14 g, 2.8 mmol) and sodium iodide (0.002 g) in dry acetonitrile (5 
ml) and dry DMF (5 ml). The reaction mixture was heated at 60 °C under 
nitrogen for 19 h, poured onto ice/water (50 ml) and extracted with diethyl ether 
(3 x 50 ml). The organic extracts were combined, dried over magnesium sulfate 
and the solvent removed in vacuo to afford an oil (0.02 g) which tic and ir 
confirmed as unreacted (149). The reaction was not pursued any further.
Reaction o f 3-hydroxymethyl-2-methvlthiothieno[2.3-b]pyridine H49") with 
Raney nickel
3-Hydroxymethyl-2-methylthiothieno[2,3-b]pyridine (149) (0.25 g, 1.18 mmol) 
in acetone (10 ml) was added, under nitrogen, to a suspension o f Raney nickel (3 
g) in acetone (60 ml). The reaction mixture was refluxed for 1 h, the Raney 
nickel was removed by gravity filtration and the filtrate was dried over sodium 
sulfate. The solvent was removed in vacuo to give a yellow oil which was 
chromatographed on silica gel. Elution with cyclohexane/ethyl acetate (20%) 
afforded unreacted 3-hydroxymethyl-2-methylthiothieno[2,3-b]pyridine (149) 
(0.005 g, 2%) which was identical (^H nmr) to an authentic sample prepared 
above. Further elution afforded 3-hydroxymethylthieno[2,3-b]pyridine (151) 
(trace); 5H(CDC13) 4.89 (s, 2H, CH2), 7.29 (dd, 1H, J=4.5 & 8.1 Hz, H-5), 7.69 
(s, 1H, H-2), 8.14 (dd, 1H, J=1.75 & 8.1 Hz, H-4) and 8.54 (dd, 1H, J=1.75 &
4.5 Hz, H-6). No mp, ir or microanalysis was obtained due to the low yield o f  
(151).
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Reaction o f 3-carboethoxv-2-methylthiothieno[2.3-b]pyridine (IQa) with Raney 
nickel
3-Carboethoxy-2-methylthiothieno[2,3-b]pyridine (70a) (0.05 g, 0.2 mmol) was 
added to a suspension o f Raney nickel (0.5 g) in acetone (20 ml). The reaction 
mixture was refluxed under nitrogen for 24 h after which time the Raney nickel 
was removed by gravity filtration and the filtrate was dried over sodium sulfate. 
The solvent was removed in vacuo to afford an oil (0.002 g) which tic and Iff 
nmr showed to be a mixture o f products thus the reaction was taken no further.
Reaction o f 3-hydroxvmethvl-2-methylthiothieno[2.3-b]pyridine 049"! with 
Raney nickel in ethanol
3-Hydroxymethyl-2-methylthiothieno[2,3-b]pyridine (149) (0.18 g, 0.85 mmol) 
was added to a suspension o f Raney nickel (3 g) in ethanol (50 ml) under 
nitrogen at -10 °C. The reaction mixture was allowed to warm to room 
temperature and stirred for 2 h. The Raney nickel was removed by gravity 
filtration and the filtrate was dried over magnesium sulfate. The solvent was 
removed in vacuo to afford an oil (0.03 g) which Iff nmr indicated to be a 
mixture o f unidentifiable products.
3-Cvanothieno[2.3-b]pvridine 052")
3-Cyano-2-methylthiothieno[2,3-b]pyridine250,251 (70c) (0.5 g, 2.42 mmol) in 
acetone (20 ml) was added under nitrogen to a suspension o f Raney nickel (5 g) 
in acetone (100 ml). The reaction mixture was refluxed for 7 h, the Raney nickel 
was removed by gravity filtration and the filtrate was dried over sodium sulfate. 
The solvent was removed in vacuo to give a yellow solid which was dissolved in 
cyclohexane and chromatographed on silica gel. Elution with cyclohexane/ethyl
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acetate (20%) afforded 3-cyanothieno[2,3-b]pyridine (152) (0.38 g, 98%) as a 
white solid, mp 107-108 °C (Found: C, 59.42; H, 2.77; N, 17.08. C8 H4 N 2S 
requires C, 59.98; H, 2.52; N, 17.49%); vmax(KBr)/cm'l 2226; 8 h (CDC1 3 ) 
7.48 (dd, 1H, J=4.5 & 8.2 Hz, H-5), 8.19 (s, 1H, H-2), 8.26 (dd, 1H, J=1.9 & 8.2 
Hz, H-4) and 8.70 (dd, 1H, J=1.9 & 4.5 Hz, H-6 ); LC-MS m/z 161 (M+H).
3.3-Dimethoxy-2-formylpropionitrile sodium salt (155)272
Sodium hydride (1.5 g, 63 mmol) and anhydrous methyl formate (6.85 ml, 110 
mmol) were added to a solution o f 3,3-dimethoxypropionitrile (154) (6.25 ml, 55 
mmol) in dry diethyl ether (75 ml). The reaction mixture was stirred under 
nitrogen at room temperature for 72 h. The precipitated solid was filtered and 
washed with diethyl ether to afford 3,3-dimethoxy-2-formylpropionitrile sodium 
sah?72 (155) (6.64 g, 73%) as an off white solid; vmax(KBr)/cm"l 3447, 2209, 
1596. The crude product was used without further purification and hence no ^H 
nmr spectrum was obtained.
Cvclisation o f 2-nitrothiophene-4-carboxylic acid (T56">
Tin powder (6.58 g, 55 mmol) was added portionwise at 40 °C under nitrogen to 
a suspension o f 2-nitrothiophene-4-carboxylic acid (156) (3.0 g, 17 mmol) in 
concentrated hydrochloric acid (60 ml). Once all the tin had reacted the yellow  
solution was cooled and the resulting precipitate was filtered off. The filtrate 
was concentrated in vacuo and a further crop o f [bis(4-carboxythienyl-2- 
ammonium)]hexachlorostannate(IV)271 (157) (4.43 g, 83%) was obtained as a 
yellow solid; 5H(d6 DMSO) 6.59 (s, 1H, H-3) and 7.46 (s, 1H, H-5).
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A solution o f (157) (3.95 g, 6.37 mmol) and concentrated hydrochloric acid 
(14.4 ml) in methanol (150 ml) was added under nitrogen to a suspension o f 3,3- 
dimethoxy-2-formyIpropionitrile sodium salt (155) (2.33 g, 14 mmol) and 
concentrated hydrochloric acid (1.4 ml) in methanol (50 ml). The reaction 
mixture was refluxed for 24 h, solvent was removed in vacuo, replaced by water 
(50 ml) and extracted with ethyl acetate (3 x 75 ml). The combined organic 
extracts were dried over magnesium sulfate and the solvent removed in vacuo to 
afford a solid which was dissolved in dichloromethane and chromatographed on 
silica gel. Elution with petroleum ether/ethyl acetate (20%) afforded 3- 
carbomethoxy-2-chloro-5-cyanothieno[2,3-b]pyridine (158) (0.25 g, 8 %) as a 
white solid, mp 141-142 °C (Found: C, 47.57; H, 1.89; N, 11.16; S, 12.66. 
C 1 0 H5 N 2 O2 SCI requires C, 47.53; H, 1.99; N, 11.09; S, 12.69%); vmax(KBr) 
/cm ' 1 2233, 1727; SH(CDCI3) 4.06 (s, 3 H, CH3), 8.77 (d, 1H, J=1.8 Hz, H-4) 
and 8.96 (d, 1H, J=1.8 Hz, H-6 ); SC(CDC13, 62.9 MHz) 52.4 (CH3), 136.0 (C-4) 
and 148.7 (C-6 ); MS m/z 253 (M+H). Further elution afforded 3-carbomethoxy- 
5-cyanothieno[2,3-b]pyridine271 (159) ( 1 . 1 2  g, 40%) as a white solid, mp 1 2 1 - 
122 °C (Found: C, 54.96; H, 2.50; N, 12.85. C i 0H6 N 2O2 S requires C, 55.04; 
H, 2.77; N, 12.84%); V n ^ K B r y c n r 1 2231, 1723; 5H(CDC13) 3.99 (s, 3H, 
CH3), 8.56 (s, 1H, H-2), 8.81 (d, 1H, J=1.8 Hz, H-4) and 9.11 (d, 1H, J=1.8 Hz, 
H-6 ).
fEyEthvl-3-f2-nitro-4-thienyDprop-2-enoate (\ 62)
Method A: 2-nitrothiophene-4-carboxaldehyde (161) (5.0 g, 31.8 mmol), 
triethylphosphonoacetate (7.8 g, 35 mmol) and tetrabutylammonium hydrogen 
sulfate (0 . 1  g) in toluene ( 1 0 0  ml) were added to a solution o f  potassium 
carbonate (29 g, 0.2 mol) in water (100 ml). The reaction mixture was stirred at 
room temperature under nitrogen for 7 days. 10% Hydrochloric acid solution 
was then added and the organic phase was separated. The aqueous phase was
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extracted with a further 2  x 2 0 0  ml o f ethyl acetate, the combined extracts dried 
over sodium sulfate and the solvent was removed in vacuo to afford a dark solid. 
The solid was dissolved in dichloromethane and chromatographed on silica gel. 
Elution with petroleum ether/ethyl acetate (20%) afforded (E)-ethyl-3-(2-nitro-4- 
thienyl)prop-2-enoate (162) (2.48 g, 34%) as a pale yellow solid, mp 104 °C  
(Found: C, 47.51; H, 4.02; N, 6.17; S, 13.90. C9 H9 NO4 S requires C, 47.57; H, 
3.99; N, 6.16; S, 14.11%); vmax(KBr)/cm-l 3074, 1700, 1639, 1509, 
1337; 5H(CDC13) 1.32 (t, 3H, J=7.2 Hz, CH3 ), 4.25 (q, 2H, J=7.2 Hz, CH2), 
6.31 (d, 1H, J= 16.2 Hz, =CHC02), 7.51 (d, 1H, J=16.2 Hz, ArCH=), 7.58 (d, 
1H, J=1.9 Hz, H-3) and 8.04 (d, 1H, J=1.9 Hz, H-5); MS m/z 198 (M-CH2 CH3). 
Further elution gave unreacted 2-nitrothiophene-4-carboxaldehyde (161) (0.30 g, 
6 %) as an orange solid which was identical (tic, ir) to an authentic sample.
Method B: A mixture o f 2-nitrothiophene-4-carboxaldehyde (161) (5.0 g, 31.8 
mmol), triethylphosphonoacetate (8.56 g, 38.2 mmol) and water (50 ml) was 
added at ice temperature to a solution o f potassium carbonate (8.79 g, 63 mmol) 
in water. The reaction was stirred under nitrogen at room temperature for 3 h, a 
further 200 ml o f water was added and then extracted with ethyl acetate (3 x 200 
ml). The combined organic extract was dried over magnesium sulfate and the 
solvent removed in vacuo to afford a dark solid which was chromatographed on 
silica gel. Elution with petroleum ether/ethyl acetate (20%) afforded (E)-ethyl- 
3-(2-nitro-4-thienyl)prop-2-enoate (162) (5.1 g, 71%) as a pale yellow solid 
which was identical (tic, ir, ^H nmr) to a sample prepared using method A. 
Further elution gave unreacted 2-nitrothiophene-4-carboxaldehyde (161) (1.01 g, 
2 0 %) as an orange solid which was identical (tic, ir) to an authentic sample.
Method C: 2-nitrothiophene-4-carboxaldehyde (161) (0.2 g, 1.27 mmol) and 
triethylphosphonoacetate (0.34 g, 1.53 mmol) was added to potassium carbonate 
(0.35 g, 2.54 mmol) in dry THF (20 ml). The reaction mixture was stirred under
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nitrogen at room temperature for 24 h. Any insoluble solids were removed by 
filtration and the filtrate was evaporated in vacuo to afford a yellow solid. The 
solid was dissolved in dichloromethane and chromatographed on silica gel. 
Elution with petroleum ether/ethyl acetate (20%) afforded (E)-ethyl-(2-nitro-4- 
thienyl)prop-2 -enoate (162) (0.18 g, 62%) as a pale yellow solid identical (tic, 
ir, Iff nmr) to a sample prepared using method A. Also eluted was unreacted 2- 
nitrothiophene-4-carboxaldehyde (161) (0.04 g, 20%) as an orange solid 
identical (tic and ir) to an authentic sample.
[Bis(TE)-ethvl-3-f2-ammonium-4-thienvnprop-2-enoate>)]hexachlorostannatefIV>)
am
Tin powder (4.35 g, 36.6 mmol) was added portionwise at 40 °C under nitrogen 
to a suspension o f (E)-ethyl-3-(2-nitro-4-thienyl)prop-2-enoate (162) (3.0 g, 22 
mmol). Once all the tin had reacted the reaction mixture was cooled and the 
precipitate was filtered. The filtrate was concentrated in vacuo and a further 
crop o f [bis((E)-ethy 1-3 -(2-ammonium-4-thieny l)prop-2-enoate)]hexachloro- 
stannate(IV) (163) (7.60 g, 95%) was obtained as a yellow solid; vmax(KBr) 
/cm " 1 3568, 3472, 3288, 3191, 2920, 1706, 1638. No nmr spectrum was 
obtained due to decomposition in solution.
Cvclisation o f [bisffEVethyl-3-(r2-ammonium-4-thienyl> prop-2-enoate>)]hexa- 
chlorostannateflV") 063^1
(a) Cyclisation in concentrated hydrochloric acid.
A suspension o f [bis((E)-ethyl-3-(2-ammonium-4-thienyl)prop-2-enoate)]hexa- 
chlorostannate(IV) (163) (7.60 g, 10.4 mmol) and concentrated hydrochloric 
acid (27.5 ml) in ethanol (80 ml) was added under nitrogen to a suspension o f
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3,3-dimethoxy-2-formylpropionitrile sodium salt (155) (4.02 g, 24.2 mmol) in 
ethanol (30 ml). The reaction mixture was refluxed for 4 h, the solvent was 
removed in vacuo, replaced by water (400 ml) and extracted with ethyl acetate (3 
x 200 ml). The combined organic extracts were dried over magnesium sulfate 
and the solvent removed in vacuo to afford a dark oil which was dissolved in 
dichloromethane and chromatographed on silica gel. Elution with petroleum 
ether/ethyl acetate (20%) afforded (E)-ethyl-3-(2-chloro-5-cyano- 
thieno[2,3-b]pyridin-3-yl)prop-2-enoate (164) [0.80 g, 12% from (162)] as a 
white solid, mp 145-147 °C (Found: C, 53.20; H, 2.90; N, 9.56; S, 10.84. 
c 1 3 h 9 n 2 0 2 SC1 requires C, 53.34; H, 3.10; N, 9.57; S, 10.95%); vmax(KBr) 
/cm " 1 2234, 1731, 1636; 5H(CDC13) 1.40 (t, 3H, J=7.2 Hz, CH3), 4.33 (q, 2H, 
J=7.2 Hz, C 0 2 CH2), 6.65 (d, 1H, J=16 Hz, =CHC02), 7.85 (d, 1H, J=16 Hz, 
ArCH=), 8.48 (d, 1H, J=1.9 Hz, H-4) and 8.80 (d, 1H, J=1.9 Hz, H-6 ); MS m\z 
293 (M+H). Further elution afforded (E)-ethyl-3-(5-cyanothieno[2,3-b]pyridin- 
3-yl)prop-2-enoate (153) [1.02 g, 18% from (162)] as a white solid, mp 135-136 
°C (Found: C, 60.12; H, 3.98; N, 10.69; S, 12.12. C 1 3 H i 0 N 2 O2S requires C, 
60.45; H, 3.90; N, 10.85; S, 12.41%); V m ^ K B rycn r 1 2238, 1716, 1639;
6H(CDC13) 1.23 (t, 3H, J=7.2 Hz, CH3), 4.29 (q, 2H, J=7.2 Hz, C 0 2 CH2), 6.49 
(d, 1H, J=16 Hz, =CHC02), 7.81 (d, 1H, J=16 Hz, ArCH=), 7.93 (s, 1H, H-2), 
8.52 (d, 1H, J=1.75 Hz, H-4) and 8.81 (d, 1H, J=1.75 Hz, H-6 ); MS m/z 259 
(M+H).
(b) Cyclisation in concentrated sulfuric acid.
A suspension o f [bis((E)-ethyl-3-(2-ammonium-4-thienyl)prop-2-enoate)]hexa- 
chlorostannate(IV) (163) (1.63 g, 2.24 mmol) and concentrated sulfuric acid 
(1.04 g) in ethanol (30 ml) was added under argon to a suspension o f 3,3- 
dimethoxy-2-formylpropionitrile sodium salt (155) (0.89 g, 5.3 mmol) in ethanol 
(5 ml). The reaction mixture was refluxed for 22 h and solvent was removed in
199
vacuo. The residue was poured onto ice/water (300 ml), neutralised with 
concentrated ammonia solution and extracted with diethyl ether (3 x 100 ml). 
The combined ether extracts were filtered through Celite to remove any 
insoluble material, dried over magnesium sulfate and solvent removed in vacuo 
to afford a brown oil. The oil was dissolved in dichloromethane and 
chromatographed on silica gel. Elution with petroleum ether/diethyl ether (50%) 
afforded (E)-ethyl-3-(2-nitro-4-thienyl)prop-2-enoate (162) (0 . 2 1  g, 17%) 
identical (tic, ir) to an authentic sample. Further elution afforded (E)-ethyl-3-(5- 
cyanothieno[2,3-b]pyridin-3-yl)prop-2-enoate (153) [0.16 g, 14% from (162)] as 
a white solid which was identical (tic, ir, nmr) to a sample o f (153) prepared 
in (a).
rEV3-r2-nitro-4-thienvl>)prop-2-enoic acid H65^
Sodium hydroxide solution (1 ml, 4.8M) was added dropwise to a solution o f  
(E)-ethyl-3-(2-nitro-4-thienyl)prop-2-enoate (162) (1.0 g, 4.4 mmol) in ethanol 
(30 ml). The reaction mixture was stirred at room temperature under nitrogen 
for 8  h until tic had indicated that no starting material remained. The ethanol 
was removed in vacuo and replaced by water (10 ml). The aqueous solution was 
extracted with ethyl acetate (3 x 50 ml), acidified to a pH o f 4 with 2M 
hydrochloric acid solution, saturated with sodium chloride and extracted with 
THF (3 x 75 ml). The combined THF washings were dried over magnesium 
sulfate and the solvent removed in vacuo to afford a solid. The solid was 
recrystallised from ethanol/dichloromethane to give (E)-3-(2-nitro-4- 
thienyl)prop-2-enoic acid (165) (0.72 g, 82%) as a yellow solid; vmax(K13r) 
/cm " 1 3110 br, 1686, 1628, 1501, 1338; 5H(d6 DMSO) 6.49 (d, 1H, J=16.8 Hz, 
=CHC02), 7.50 (d, 1H, J=16.8 Hz, ArCH=), 8.24 (s, 1 H, H-3) and 8.43 (s, 1H, 
H-5). In spite o f several attempts at recrystallisation the product was not o f  
sufficient purity for melting point or microanalysis.
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fEyM ethvl^^-cyanothienopj-bjpvridin^-vDprop^-enoate (166)
Tin powder (1.96 g, 16 mmol) was added portionwise at 40 °C under nitrogen to 
a stirring suspension o f (E)-3-(2-nitro-4-thienyl)prop-2-enoic acid (165) (1.03 g,
5.2 mmol) in concentrated hydrochloric acid (30 ml). Once all the tin had 
reacted the hydrochloric acid was removed in vacuo to afford a brown solid 
(3.43 g). A suspension o f the solid and concentrated hydrochloric acid (5.5 ml) 
in methanol (70 ml) was added to a suspension o f 3,3-dimethoxy-2- 
formylpropionitrile sodium salt (155) (0.89 g, 5.35 mmol) in methanol (20 ml). 
The reaction mixture was refluxed for 24 h, the methanol was removed in vacuo 
and replaced by water (200 ml). The aqueous mixture was extracted with ethyl 
acetate (3 x 100 ml), the combined extracts were dried over magnesium sulfate 
and the solvent removed in vacuo to give a yellow solid. The solid was 
chromatographed on silica gel. Elution with petroleum ether/ethyl acetate (20%) 
afforded (E)-methyl-3-(5-cyanothieno[2,3-b]pyridin-3-yl)prop-2-enoate (166) 
(0.12 g, 10%) as a white solid, mp 202-204 °C; vmax(KBr)/cm"l 2230, 1717, 
1635; 5H(CDC13) 3.86 (s, 3H, CH3), 6.54 (d, 1H, J=16 Hz, =CHC02), 7.86 (d, 
1H, J=16 Hz, ArCH=), 8.05 (s, 1H, H-2), 8.56 (d, 1H, J=1.75 Hz, H-4) and 8.85 
(d, 1H, J=1.75 Hz, H-6 ); LC-MS m/z 245.1 (M+H).
Attempted hydrogenation o f fEVethyl^-^-nitro^-thienyPprop^-enoate H62)
(a) Reaction with palladium on carbon and ammonium formate.
5% Palladium on carbon (0.1 g) and ammonium formate (0.2 g, 4.3 mmol) were 
added under nitrogen to a solution o f (E)-ethyl-3-(2-nitro-4-thienyl)prop-2- 
enoate (162) (0.25 g, 1.1 mmol) in glacial acetic acid (5 ml). The reaction 
mixture was refluxed for 2  h, diethyl ether ( 2 0  ml) was added and filtered
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through Celite. The organic solution was washed with water (30 ml) and 2M 
sodium hydroxide solution (30 ml) then dried over magnesium sulfate. The 
solvent was removed in vacuo to give a solid which was recrystallised from 
ethanol to afford unreacted (E)-ethyl-3-(2-nitro-4-thienyl)prop-2-enoate (162) 
(0 . 2 0  g, 80%) as a pale yellow solid which was identical (tic, nmr, ir) to an 
authentic sample.
(b) Reaction with sodium borohydride and copper(I) chloride.
Sodium borohydride (0.47 g, 12.4 mmol) was added portionwise over a period 
o f 0.5 h at ice temperature under nitrogen to a suspension o f copper(I) chloride 
(0.24 g, 2.42 mmol) and (E)-ethyl-3-(2-nitro-4-thienyl)prop-2-enoate (162) (0.25 
g, 1.1 mmol) in methanol (10 ml). Stirring was continued for a further 0.5 h, 
diethyl ether (50 ml) was added and the organic solution was washed with water 
(2 x 50 ml) then dried over magnesium sulfate. The solvent was removed in 
vacuo to afford a brown solid (0 . 1  g) which decomposed on exposure to the 
atmosphere and the nmr spectrum indicated that no aromatic protons were 
present.
One step synthesis o f rEVethvl-3-r5-cyanothieno[2.3-b]pyridin-3-yllprop-2- 
enoate 053")
Tin(II) chloride.2 H2 0  (0.74 g, 3.3 mmol) was added portionwise at 40 °C under 
nitrogen to a solution o f (E)-ethyl-3-(2-nitro-4-thienyl)prop-2-enoate (162) (0.15 
g, 0.66 mmol) in ethanol (10 ml). Heating at 40 °C was continued until tic 
indicated that no starting material remained. A suspension o f 3,3-dimethoxy-2- 
formylpropionitrile sodium salt (155) (0.12 g, 0.72 mmol) and concentrated 
hydrochloric acid (0.7 ml) in ethanol (10 ml) was then added and the reaction 
mixture was refluxed for 48 h. The ethanol was removed in vacuo and replaced
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by water (100 ml). The aqueous solution was extracted with ethyl acetate (3 x 
1 0 0  ml), the combined organic extracts were dried over magnesium sulfate and 
the solvent removed in vacuo to give an oil. The oil was chromatographed on 
silica gel using a gradient elution with petroleum ether/ethyl acetate (0-50%) to 
afford (E)-ethyl-3-(5-cyanothieno[2,3-b]pyridin-3-yl)prop-2-enoate (153) (0.005 
g, 3%) identical (tic, nmr) to an authentic sample o f (153).
Attempted hydrogenation o f fEVethyl-3-f5-cyanothieno[2.3-b]pvridin-3-vnprop- 
2-enoate H53)
(a) Catalytic hydrogenation.
A suspension o f (E)-ethyl-3-(5-cyanothieno[2,3-b]pyridin-3-yl)prop-2-enoate 
(153) (0.09 g, 0.35 mmol) and 10% palladium on carbon (0.02 g) in dry ethanol 
(20 ml) was stirred under hydrogen gas at atmospheric pressure for 1.5 h. The 
hydrogen gas source was removed and the reaction flask was purged with argon. 
The reaction mixture was filtered through Celite, the ethanol was removed in 
vacuo and the crude solid was recrystallised from ethanol to afford unreacted 
(E)-ethyl-3-(5-cyanothieno[2,3-b]pyridin-3-yl)prop-2-enoate (153) (0.08 g, 89%) 
identical (tic, nmr, ir) to an authentic sample.
(b) Reaction with sodium borohydride and copper(I) chloride.
Sodium borohydride (0.37 g, 9.7 mmol) was added portionwise over a period o f  
0.5 h at ice temperature under nitrogen to a suspension o f copper(I) chloride 
(0.14 g, 1.4 mmol) and (E)-ethyl-3-(5-cyanothieno[2,3-b]pyridin-3-yl)prop-2- 
enoate (153) (0.25 g, 0.97 mmol) in methanol (20 ml). Stirring was continued 
for a further 1 h then ethyl acetate (100 ml) was added. The organic solution 
was washed with water (50 ml) and brine (50 ml), dried over magnesium sulfate
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and the solvent removed in vacuo to give a brown solid which was dissolved in a 
little dichloromethane and chromatographed on silica gel. Elution with 
petroleum ether/ethyl acetate (2 0 %) afforded ethyl-3-(5- 
cyanothieno[2,3-b]pyridin-3-yl)propanoate (167) (0.14 g, 55%) as a white solid, 
mp 102-103 °C (Found: C, 59.96; H, 4.80; N, 10.46; S, 12.17. C 1 3 H 1 2 N 2 0 2S 
requires C, 59.98; H, 4.65; N, 10.76; S, 12.32%); V n ^ K B r y c n r 1 3055, 2235, 
1736; 6H(CDC13) 1.25 (t, 3H, J=7.2 Hz, CH3), 2.77 (t, 2H, J=7.2 Hz, CH2 C 0 2), 
3.20 (t, 2H, J=7.2 Hz, ArCH2), 4.15 (q, 2H, J=7.2 Hz, C 0 2 CH2), 7.40 (s, 1H, 
H-2), 8.33 (d, 1H, J=1.92 Hz, H-4) and 8.80 (d, 1H, J=1.92 Hz, H-6 ); MS m/z 
261 (M+H); LC-MS m/z 261.1 (M+H).
(c) Reaction with palladium on carbon and ammonium formate.
10% Palladium on carbon (0.13 g) and ammonium formate (0.13 g, 2.4 mmol) 
were added under nitrogen to a solution o f (E)-ethyl-3-(5-cyanothieno[2,3-b] 
pyridin-3-yl)prop-2-enoate (153) (0.2 g, 0.77 mmol) in glacial acetic acid (5 ml). 
The reaction mixture was refluxed for 2 h, diethyl ether (100 ml) was added and 
filtered through Celite. The organic solution was washed with water (50 ml) and 
2M sodium hydroxide solution (50 ml) then dried over magnesium sulfate. The 
solvent was removed in vacuo to give a yellow solid. The solid was 
chromatographed on silica gel. Elution with petroleum ether/diethyl ether (50%) 
afforded ethyl-3-(5-cyanothieno[2,3-b]pyridin-3-yl)propanoate (167) (0.06 g, 
30%) as a white solid identical (tic, *H nmr, ir) to an authentic sample obtained 
from method (b) above.
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Attempted reaction o f 3-carbomethoxy-5-cyanothieno[2.3-b]pvridine 059^ with 
sodium iodide and chlorotrimethylsilane
Sodium iodide (0.27 g, 1.8 mmol) and chlorotrimethylsilane (0.33 g, 3 mmol) 
were added to a solution o f 3-carbomethoxy-5-cyanothieno[2,3-b]pyridine (159) 
(0.20 g, 0.9 mmol) in dry acetonitrile (20 ml). The reaction mixture was 
refluxed for 48 h then poured onto ice/water (50 ml) and extracted with diethyl 
ether (3 x 100 ml). The combined ether extracts were dried over magnesium 
sulfate and the solvent was removed in vacuo to afford unreacted 3- 
carbomethoxy-5-cyanothieno[2,3-b]pyridine (159) (0.12 g, 60%) as a yellow  
solid identical (tic, Iff nmr) to an authentic sample.
5-cyanothieno[2.3-b]pyridine-3-carboxvlic acid 0 6 8 )
3-Carbomethoxy-5-cyanothieno[2,3-b]pyridine (159) (0.69 g, 3.16 mmol) and 
2M sodium hydroxide solution (2 ml) in methanol (30 ml) was stirred at room 
temperature under nitrogen for 24 h until tic showed no starting material 
remained. The methanol was removed in vacuo and the residue was dissolved in 
water (30 ml). 2M Hydrochloric acid solution was added dropwise and the 
white precipitate was filtered to afford 5-cyanothieno[2,3-b]pyridine-3- 
carboxylic acid (168) (0.47 g, 6 8 %) as a white solid, mp >250 °C; vmax(KBr) 
/cm ' 1 3127 ,3079 ,2922,2578,2235 , 1706; DMSO) 8.90 (s, 1H, H-2) and
9.05 (m, 2H, H-4 & H-6 ); LC-MS m/z 203 (M -l), 159 (M-CO2 H). A suitable 
sample for microanalysis could not be prepared due to solubility problems 
however LC-MS indicated the presence o f a single pure product.
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A solution o f 5-cyanothieno[2,3-b]pyridine-3-carboxylic acid (168) (0.08 g, 0.39 
mmol), diphenylphosphorylazide (0.22 g, 0.78 mmol) and triethylamine (0.08 g, 
0.78 mmol) in dry /-butanol was refluxed under nitrogen for 18 h. The reaction 
mixture was cooled and the /-butanol was removed in vacuo. The residue was 
dissolved in ethyl acetate (50 ml) and washed with saturated sodium hydrogen 
carbonate solution (50 ml) and brine (50 ml). The organic phase was dried over 
magnesium sulfate and the solvent removed in vacuo to afford a yellow oil 
(0.006 g) which tic indicated to be a complex mixture o f components. The 
aqueous washings were acidified with 2M hydrochloric acid and extracted with 
ethyl acetate (3 x 50 ml). The combined extracts were dried over magnesium 
sulfate and the solvent removed in vacuo to afford a solid (0.08 g) which nmr 
indicated to consist mainly o f unreacted 5-cyanothieno[2,3-b]pyridine-3- 
carboxylic acid (168).
3-Azidocarbonyl-5-cyanothieno[2.3-b]pyridine (1691
Ethyl chloroformate (0.27 g, 2.49 mmol) was added dropwise under argon to a 
stirred solution o f 5-cyanothieno[2,3-b]pyridine-3-carboxylic acid (168) (0.39 g, 
1.91 mmol) and triethylamine (0.23 g, 2.27 mmol) in acetone (20 ml) at ice 
temperature. The reaction mixture was stirred for 3 h then a solution o f sodium 
azide (0.21 g, 3.23 mmol) in water (2 ml) was added. Stirring was continued for 
a further 2.5 h then the mixture was poured onto ice/water (20 ml) and extracted 
with dichloromethane (3 x 50 ml). The combined organic extracts were dried 
over magnesium sulfate and the solvent removed in vacuo to afford a solid 
which was chromatographed on silica gel. Elution with petroleum ether/ethyl 
acetate (20%) afforded 3-azidocarbonyl-5-cyanothieno[2,3-b]pyridine (169)
Reaction of 5-cyanothieno[2.3-b]pvridine-3-carboxylic acid H68  ^with diphenvl-
phosphorvl azide
206
(0.44 g, 100%) as a white solid, mp 137-138 °C d (Found: C, 46.96; H, 1.29; N, 
29.65; S, 13.76. C9 H3 N 5 OS requires C, 47.16; H, 1.32; N, 30.55; S, 13.99%); 
vmax( K B r ) / c m ' 1 2232, 2181, 1694; 8 H(CDCl3 ) 8.65 (s, 1H, H-2), 8.84 (d, 1H, 
J=1.95 Hz, H-4) and 9.18 (d, 1H, J=1.95 Hz, H-6 ).
3-[Y/L-Butoxvcarbonvnamino]-5-cyanothieno[2.3-b]pyridine (1701
3-Azidocarbonyl-5-cyanothieno[2,3-b]pyridine (169) (0.28 g, 1.22 mmol) was 
refluxed in dry /-butanol for 1 0  h under nitrogen until tic indicated no starting 
material remained. The solvent was removed in vacuo to afford a brown solid 
which was dissolved in a little dichloromethane and chromatographed on silica 
gel. Elution with petroleum ether/ethyl acetate (20%) afforded 3-[(/- 
butoxycarbonyl)amino]-5-cyanothieno[2,3-b]pyridine (170) (0.23 g, 6 8 %) as a 
white solid, mp 199-201 °C d (Found: C, 56.64; H, 4.66; N, 15.15; S, 11.51. 
C 1 3 H 1 3 N 3 O2 S requires C, 56.71; H, 4.76; N, 15.26; S, 11.65%); vmax(KBr) 
/cm - 1 3276, 3174, 2231, 1689, 1563; 6H(CDC13) 1.61 (s, 9H, 3 x CH3 ), 6.83 (s, 
1H, NH), 7.75 (s br, 1H, H-2), 8.26 (s br, 1H, H-4) and 8.80 (d, 1H, J=1.85 Hz, 
H-6 ); MS m/z 276 (M+H).
3-[(7-Butoxycarbonynamino]-5-carboxamidothieno[2.3-b]pyridine (171)
3-[(/-Butoxycarbonyl)amino]-5-cyanothieno[2,3-b]pyridine (170) (0.1 g, 0.36 
mmol), concentrated ammonia solution ( 1  ml, sg 0.88) and 30% hydrogen 
peroxide solution (0.07 g) were stirred in ethanol (20 ml) at room temperature 
under nitrogen for 24 h. The solvent was removed in vacuo to afford a solid 
which was recrystallised from methanol/water to afford 3-[(/- 
butoxycarbonyl)amino]-5-carboxamido-thieno[2,3-b]pyridine (171) (0.11 g,
100%) as a white solid, mp 206-207 °C; VmaxCKBrycnr1 3418 ,3211 ,3060 , 
2984, 1668; SH(dg acetone) 1.52 (s, 9H, 3 x CH3), 5.62 (s, 1H, NH-CO2 ), 7.82
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(s br, 1H, H-2), 9.01 (s br, 1H, H-4) and 9.08 (d, 1H, J=1.85 Hz, H-6 ); MS m/z 
294 (M+H); LC-MS 294.2 (M+H).
Reaction o f 3-carbomethoxv-2-chloro-5-cvanothieno[2.3-b]pyridine H581 with 
guanidine hydrochloride
3-Carbomethoxy-2-chloro-5-cyanothieno[2,3-b]pyridine (158) (0.03 g, 0.118 
mmol), guanidine hydrochloride (0.012 g, 0.13 mmol) and sodium hydride 
(0.006 g, 0.26 mmol) were refluxed in DMF (2 ml) under nitrogen for 4 h. The 
reaction mixture was poured onto ice/water (40 ml) and extracted with ethyl 
acetate (3 x 50 ml). The combined organic extracts were dried over magnesium 
sulfate and the solvent removed in vacuo to give a solid (0 . 0 2  g) which was 
identical (tic, nmr) to unreacted 3-carbomethoxy-2-chloro-5-
cyanothieno[2,3-b]pyridine (158).
Hydrolysis o f ethvl-3-f5-cyanothieno[2.3-b]pvridin-3-vl>propanoate (T67^
2M Sodium hydroxide solution (2 ml) was added dropwise to a solution o f ethyl- 
3-(5-cyanothieno[2,3-b]pyridin-3-yl)propanoate (167) (0.53 g, 2.03 mmol) in 
ethanol (20 ml) under nitrogen. The reaction mixture was stirred at room 
temperature for 24 h until tic had indicated that no starting material remained. 
The ethanol was removed in vacuo and replaced by water (50 ml). The aqueous 
solution was acidified with 2M hydrochloric acid and the precipitated solid (0.5 
g) was filtered. Any attempts to purify the solid failed due to poor solubility in 
all common solvents; vmax(KBr)/cm"l 3439-2586 br, 2232, 1717. No ^H nmr 
spectrum was obtained due to the solubility problems and the product was 
assumed to be crude 3-(5-cyanothieno[2,3-b]pyridin-3-yl)propanoic acid (173).
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Ethyl chloroformate (0.27 g, 2.49 mmol) was added dropwise under nitrogen to 
a stirred solution o f crude 3-(5-cyanothieno[2,3-b]pyridin-3-yl)propanoic acid 
(173) (0.29 g, 1.25 mmol) and triethylamine (0.25 g, 2.47 mmol) in acetone (20 
ml) at room temperature. The reaction mixture was stirred at room temperature 
for 2 h then a solution o f sodium azide (0.16 g, 2.49 mmol) in water (1 ml) was 
added and stirring continued for a further 2 h. Dichloromethane (20 ml) was 
added and any insoluble solids were removed by filtration. The filtrate was 
washed with water (2 x 30 ml), dried over magnesium sulfate and the solvent 
removed in vacuo to give a solid. Chromatography on silica gel eluting with 
petroleum ether/ethyl acetate (20%) afforded a white solid (0.12 g, 37%) which 
was identical (tic, nmr) to an authentic sample o f ethyl-3-(5-
cyanothieno[2,3-b]pyridin-3-yl)propanoate (167).
Attempted Curtius rearrangement o f 3-f5-cyanothieno[2.3-b]pvridin-3-
vnpropanoic acid fl7 3 i without characterising the intermediate
Ethyl chloroformate (0.34 g, 3.2 mmol) was added under nitrogen to a solution 
o f 3-(5-cyanothieno[2,3-b]pyridin-3-yl)propanoic acid (173) (0.37 g, 1.6 mmol) 
and triethylamine (0.32 g, 3.2 mmol) in acetone (30 ml) at room temperature. 
The reaction mixture was stirred for 2 h then a solution o f sodium azide (0.17 g,
2.7 mmol) in water (1 ml) was added and stirring continued for a further 2 h. 
Dichloromethane (50 ml) was added and any insoluble solids were removed by 
filtration. The filtrate was washed with water (2 x 3 0  ml), dried over magnesium 
sulfate and the solvent removed in vacuo to afford a brown solid. The solid, 
without further purification, was refluxed under nitrogen in dry /-butanol ( 2 0  ml) 
for 2 h. The /-butanol was removed in vacuo and replaced by a mixture o f o-
Reaction of 3-f5-cyanothieno[2.3-b]pvridin-3-ylipropanoic acid H73") with
triethvlamine. ethyl chloroformate and sodium azide
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xylene (15 ml) and /-butanol (5 ml) and reflux was continued for a further 17 h. 
Solvents were removed in vacuo to afford an oil which tic indicated to be a 
complex mixture o f products. The oil was dissolved in dichloromethane and 
chromatographed on silica gel. Elution with petroleum ether/ethyl acetate (10%) 
afforded a brown solid (0.028 g) which nmr indicated was mainly ethyl-3-(5- 
cyanothieno[2,3-b]pyridin-3-yl)propanoate (167).
Attempted reaction o f 3-f5-cvanothieno[2.3-b]pyridin-3-ynpropanoic acid 073") 
with thionvl chloride and sodium azide
3-(5-Cyanothieno[2,3-b]pyridin-3-yl)propanoic acid (173) (0.35 g, 1.53 mmol) 
and thionyl chloride (50 ml) were refluxed under nitrogen for 24 h. The thionyl 
chloride was evaporated in vacuo and replaced by acetone (20 ml). Sodium 
azide (0.1 g, 1.53 mmol) was added and the reaction mixture was stirred at room 
temperature under nitrogen for 5 h. The acetone was removed in vacuo and the 
crude solid was dissolved in dichloromethane (100 ml), washed with water (50 
ml) and brine (50 ml). The organic phase was dried over magnesium sulfate and 
the dichloromethane was removed in vacuo to afford a solid which was 
chromatographed on silica gel. Elution with petroleum ether/ethyl acetate (10%) 
afforded two compounds but the infrared spectra o f both showed no peaks 
indicative o f a nitrile group.
Reaction o f 3-/5-cyanothieno[2.3-b1pyridin-3-yDpropanoic acid fl73^ with 
diphenvlphosphorvl azide
A solution o f 3-(5-cyanothieno[2,3-b]pyridin-3-yl)propanoic acid (173) (0.1 g, 
0.43 mmol) and triethylamine (0.09 g, 0.9 mmol) in /-butanol ( 6  ml) was heated 
at 50 °C for 1 h under nitrogen. Diphenylphosphoryl azide (0.13 g, 0.47 mmol) 
was added and the reaction mixture was refluxed for 18 h, cooled to room
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temperature and stirred for a further 24 h. Saturated sodium hydrogen carbonate 
solution (50 ml) was added and the mixture was extracted with ethyl acetate (3 x 
50 ml). The combined organic extracts were dried over magnesium sulfate and 
the solvent removed in vacuo to afford a viscous oil. The oil was dissolved in 
dichloromethane and chromatographed on silica gel using a gradient elution with 
petroleum ether/ethyl acetate (0-40%) to afford a brown oil (0.01 g). *H nmr 
indicated that no thieno[2,3-b]pyridine was present.
Attempted synthesis o f 3-f2-chloroethvlT5-cvanothieno[2.3-b]pyridine H75^
Lead tetraacetate (0.19 g, 0.44 mmol) and lithium chloride (0.018 g, 0.44 mmol) 
were added at room temperature under argon to a suspension o f 3-(5- 
cyanothieno[2,3-b]pyridin-3-yl)propanoic acid (173) (0.3 g, 1.29 mmol) in dry 
toluene (4 ml). The reaction mixture was heated at 80 °C for 3 h, diethyl ether 
(50 ml) was then added and the solution was washed with saturated sodium 
hydrogen carbonate solution (2 x 50 ml). The ether solution was then dried over 
magnesium sulfate and the solvent removed in vacuo to afford a solid (0.015 g). 
The !h  nmr spectrum indicated a mixture o f products thus the reaction was 
taken no further. The aqueous washings were acidified with 6 M hydrochloric 
acid and extracted with ethyl acetate ( 2  x 2 0 0  ml), the organic extracts were 
dried over magnesium sulfate and the solvent removed in vacuo to afford a solid 
(0.08 g) which ir indicated to be unreacted crude (173).
Attempted Hofmann rearrangement
A solution o f ethyl-3-(5-cyanothieno[2,3-b]pyridin-3-yl)propanoate (167) (0.1 g, 
0.38 mmol), sodium cyanide (2 mg), concentrated ammonia solution (25 ml, sg 
0.88) and ethanol (25 ml) was refluxed for 24 h until tic indicated that no starting 
material remained. The solvent was removed in vacuo, replaced by brine (20
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ml) and the reaction mixture was extracted with THF (3 x 50 ml). The combined 
organic extracts were dried over magnesium sulfate and the solvent removed in 
vacuo to afford an oil (0.14 g). The infrared spectrum o f the crude product 
indicated the presence o f a nitrile and amide; vmax/cm“l 2238, 1684.
Bromine (0.015 ml) was added at ice temperature to a solution o f sodium 
hydroxide (0.06 g, 1.4 mmol) in water (2 ml). This mixture was then added to 
the crude amide prepared above (0.14 g) and the reaction mixture was heated at 
90 °C for 3 h. Brine was added and the aqueous phase was extracted with THF 
( 4 x 1 0  ml), the THF extracts were dried over magnesium sulfate and the THF 
was removed in vacuo and replaced with dry diethyl ether (10 ml). Dry 
hydrogen chloride gas was bubbled through the ether solution which afforded a 
solid which darkened on exposure to air. The *H nmr spectrum o f the solid 
indicated that no thieno[2,3-b]pyridine was present.
flT)-l -[f/-butoxycarbonyDamino]-2-f2-nitro-4-thienvnethene (176)
Ethyl chloroformate (0.25 g, 2.34 mmol) was added under nitrogen at ice 
temperature to a solution o f (E)-3-(2-nitro-4-thienyl)prop-2-enoic acid (165) 
(0.39 g, 1.95 mmol) and triethylamine (0.23 g, 2.34 mmol) in acetone (30 ml). 
The reaction mixture was stirred for 1 h then sodium azide (0.21 g, 3.3 mmol) 
was added and stirring was continued for a further 1 h. Water (100 ml) was 
added and the reaction mixture was extracted with diethyl ether (3 x 50 ml), the 
combined extracts were dried over magnesium sulfate and the solvent removed 
in vacuo to afford a pale yellow solid (0.15 g); vmax( K B r ) / c m ' 1 3102, 2144, 
1684, 1498, 1347. The solid was refluxed in dry ^-butanol under nitrogen for 4 
h. The solvent was then removed in vacuo to give an orange solid which was 
chromatographed on silica gel. Elution with petroleum ether/ethyl acetate (20%) 
afforded (E)-1-[(^-butoxy carbonyl) amino]-2-(2-nitro-4-thienyl)ethene (176)
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(0.15 g, 28%) as an orange solid, mp 144-146 °C; vmax(KBr)/cm_l 3354, 3083, 
1700, 1654, 1499, 1326; 5H(CDC13) 1.25 (s, 9H, 3 x CH3), 5.82 (d, 1H, J=14.6 
Hz, ArCH=), 6.61 (d, 1H, J=14.6 Hz, =CH-N), 7.11 (d, 1H, J=1.7 Hz, H-3) and 
7.86 (d, 1H, J=1.7 Hz, H-5); MS m/z 269 (M -l).
Attempted cvclisation o f rEVl-[^-butoxvcarbonyl>)amino]-2-r2-nitro-4-thienyn 
ethene 076"!
Tin powder (0.12 g, 1.0 mmol) was added portionwise over 0.5 h to a suspension 
o f (E)-l-[(/l-butoxycarbonyl)amino]-2-(2-nitro-4-thienyl)ethene (176) (0.15 g, 
0.55 mmol) in concentrated hydrochloric acid (5 ml) at 40 °C under nitrogen. 
The reaction mixture was stirred until no unreacted tin remained. 3,3- 
Dimethoxy-2-formylpropionitrile sodium salt (155) (0.11 g, 0.66 mmol) and 
ethanol (50 ml) were then added and the reaction mixture was refluxed for 16 h. 
The solvent was removed in vacuo and replaced by water (50 ml). Concentrated 
ammonia solution was added to neutralise the acid and the aqueous mixture was 
extracted with ethyl acetate (3 x 100 ml). The combined extracts were dried 
over magnesium sulfate and the solvent was removed in vacuo to afford a brown 
solid (0.14 g) which tic indicated to be a complex mixture o f products which 
were inseparable by column chromatography.
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